CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Multiple Myeloma | Page 5</title><meta name="description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta property="og:url" content="https://www.ajmc.com/compendium/multiple-myeloma "/><meta property="og:title" content="Multiple Myeloma | Page 5"/><meta property="og:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta property="og:site_name" content="AJMC"/><meta property="og:description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Multiple Myeloma | Page 5"/><meta name="twitter:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta name="twitter:site" content="@@AJMC_Journal"/><meta name="twitter:description" content="The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.ajmc.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Multiple Myeloma | Page 5", dimension9: "compendium/multiple-myeloma", dimension11: "", dimension12: "", dimension13: "", dimension14: "", dimension15: "compendium/multiple-myeloma", dimension18: "", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NK5KQXS'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.ajmc.com/compendium/multiple-myeloma"/><meta name="next-head-count" content="10"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <link rel="preload" href="/_next/static/css/8f41769b94d1711a.css" as="style"/><link rel="stylesheet" href="/_next/static/css/8f41769b94d1711a.css" data-n-g=""/><link rel="preload" href="/_next/static/css/1fd9d1dcb68b7a42.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1fd9d1dcb68b7a42.css" data-n-p=""/><link rel="preload" href="/_next/static/css/73c00cd95dc66651.css" as="style"/><link rel="stylesheet" href="/_next/static/css/73c00cd95dc66651.css" data-n-p=""/><link rel="preload" href="/_next/static/css/0f1de527bcd6b2b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0f1de527bcd6b2b3.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-cdc4e4b016deb907.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-00d4f6171a46c55f.js" defer=""></script><script src="/_next/static/chunks/8eec4907-bd18a9d50c17fbc1.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/72585f70-0d4479e14d41a365.js" defer=""></script><script src="/_next/static/chunks/59b4e022-07228b5f1b83aaf8.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e893f787-08b93252db7fc864.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/c8eae200-9f0c2beb62006a40.js" defer=""></script><script src="/_next/static/chunks/a29ae703-70c961c34719afa8.js" defer=""></script><script src="/_next/static/chunks/4592-37f767f9d2e595fc.js" defer=""></script><script src="/_next/static/chunks/1212-e69ee8c76b24c02a.js" defer=""></script><script src="/_next/static/chunks/4179-91956f2d2c4bf724.js" defer=""></script><script src="/_next/static/chunks/9879-c84885d45ee98d34.js" defer=""></script><script src="/_next/static/chunks/9355-c793747e2dd7fab4.js" defer=""></script><script src="/_next/static/chunks/3499-b4daf1c9382343af.js" defer=""></script><script src="/_next/static/chunks/4386-1eb6319d7e5f2437.js" defer=""></script><script src="/_next/static/chunks/8421-a4cb4c694745bc83.js" defer=""></script><script src="/_next/static/chunks/8412-bd07abe8ce76d08f.js" defer=""></script><script src="/_next/static/chunks/430-ec5773e97694cd78.js" defer=""></script><script src="/_next/static/chunks/173-d652f6350242b7ad.js" defer=""></script><script src="/_next/static/chunks/7707-0a9d2eb68940c393.js" defer=""></script><script src="/_next/static/chunks/475-8933b8b0e2730387.js" defer=""></script><script src="/_next/static/chunks/9323-fbb62165c37c2d73.js" defer=""></script><script src="/_next/static/chunks/4978-93f3851c23363751.js" defer=""></script><script src="/_next/static/chunks/4063-f338377ebed73baf.js" defer=""></script><script src="/_next/static/chunks/pages/%5B...slug%5D-1b8b61a43bc98d83.js" defer=""></script><script src="/_next/static/T5sqxRTLols3JYvQxG45F/_buildManifest.js" defer=""></script><script src="/_next/static/T5sqxRTLols3JYvQxG45F/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-2416765321">.bottomDiv.jsx-2416765321{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2416765321::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2416765321::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2416765321{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2416765321{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2416765321{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0a5cbd8bf-fdcc-4c2d-ba39-a4a9116a0449.jsx-2416765321:hover{background:var(--secondary)}.view-more-wrap0a5cbd8bf-fdcc-4c2d-ba39-a4a9116a0449.jsx-2416765321{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0a5cbd8bf-fdcc-4c2d-ba39-a4a9116a0449.jsx-2416765321:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2416765321{background-position:right bottom}.text-white.jsx-2416765321{color:var(--primary)}</style><style id="__jsx-3925978785">.bottomDiv.jsx-3925978785{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3925978785::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3925978785::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3925978785{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3925978785{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3925978785{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore112fd7f9e-81d9-4057-8766-586fbb17f357.jsx-3925978785:hover{background:var(--secondary)}.view-more-wrap112fd7f9e-81d9-4057-8766-586fbb17f357.jsx-3925978785{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap112fd7f9e-81d9-4057-8766-586fbb17f357.jsx-3925978785:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3925978785{background-position:right bottom}.text-white.jsx-3925978785{color:var(--primary)}</style><style id="__jsx-1505351878">.bottomDiv.jsx-1505351878{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1505351878::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1505351878::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1505351878{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1505351878{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1505351878{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2e7461055-aba3-4aea-bc45-bc12fdb0fd6e.jsx-1505351878:hover{background:var(--secondary)}.view-more-wrap2e7461055-aba3-4aea-bc45-bc12fdb0fd6e.jsx-1505351878{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2e7461055-aba3-4aea-bc45-bc12fdb0fd6e.jsx-1505351878:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1505351878{background-position:right bottom}.text-white.jsx-1505351878{color:var(--primary)}</style><style id="__jsx-644232506">.bottomDiv.jsx-644232506{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-644232506::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-644232506::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-644232506{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-644232506{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-644232506{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore34b06c045-2383-4cde-be29-758255ff6e1c.jsx-644232506:hover{background:var(--secondary)}.view-more-wrap34b06c045-2383-4cde-be29-758255ff6e1c.jsx-644232506{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap34b06c045-2383-4cde-be29-758255ff6e1c.jsx-644232506:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-644232506{background-position:right bottom}.text-white.jsx-644232506{color:var(--primary)}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 z-[999999]"><div class="h-full w-full"><nav role="navigation" class=" w-full mx-auto hidden lg:block bg-white shadow-md relative"><div class="bg-primary" id="topnav"><div class="container px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto "><div class="h-full flex items-center flex-1 justify-between mr-4"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></a><div class="hidden md:block"><div class="bg-primary py-2 whitespace-nowrap"><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 items-end"><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">News<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/news" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All News</a><a href="/press-release" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Press Releases</a><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Video<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/video-hub" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Video Types</a><a href="/interviews" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC TV</a><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a><a href="/insights" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insights</a><a href="/onlocation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">OnLocation</a><a href="/payer-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Payer Perspectives</a><a href="/peer-exchange" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Peer Exchange</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a><a href="/stakeholder-summit" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Stakeholder Summit</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/podcasts">Podcasts</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/latest-conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Coverage</a><a href="/conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Listing</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Journals<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/publications" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Journals</a><a href="/publications/issue" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">The American Journal of Managed Care</a><a href="/publications/ajac" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health, Equity & Outcomes</a><a href="/publications/evidence-based-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Evidence-Based Oncology</a><a href="/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">About Supplements and Featured Publications</a><a href="/publications/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Supplements and Featured Publications Issues</a><a href="/submit-a-manuscript" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Submit a Manuscript</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Events<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/ivbmevents" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Institute for Value-Based Medicine</a><a href="https://pcoc.ajmc.com/" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Patient-Centered Oncology Care</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/interactive-tools" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Interactive Tools</a><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary Central</a><a href="/clinical-spotlight" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Clinical Spotlight</a><a href="/custom-email" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Microsites</a><a href="/sponsored" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sponsored Content</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/continuing-education">CE</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">About AJMC<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/editorial" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC Staff</a><a href="/anniversary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Anniversary</a><a href="/about/seema-sonnad-nomination" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Seema Sonnad Award</a><a href="/partners" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Strategic Alliance Partners</a></div></div></div></div></div></div></div><div class="md:flex items-center justify-end hidden"><div class="flex items-center"><div class="md:pr-10 lg:pr-0 h-full flex items-center"><button class="w-6 h-6 relative"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button><div class="hidden bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center z-[99999] "><form method="GET" action="/search"><div class="relative"><div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg" class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search"/></div></form></div></div></div><a href="https://one.ajmc.com/subscribe" class="bg-subscribe-btn rounded text-white py-1.5 px-3 text-[14px] ml-4 uppercase font-semibold">Subscribe</a></div></div></div><div class="bg-white" id="bottomnav"><div style="max-height:60px" class="px-4 transition-all container justify-between h-14 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-row gap-2 mr-4"><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div><div class="flex flex-1 items-center gap-3 overflow-hidden justify-start"><span class="text-md font-semibold whitespace-pre !text-primary filter brightness-75">Spotlight</span><ul id="spotlight-links" class="flex gap-2 h-4 overflow-hidden flex-wrap"><li class="text-xs pt-0.5 whitespace-pre cursor-pointer hover:underline text-gray-800"><a href="/ivbmevents?display=home">Free In-Person Regional Events Focused on Oncology and Population Health</a></li></ul></div></div></div></div></nav><nav class="lg:hidden"><div class="w-full shadow-md bg-primary sticky top-0 z-40"><div class="flex mx-auto container"><div class=" py-4 flex items-stretch justify-between mx-4 items-center w-full"><div class="flex items-center justify-end"><div class="flex items-center"><div class="h-full flex items-center"><button id="menu" aria-label="open menu" aria-expanded="false" class="focus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md text-white"><svg width="30" height="30" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M21 10H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 6H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 14H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 18H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path></svg></button></div></div></div><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-10 w-40"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center" loading="lazy"/></noscript></span></a></div><div class="relative w-8 h-8 my grid items-center"><a class="absolute lg:hidden inset-0 mt-1" href="/search"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></a></div></div></div><div style="max-height:50px" class="bg-white px-4 transition-all h-12 md:items-stretch mx-auto" id="bottomnav-mobile"><div class="container justify-between h-12 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-1 justify-center xs:justify-start items-center relative group h-full z-50 gap-2"><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/compendium/cardiorenalmetabolic" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</a><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/gastroenterology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gastroenterology</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><a href="/compendium/hepatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mash" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">MASH</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><a href="/compendium/neurology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</a><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Small Cell Lung Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><a href="/compendium/pulmonology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</a><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div></div></div></div></div><div class="fixed top-0 w-[85vw] h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg" id="mobile-nav"><div class="w-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out"><div class="px-5 h-full"><div class="flex flex-col justify-between h-full w-full"><div><div class="mt-6 flex w-full items-center justify-between"><div class="border-b border-gray-200 pb-2 flex items-center justify-between w-full"><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-16 w-40 "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></div><button aria-label="close menu" class="focus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold"><svg width="18" height="18" viewBox="0 0 14 14" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M13 1L1 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path><path d="M1 1L13 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path></svg></button></div></div><ul role="list" class="flex flex-1 flex-col gap-y-7 mt-6"><li><ul role="list" class="-mx-2 space-y-1"><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Spotlight</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>News</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Video</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/podcasts"><span>Podcasts</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Conferences</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Journals</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Events</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Resources</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/continuing-education"><span>CE</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>About AJMC</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="https://one.ajmc.com/subscribe"><span>Subscribe</span></a></li></ul></li></ul><div class="flex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t"><a rel="noreferrer noopener" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="21" height="21" viewBox="12.65 12.65 118.02 118.02"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z" fill="#FFFFFF"></path></g></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="27" width="27" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.instagram.com/ajmcjournal/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="/rss"></a></div></div></div></div></div></div></nav></div></div><div class="container top-ad-div px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><hr class="mt-8 pt-8 -mb-4 pb-0"/><div id="multiple-myeloma" class="container mx-auto flex m-1 min-h-[57vh] px-4"><div class="flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="pb-24 my-2"><div class="flex"><h1 class="text-[19px] mt-1 md:mt-0 md:text-3xl mb-2">Multiple Myeloma</h1><div class="flex justify-center px-0 -mt-1 sm:-mt-2 align-center"></div></div><div class="w-full mb-2 border border-secondary"></div><div id="description-summary" class="text-sm text-gray-500"><div class="blockText_blockContent__TbCXh"><p class="pb-2">The <em>AJMC</em><sup class="text-inherit">®</sup> Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.</p></div><div class="clear-both"></div></div><div class="relative w-full py-4"><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">Latest News</h2></div><div class="grid grid-cols-1 gap-4 md:grid-cols-2"><div class="grid grid-cols-4 gap-3 mt-3 md:col-span-2"><a href="/view/rapid-iv-isatuximab-could-shift-care-practices-in-mm"><div class="w-full aspect-square overflow-hidden rounded-bl-[10%] md:rounded-bl-none md:rounded-tl-[10%]"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27250%27%20height=%27250%27/%3e"/></span><img alt="Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com" title="Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" class="object-cover w-full h-full" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover"/><noscript><img alt="Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com" title="Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F11ee9be36fc4be88ca66a17e7b37ebc45bb91d87-6048x4024.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=256&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F11ee9be36fc4be88ca66a17e7b37ebc45bb91d87-6048x4024.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F11ee9be36fc4be88ca66a17e7b37ebc45bb91d87-6048x4024.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="object-cover w-full h-full" loading="lazy"/></noscript></span></div></a><div class="col-span-3 space-y-1"><a class="font-bold text-md md:text-lg" href="/view/rapid-iv-isatuximab-could-shift-care-practices-in-mm">Rapid IV Isatuximab Could Shift Care Practices in MM</a><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz">Kyle Munz</a></span></div><p class="text-sm text-gray-500">February 13th 2025</p><p class="text-md block">Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike. </p></div></div><div class="grid grid-cols-4 gap-3 mt-3 "><a href="/view/prolonged-survival-in-mm-insights-from-the-largest-ongoing-us-registry"><div class="w-full aspect-square overflow-hidden rounded-bl-[10%]"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27250%27%20height=%27250%27/%3e"/></span><img alt="cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com" title="cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" class="object-cover w-full h-full" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:"/><noscript><img alt="cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com" title="cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F712ebcfc9e4a74f95125a3aa12de4fbfe735b3d7-10000x6600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=256&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F712ebcfc9e4a74f95125a3aa12de4fbfe735b3d7-10000x6600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F712ebcfc9e4a74f95125a3aa12de4fbfe735b3d7-10000x6600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:" class="object-cover w-full h-full" loading="lazy"/></noscript></span></div></a><div class="col-span-3 space-y-1"><a class="font-bold text-md md:text-lg" href="/view/prolonged-survival-in-mm-insights-from-the-largest-ongoing-us-registry">Prolonged Survival in MM: Insights From the Largest Ongoing US Registry</a><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz">Kyle Munz</a></span></div><p class="text-sm text-gray-500">February 7th 2025</p><p class="text-md hidden">The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics. </p></div></div><div class="grid grid-cols-4 gap-3 mt-3 "><a href="/view/dr-kirollos-hanna-an-argument-for-outpatient-bispecific-antibody-delivery"><div class="w-full aspect-square overflow-hidden rounded-bl-[10%]"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27250%27%20height=%27250%27/%3e"/></span><img alt="Kirollos Hanna, PharmD" title="Kirollos Hanna, PharmD" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" class="object-cover w-full h-full" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:"/><noscript><img alt="Kirollos Hanna, PharmD" title="Kirollos Hanna, PharmD" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=256&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ff698018f94ae99ba6f548f81a15462f47765951b-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:" class="object-cover w-full h-full" loading="lazy"/></noscript></span></div></a><div class="col-span-3 space-y-1"><a class="font-bold text-md md:text-lg" href="/view/dr-kirollos-hanna-an-argument-for-outpatient-bispecific-antibody-delivery">An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna</a><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz">Kyle Munz</a></span><span class="text-md "><span class="mr-1 italic"><br/></span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kirollow-hanna-pharmd">Kirollos Hanna, PharmD</a></span></div><p class="text-sm text-gray-500">January 25th 2025</p><p class="text-md hidden">Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings. </p></div></div><div class="grid grid-cols-4 gap-3 mt-3 "><a href="/view/study-of-prophylactic-tocilizumab-may-soon-add-talquetamab-arm"><div class="w-full aspect-square overflow-hidden rounded-bl-[10%]"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27250%27%20height=%27250%27/%3e"/></span><img alt="Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers" title="Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" class="object-cover w-full h-full" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:"/><noscript><img alt="Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers" title="Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffc139fac19e253d5099151f537e4fe6cddfd07a0-1600x1600.webp%3Ffit%3Dcrop%26auto%3Dformat&w=256&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffc139fac19e253d5099151f537e4fe6cddfd07a0-1600x1600.webp%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffc139fac19e253d5099151f537e4fe6cddfd07a0-1600x1600.webp%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:" class="object-cover w-full h-full" loading="lazy"/></noscript></span></div></a><div class="col-span-3 space-y-1"><a class="font-bold text-md md:text-lg" href="/view/study-of-prophylactic-tocilizumab-may-soon-add-talquetamab-arm">Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm</a><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/luke-halpern">Luke Halpern</a></span><span class="text-md "><span class="mr-1 italic"><br/></span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/laura-joszt">Laura Joszt, MA</a></span></div><p class="text-sm text-gray-500">January 22nd 2025</p><p class="text-md hidden"></p></div></div><div class="grid grid-cols-4 gap-3 mt-3 "><a href="/view/high-infection-risk-in-mm-insights-from-the-pre-immunotherapy-era"><div class="w-full aspect-square overflow-hidden rounded-bl-[10%]"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27250%27%20height=%27250%27/%3e"/></span><img alt="Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com" title="Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" class="object-cover w-full h-full" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:"/><noscript><img alt="Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com" title="Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7286b9eed868f8255bff55121b38c06742c21073-4032x2688.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=256&q=75 1x, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7286b9eed868f8255bff55121b38c06742c21073-4032x2688.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 2x" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7286b9eed868f8255bff55121b38c06742c21073-4032x2688.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:" class="object-cover w-full h-full" loading="lazy"/></noscript></span></div></a><div class="col-span-3 space-y-1"><a class="font-bold text-md md:text-lg" href="/view/high-infection-risk-in-mm-insights-from-the-pre-immunotherapy-era">High Infection Risk in MM: Insights From the Preimmunotherapy Era</a><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kyle-munz">Kyle Munz</a></span></div><p class="text-sm text-gray-500">January 21st 2025</p><p class="text-md hidden">Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies. </p></div></div></div></div><div class="border-b-[2px] border-[#EEE] my-4"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Continuing Medical Education</div><a href="/continuing-education" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-2416765321 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-2416765321 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2416765321 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2416765321 content-wrap"><span class="jsx-2416765321 py-3 text-sm text-gray-500 text-left"><i class="jsx-2416765321">February 23rd 2025</i></span><div class="jsx-2416765321 w-full h-fit mb-4"><p class="jsx-2416765321 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care</p></div><div class="jsx-2416765321 text-left text-[12px] text-[#000] py-6">1.5 Credits / Hematology, Hematologic Cancer, Oncology</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3925978785 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3925978785 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3925978785 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3925978785 content-wrap"><span class="jsx-3925978785 py-3 text-sm text-gray-500 text-left"><i class="jsx-3925978785">February 23rd 2025</i></span><div class="jsx-3925978785 w-full h-fit mb-4"><p class="jsx-3925978785 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy</p></div><div class="jsx-3925978785 text-left text-[12px] text-[#000] py-6">1.5 Credits / Oncology, Hematology, Hematologic Cancer</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-1505351878 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/closing-gaps-in-cll-care-managed-care-insights-and-strategies-sy5b?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-1505351878 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1505351878 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1505351878 content-wrap"><span class="jsx-1505351878 py-3 text-sm text-gray-500 text-left"><i class="jsx-1505351878">February 23rd 2025</i></span><div class="jsx-1505351878 w-full h-fit mb-4"><p class="jsx-1505351878 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Closing Gaps in CLL Care: Managed Care Insights and Strategies</p></div><div class="jsx-1505351878 text-left text-[12px] text-[#000] py-6">1.5 Credit / Hematologic Cancer, Oncology</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-644232506 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care-4c5t?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-644232506 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-644232506 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fjr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-644232506 content-wrap"><span class="jsx-644232506 py-3 text-sm text-gray-500 text-left"><i class="jsx-644232506">February 23rd 2025</i></span><div class="jsx-644232506 w-full h-fit mb-4"><p class="jsx-644232506 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care</p></div><div class="jsx-644232506 text-left text-[12px] text-[#000] py-6">1.0 Credit / Oncology, Hematology, Hematologic Cancer</div></div></div></a></div></div></div><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">More News</h2></div><div class="flex flex-wrap w-full pb-4"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/study-identifies-treatment-outcomes-impacting-hrqol-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5cb1b1799fda7be235244ab4533721830a9dea20-1280x853.jpg?fit=crop&auto=format" alt="Patient in hospital" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 15th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/study-identifies-treatment-outcomes-impacting-hrqol-in-multiple-myeloma">Study Identifies Treatment Outcomes Impacting HRQOL in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/study-identifies-treatment-outcomes-impacting-hrqol-in-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The review aimed to characterize the impacts of clinical response, delayed disease progression, and lines of therapy on health-related quality of life (HRQOL) for patients with multiple myeloma. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ixazomib-shows-pfs-benefit-across-age-and-frailty-subgroups-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/85c5cc435f9ad6f8516674d60db04a982ea9384d-1000x500.jpg?fit=crop&auto=format" alt="Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 12th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ixazomib-shows-pfs-benefit-across-age-and-frailty-subgroups-in-multiple-myeloma">Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ixazomib-shows-pfs-benefit-across-age-and-frailty-subgroups-in-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-fast-tracks-bcma-targeted-car-t-cell-therapy-for-r-r-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5e7e53531c567cf65c0116940955c2b7e0e99daa-268x188.jpg?fit=crop&auto=format" alt="FDA Fast Tracks BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 8th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-fast-tracks-bcma-targeted-car-t-cell-therapy-for-r-r-multiple-myeloma">FDA Fast Tracks BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jason-harris">Jason Harris</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-fast-tracks-bcma-targeted-car-t-cell-therapy-for-r-r-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/characteristics-of-relapse-affect-treatment-choices-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/6ded36225173042d811302852e27644955729b26-240x245.jpg?fit=crop&auto=format" alt="Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 3rd 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/characteristics-of-relapse-affect-treatment-choices-in-multiple-myeloma">Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/characteristics-of-relapse-affect-treatment-choices-in-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-benefit-vs-standard-regimens-in-heavily-pretreated-r-r-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/92b8d6a11dd16453fd5493233ba4e5549a4ae097-1200x800.jpg?fit=crop&auto=format" alt="CAR T cell" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 30th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-benefit-vs-standard-regimens-in-heavily-pretreated-r-r-multiple-myeloma">Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-benefit-vs-standard-regimens-in-heavily-pretreated-r-r-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/study-characterizes-infections-in-patients-treated-with-bispecific-antibodies-for-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/d616fdfdf8859d3a7c9f83f7d32c8f7f5d6c532e-2699x1518.jpg?fit=crop&auto=format" alt="Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 23rd 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/study-characterizes-infections-in-patients-treated-with-bispecific-antibodies-for-multiple-myeloma">Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/study-characterizes-infections-in-patients-treated-with-bispecific-antibodies-for-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-7"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/the-information-patients-receive-during-multiple-myeloma-treatment-may-differ-from-what-they-want-to-know"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/28668d9bbd3173fef97cb49c3785f65f9530e4df-5175x3386.jpg?fit=crop&auto=format" alt="Doctor speaking to patient" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 15th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/the-information-patients-receive-during-multiple-myeloma-treatment-may-differ-from-what-they-want-to-know">The Information Patients Receive During Multiple Myeloma Treatment May Differ From What They Want to Know</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/the-information-patients-receive-during-multiple-myeloma-treatment-may-differ-from-what-they-want-to-know"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dr-ajai-chari-patients-in-high-risk-subgroups-benefited-from-daratumumab-plus-triplet"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/67ca4b5ff59476fd318153a42915ca90d30d440e-130x170.jpg?fit=crop&auto=format" alt="Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 9th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dr-ajai-chari-patients-in-high-risk-subgroups-benefited-from-daratumumab-plus-triplet">Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dr-ajai-chari-patients-in-high-risk-subgroups-benefited-from-daratumumab-plus-triplet"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/screening-protocols-during-early-phase-of-covid-19-improved-outcomes-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/a4a846d81399f3b79dffead23818297dc2dc8d04-1200x600.jpg?fit=crop&auto=format" alt="Image of clinician running a multiple myeloma test: angellodeco - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 6th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/screening-protocols-during-early-phase-of-covid-19-improved-outcomes-in-mm">Screening Protocols During Early Phase of COVID-19 Improved Outcomes in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jaime-rosenberg">Jaime Rosenberg</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/screening-protocols-during-early-phase-of-covid-19-improved-outcomes-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Researchers retrospectively analyzed data from patients who visited 2 myeloma centers between March and October 2020, before vaccines were widely available but during large-scale implementation of regular screening processes. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/diagnosis-of-second-primary-malignancies-associated-with-prolonged-survival-among-patients-with-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/661fb0cf373b8ba0be010d838bc722bf422821f2-5472x3648.jpg?fit=crop&auto=format" alt="Multiple myeloma " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 3rd 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/diagnosis-of-second-primary-malignancies-associated-with-prolonged-survival-among-patients-with-mm">Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/matthew-gavidia">Matthew Gavidia</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/diagnosis-of-second-primary-malignancies-associated-with-prolonged-survival-among-patients-with-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Incidences of certain second primary malignancies were associated with increased overall survival among patients with multiple myeloma in a retrospective analysis of real-world data. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-superior-survival-in-hard-to-treat-patients-with-r-r-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/588a791508f7415f901139b3d5d3ea54c0b55704-1000x667.jpg?fit=crop&auto=format" alt="Image of red blood cells" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">March 1st 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-superior-survival-in-hard-to-treat-patients-with-r-r-mm">Ide-Cel Shows Superior Survival in Hard-to-Treat Patients With R/R MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jaime-rosenberg">Jaime Rosenberg</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ide-cel-shows-superior-survival-in-hard-to-treat-patients-with-r-r-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Idecabtagene vicleucel (ide-cel) reduced the risk of disease progression or death by 51% in patients with triple-class–exposed relapsed or refractory multiple myeloma (R/R MM). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/population-based-study-finds-increased-risk-of-stroke-heart-attack-in-patients-with-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5bdbbd61ca37e863c013eb9ac01a5a101b0b79ba-1200x600.jpg?fit=crop&auto=format" alt="Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 23rd 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/population-based-study-finds-increased-risk-of-stroke-heart-attack-in-patients-with-mm">Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/population-based-study-finds-increased-risk-of-stroke-heart-attack-in-patients-with-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-13"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/cases-of-scc-related-hospitalizations-increasing-among-patients-with-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/07e9f03995bb4832572c0e57331346bd60825bfd-1200x602.jpg?fit=crop&auto=format" alt="Image of a hospital corridor" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 15th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/cases-of-scc-related-hospitalizations-increasing-among-patients-with-multiple-myeloma">Cases of SCC-Related Hospitalizations Increasing Among Patients With Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jaime-rosenberg">Jaime Rosenberg</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/cases-of-scc-related-hospitalizations-increasing-among-patients-with-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Throughout this study's 12-year period, the average annual percent change showed an uptrend for all groups in hospitalization for spinal cord compression (SCC), and this was higher for non-Hispanic Black patients vs Hispanic patients and non-Hispanic White patients. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/preferred-treatment-sequencing-for-patients-with-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Preferred Treatment Sequencing for Patients with MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 8th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/preferred-treatment-sequencing-for-patients-with-mm">Preferred Treatment Sequencing for Patients with MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/preferred-treatment-sequencing-for-patients-with-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/partnering-academic-and-community-settings-to-optimize-care-for-patients-with-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Partnering Academic and Community Settings to Optimize Care for Patients with MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 8th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/partnering-academic-and-community-settings-to-optimize-care-for-patients-with-mm">Partnering Academic and Community Settings to Optimize Care for Patients with MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/partnering-academic-and-community-settings-to-optimize-care-for-patients-with-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Dr Nadeem provides community and clinical strategies to treat patients with MM.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/daily-physical-activity-has-positive-impact-on-immune-stimulation-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/74ae2eb7b76346c7dca9c40e7252e18ef7258610-1000x667.jpg?fit=crop&auto=format" alt="Image of exercise equipment" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 8th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/daily-physical-activity-has-positive-impact-on-immune-stimulation-in-mm">Daily Physical Activity Has Positive Impact on Immune Stimulation in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jaime-rosenberg">Jaime Rosenberg</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/daily-physical-activity-has-positive-impact-on-immune-stimulation-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The effects of physical activity and exercise have previously been reported, with data pointing to improvements in quality of life as well as such clinical markers as immune response in tumors</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/allogeneic-stem-cell-transplant-shows-minimal-os-pfs-benefits-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/f644f044981a59647daa7d201b84487c66cfee12-1279x853.jpg?fit=crop&auto=format" alt="Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 5th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/allogeneic-stem-cell-transplant-shows-minimal-os-pfs-benefits-in-mm">Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/allogeneic-stem-cell-transplant-shows-minimal-os-pfs-benefits-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Although allogenic stem cell transplant is increasingly used to treat multiple myeloma (MM) and other hematological conditions, there have been mixed efficacy results in the context of MM.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/including-mrd-status-reduces-uncertainty-in-long-term-survival-models-of-ndmm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/3d9dcde1c8a02070f0dded76bb52e5b8fc0b79b7-1200x600.jpg?fit=crop&auto=format" alt="Image of blood cells" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 3rd 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/including-mrd-status-reduces-uncertainty-in-long-term-survival-models-of-ndmm">Including MRD Status Reduces Uncertainty in Long-term Survival Models of NDMM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jaime-rosenberg">Jaime Rosenberg</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/including-mrd-status-reduces-uncertainty-in-long-term-survival-models-of-ndmm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-19"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/differences-in-care-between-academic-and-community-settings-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Differences in Care Between Academic and Community Settings in Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 1st 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/differences-in-care-between-academic-and-community-settings-in-multiple-myeloma">Differences in Care Between Academic and Community Settings in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/differences-in-care-between-academic-and-community-settings-in-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Dr Lipe shares disparities between academic and community practice settings for patients with MM.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/updates-in-nccn-guidelines-of-frontline-treatment-for-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Updates in NCCN Guidelines of Frontline Treatment for MM " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 1st 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/updates-in-nccn-guidelines-of-frontline-treatment-for-mm">Updates in NCCN Guidelines of Frontline Treatment for MM </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/updates-in-nccn-guidelines-of-frontline-treatment-for-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/griffin-daratumumab-plus-rvd-improved-responses-for-older-and-some-high-risk-patients-compared-with-triplet-alone-in-newly-diagnosed-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/e12b86c6334b0e40b3e09e96b16174283026cafd-673x378.jpg?fit=crop&auto=format" alt="Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 29th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/griffin-daratumumab-plus-rvd-improved-responses-for-older-and-some-high-risk-patients-compared-with-triplet-alone-in-newly-diagnosed-mm">Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/griffin-daratumumab-plus-rvd-improved-responses-for-older-and-some-high-risk-patients-compared-with-triplet-alone-in-newly-diagnosed-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/in-community-based-study-switching-to-ixazomib-in-newly-diagnosed-mm-brought-improved-responses-across-age-groups"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/661fb0cf373b8ba0be010d838bc722bf422821f2-5472x3648.jpg?fit=crop&auto=format" alt="Patient and Doctor" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 25th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/in-community-based-study-switching-to-ixazomib-in-newly-diagnosed-mm-brought-improved-responses-across-age-groups">In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/in-community-based-study-switching-to-ixazomib-in-newly-diagnosed-mm-brought-improved-responses-across-age-groups"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/product-preference-with-nccn-category-1-status"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Product Preference with NCCN Category 1 Status" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 25th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/product-preference-with-nccn-category-1-status">Product Preference with NCCN Category 1 Status</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/product-preference-with-nccn-category-1-status"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/providing-incentives-for-provider-adherence-to-mm-pathway"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Providing Incentives for Provider Adherence to MM Pathway" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 25th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/providing-incentives-for-provider-adherence-to-mm-pathway">Providing Incentives for Provider Adherence to MM Pathway</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/providing-incentives-for-provider-adherence-to-mm-pathway"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-25"></div></div></div><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/study-finds-ixazomib-beneficial-in-mm-patients-with-high-risk-cytogenic-traits"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/57ab17d634d1804c6b621d69ba7eeaefb7bfc5bf-300x200.jpg?fit=crop&auto=format" alt="Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 20th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/study-finds-ixazomib-beneficial-in-mm-patients-with-high-risk-cytogenic-traits">Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/study-finds-ixazomib-beneficial-in-mm-patients-with-high-risk-cytogenic-traits"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/clinical-collaboration-driving-mm-treatment-pathways"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Clinical Collaboration Driving MM Treatment Pathways" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 18th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/clinical-collaboration-driving-mm-treatment-pathways">Clinical Collaboration Driving MM Treatment Pathways</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/clinical-collaboration-driving-mm-treatment-pathways"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/clinical-pathways-guiding-treatment-selection-in-multiple-myeloma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Clinical Pathways Guiding Treatment Selection in Multiple Myeloma" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 18th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/clinical-pathways-guiding-treatment-selection-in-multiple-myeloma">Clinical Pathways Guiding Treatment Selection in Multiple Myeloma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/clinical-pathways-guiding-treatment-selection-in-multiple-myeloma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A panel of experts discuss the value of clinical pathways in MM disease management.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/disparities-in-multiple-myeloma-quality-improvement-initiative-reveals-gaps-between-oncology-providers-patients-in-views-of-costs-risk-of-treatments"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/ec0ad2dac13cc1703b788d3fcaefd1ae093fa212-500x624.png?fit=crop&auto=format" alt="Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 12th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/disparities-in-multiple-myeloma-quality-improvement-initiative-reveals-gaps-between-oncology-providers-patients-in-views-of-costs-risk-of-treatments">Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/interview-by-mary-caffrey">Interview by Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/disparities-in-multiple-myeloma-quality-improvement-initiative-reveals-gaps-between-oncology-providers-patients-in-views-of-costs-risk-of-treatments"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/utilizing-available-frontline-treatment-in-mm"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Utilizing Available Frontline Treatment in MM" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 11th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/utilizing-available-frontline-treatment-in-mm">Utilizing Available Frontline Treatment in MM</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/utilizing-available-frontline-treatment-in-mm"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Daratumumab can be an effective frontline MM treatment option.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/adequate-treatment-response-in-transplant-ineligible-mm-patients"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672.png?fit=crop&auto=format" alt="Adequate Treatment Response in Transplant-Ineligible MM Patients" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">January 11th 2023</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/adequate-treatment-response-in-transplant-ineligible-mm-patients">Adequate Treatment Response in Transplant-Ineligible MM Patients</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/adequate-treatment-response-in-transplant-ineligible-mm-patients"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div><div class="w-full text-center flex justify-center pb-24"><a class="px-4 py-2 border" href="/compendium/multiple-myeloma?page=4"><</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=1">1</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=2">2</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=3">3</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=4">4</a><a class="px-4 py-2 border-y border-r bg-primary text-white" href="/compendium/multiple-myeloma?page=5">5</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=6">6</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=7">7</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=8">8</a><a class="px-4 py-2 border-y border-r " href="/compendium/multiple-myeloma?page=9">9</a><a class="px-4 py-2 border-y border-r" href="/compendium/multiple-myeloma?page=10">10</a><a class="px-4 py-2 border-y border-r" href="/compendium/multiple-myeloma?page=6">></a></div></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK5KQXS" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class=" mx-auto flex"><div class="bg-[#00598D] xl:w-[70%] w-[70%] py-12 pl-auto"><div class="xxl:w-[75%] w-[90%] ml-auto"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27300%27%20height=%2744%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=384&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div><div class="flex"><div class="flex justify-between pt-6"><div class="w-[40%]"><div class="text-footer-text-color text-xs"><p>2 Commerce Drive<br/>Suite 100<br/>Cranbury, NJ 08512</p></div><div class="self-start py-6" style="display:flex;flex-wrap:wrap"><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="25" height="25" viewBox="1.41 1.41 252.9 252.9"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><polygon points="24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)"></polygon><path d="M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)" stroke-linecap="round"></path></g></svg></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.instagram.com/ajmcjournal/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='instagram' fill='#FFFFFF' fillRule='nonzero'> <path d='M305,256 C305,283.0625 283.0625,305 256,305 C228.9375,305 207,283.0625 207,256 C207,228.9375 228.9375,207 256,207 C283.0625,207 305,228.9375 305,256 Z' id='Path' /> <path d='M370.59375,169.304688 C368.238281,162.921875 364.480469,157.144531 359.597656,152.402344 C354.855469,147.519531 349.082031,143.761719 342.695312,141.40625 C337.515625,139.394531 329.734375,137 315.402344,136.347656 C299.898438,135.640625 295.25,135.488281 256,135.488281 C216.746094,135.488281 212.097656,135.636719 196.597656,136.34375 C182.265625,137 174.480469,139.394531 169.304688,141.40625 C162.917969,143.761719 157.140625,147.519531 152.402344,152.402344 C147.519531,157.144531 143.761719,162.917969 141.402344,169.304688 C139.390625,174.484375 136.996094,182.269531 136.34375,196.601562 C135.636719,212.101562 135.484375,216.75 135.484375,256.003906 C135.484375,295.253906 135.636719,299.902344 136.34375,315.40625 C136.996094,329.738281 139.390625,337.519531 141.402344,342.699219 C143.761719,349.085938 147.515625,354.859375 152.398438,359.601562 C157.140625,364.484375 162.914062,368.242188 169.300781,370.597656 C174.480469,372.613281 182.265625,375.007812 196.597656,375.660156 C212.097656,376.367188 216.742188,376.515625 255.996094,376.515625 C295.253906,376.515625 299.902344,376.367188 315.398438,375.660156 C329.730469,375.007812 337.515625,372.613281 342.695312,370.597656 C355.515625,365.652344 365.648438,355.519531 370.59375,342.699219 C372.605469,337.519531 375,329.738281 375.65625,315.40625 C376.363281,299.902344 376.511719,295.253906 376.511719,256.003906 C376.511719,216.75 376.363281,212.101562 375.65625,196.601562 C375.003906,182.269531 372.609375,174.484375 370.59375,169.304688 L370.59375,169.304688 Z M256,331.484375 C214.308594,331.484375 180.511719,297.691406 180.511719,256 C180.511719,214.308594 214.308594,180.515625 256,180.515625 C297.6875,180.515625 331.484375,214.308594 331.484375,256 C331.484375,297.691406 297.6875,331.484375 256,331.484375 Z M334.46875,195.171875 C324.726562,195.171875 316.828125,187.273438 316.828125,177.53125 C316.828125,167.789062 324.726562,159.890625 334.46875,159.890625 C344.210938,159.890625 352.109375,167.789062 352.109375,177.53125 C352.105469,187.273438 344.210938,195.171875 334.46875,195.171875 Z' id='Shape' /> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M402.113281,316.605469 C401.402344,332.253906 398.914062,342.9375 395.28125,352.289062 C387.644531,372.035156 372.035156,387.644531 352.289062,395.28125 C342.941406,398.914062 332.253906,401.398438 316.609375,402.113281 C300.933594,402.828125 295.925781,403 256.003906,403 C216.078125,403 211.074219,402.828125 195.394531,402.113281 C179.75,401.398438 169.0625,398.914062 159.714844,395.28125 C149.902344,391.589844 141.019531,385.804688 133.675781,378.324219 C126.199219,370.984375 120.414062,362.097656 116.722656,352.289062 C113.089844,342.941406 110.601562,332.253906 109.890625,316.609375 C109.167969,300.929688 109,295.921875 109,256 C109,216.078125 109.167969,211.070312 109.886719,195.394531 C110.597656,179.746094 113.082031,169.0625 116.714844,159.710938 C120.40625,149.902344 126.195312,141.015625 133.675781,133.675781 C141.015625,126.195312 149.902344,120.410156 159.710938,116.71875 C169.0625,113.085938 179.746094,110.601562 195.394531,109.886719 C211.070312,109.171875 216.078125,109 256,109 C295.921875,109 300.929688,109.171875 316.605469,109.890625 C332.253906,110.601562 342.9375,113.085938 352.289062,116.714844 C362.097656,120.40625 370.984375,126.195312 378.328125,133.675781 C385.804688,141.019531 391.59375,149.902344 395.28125,159.710938 C398.917969,169.0625 401.402344,179.746094 402.117188,195.394531 C402.832031,211.070312 403,216.078125 403,256 C403,295.921875 402.832031,300.929688 402.113281,316.605469 L402.113281,316.605469 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a></div><div class="text-footer-text-color text-xs"><p>© 2025 MJH Life Sciences<sup>®</sup> and AJMC®.<br/> All rights reserved.</p></div></div><div class="flex flex-row flex-wrap self-start w-[60%]"><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about-us">About</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contactus">Contact</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-boards">Editorial Boards</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com">Do Not Sell My Information</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms & Conditions</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div></div><div class="flex items-start mr-6 lg:mr-10"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2768%27/%3e"/></span><img alt="AJMC Managed Markets Network Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="AJMC Managed Markets Network Logo" srcSet="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=256&q=75 1x, /_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75 2x" src="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div></div></div></div><div class="w-[30%] bg-[#003767] flex items-center justify-center "><div class="flex flex-col justify-between "><a target="_self" rel="noopener noreferrer" class="my-2 px-8" href="/topic/center-on-health-equity-and-access"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="CH Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="CH Logo" srcSet="/_next/image?url=%2FCHA_Logo.png&w=384&q=75 1x, /_next/image?url=%2FCHA_Logo.png&w=640&q=75 2x" src="/_next/image?url=%2FCHA_Logo.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a><a target="_blank" rel="noopener noreferrer" class="my-2 px-8" href="https://www.centerforbiosimilars.com/"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="Center for Biosimilars Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Center for Biosimilars Logo" srcSet="/_next/image?url=%2FCB.png&w=384&q=75 1x, /_next/image?url=%2FCB.png&w=640&q=75 2x" src="/_next/image?url=%2FCB.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"name":"News","_id":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","is_active":true,"navParent":null,"_createdAt":"2020-04-14T13:26:14Z","_rev":"Yw6MEKZDMdk6hC2JCRdGN7","_updatedAt":"2020-04-14T13:26:21Z","subQuery":[{"url":"/news","navParent":{"_type":"reference","_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b"},"_type":"mainNavigation","children":[],"is_active":true,"_createdAt":"2020-04-14T13:30:35Z","_rev":"sBk7YzjWMuBuhiatU3YIhQ","name":"All News","_updatedAt":"2020-04-14T13:30:35Z","_id":"1376963d-32e8-4647-bb5e-59c984e35893"},{"_rev":"QxOJBWa4XErmibN6Cb5OcA","children":[],"_type":"mainNavigation","_updatedAt":"2020-04-14T13:30:57Z","_createdAt":"2020-04-14T13:30:57Z","url":"/press-release","_id":"2af5da5e-78c2-42c8-90b8-3900f8c89889","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"name":"Press Releases","is_active":true},{"url":"/approvals-launches","is_active":true,"_createdAt":"2021-07-29T12:15:49Z","_updatedAt":"2022-01-07T20:44:44Z","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_type":"mainNavigation","_id":"854a1ad1-9831-4387-bda9-ffb93a074ace","name":"Product Approvals and Launches","_rev":"jvOgZ3KZdbRHfWlt9ePmOA","children":[]}],"sortOrder":1,"_type":"mainNavigation"},{"is_active":true,"_type":"mainNavigation","_createdAt":"2020-04-14T13:26:30Z","_rev":"rcwwj6TiN2Q0ymhqDzIFjO","_id":"821e259a-db55-4862-985a-5cd089bbf894","navParent":null,"sortOrder":2,"_updatedAt":"2024-05-24T16:36:15Z","name":"Video","subQuery":[{"_rev":"rcwwj6TiN2Q0ymhqDzJ8ty","url":"/video-hub","_updatedAt":"2024-05-24T16:52:54Z","children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","name":"All Video Types","is_active":true,"_id":"f51d85fa-cabc-4c7d-85d0-11301088b7f6","_createdAt":"2024-05-24T16:37:06Z","sortOrder":1},{"_type":"mainNavigation","name":"AJMC TV","children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"LJrwYxwtzLC9JsOYMk8TBr","_updatedAt":"2024-05-28T19:38:54Z","url":"/interviews","_id":"a99a3683-5173-46b3-94b0-21b7d6b06a24","_createdAt":"2024-05-24T16:38:14Z","is_active":true},{"is_active":true,"name":"Guidelines","url":"/guidelines","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","_id":"9affe463-8f89-4d72-b806-62281069ebba","_updatedAt":"2025-02-14T19:41:11Z","children":[],"_createdAt":"2025-02-14T19:40:54Z","_rev":"4IWvQAHLC63503PAHcJfUU"},{"url":"/insights","_createdAt":"2020-04-14T13:43:45Z","name":"Insights","_id":"b03ccbf6-6387-48de-8edc-4f1f23debe40","is_active":true,"_updatedAt":"2020-04-14T13:43:45Z","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"Yw6MEKZDMdk6hC2JCRda8Z","_type":"mainNavigation","children":[]},{"_updatedAt":"2020-04-14T13:44:19Z","_createdAt":"2020-04-14T13:44:19Z","children":[],"_type":"mainNavigation","url":"/onlocation","_id":"f3d69d10-636b-4927-8ff4-4f54fabc940a","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"k6N5FycA5UhVnvpzSEa3Rp","name":"OnLocation"},{"is_active":true,"children":[],"_rev":"37PW14Mg02p9z7FTF1SGE9","_type":"mainNavigation","name":"Payer Perspectives","_updatedAt":"2022-10-05T15:29:11Z","_createdAt":"2022-10-05T15:29:11Z","url":"/payer-perspectives","navParent":{"_type":"reference","_ref":"821e259a-db55-4862-985a-5cd089bbf894"},"_id":"d4e3d69c-8a07-4191-af89-27d7e838af08"},{"name":"Peer Exchange","_id":"8f602f1e-1840-4c32-8cdb-9a26d6c0e873","is_active":true,"url":"/peer-exchange","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2020-04-14T13:44:43Z","_rev":"VdTcsTJkAuZveXGf2i9Pes","_type":"mainNavigation","_updatedAt":"2020-04-14T13:44:43Z","children":[]},{"_id":"0f532685-cd4c-4350-89cd-b8a388e6495b","_type":"mainNavigation","name":"Post Conference Perspectives","url":"/post-conference-perspectives","_rev":"Jz2W7keLhiw1UYkGHgA51N","_updatedAt":"2024-05-24T18:27:43Z","is_active":true,"children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2024-05-24T18:27:43Z"},{"is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_type":"mainNavigation","children":[],"_updatedAt":"2020-12-01T22:43:26Z","_createdAt":"2020-12-01T22:43:10Z","_rev":"y3lsbm3yQTliOnC9CU5TiR","_id":"bbc55ff8-1532-475e-9f51-f9d5eb39e369","url":"/stakeholder-summit","name":"Stakeholder Summit"}]},{"_type":"mainNavigation","name":"Podcasts","url":"/podcasts","is_active":true,"_createdAt":"2024-05-24T16:40:58Z","_rev":"rcwwj6TiN2Q0ymhqDzIUb7","sortOrder":3,"_id":"4939ee15-ae6f-4aba-8481-9ee27ce729d3","_updatedAt":"2024-05-24T16:41:18Z","navParent":null,"subQuery":[]},{"_id":"6841664a-93f2-4f56-8760-836ec9c7b483","_createdAt":"2020-04-14T13:27:01Z","_updatedAt":"2024-05-24T16:41:40Z","navParent":null,"_type":"mainNavigation","is_active":true,"sortOrder":4,"_rev":"rcwwj6TiN2Q0ymhqDzIVAU","subQuery":[{"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_rev":"pI9SawGKsTP14Lioy589Kx","_updatedAt":"2020-08-21T22:11:23Z","children":[],"is_active":true,"_createdAt":"2020-06-12T15:17:29Z","_type":"mainNavigation","url":"/latest-conference","sortOrder":1,"name":"Conference Coverage","_id":"f45b532b-23e3-4b44-8d7f-2f3c13c9ae81"},{"_rev":"FxFuWbqTkFGbPWgBBSR6xp","_type":"mainNavigation","is_active":true,"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_updatedAt":"2020-06-12T15:19:26Z","_createdAt":"2020-06-12T15:18:28Z","sortOrder":2,"name":"Conference Listing","url":"/conference","children":[],"_id":"004461ae-46cb-45ef-916e-f03c6d99d6d3"},{"children":[],"_createdAt":"2024-07-03T19:00:13Z","_rev":"ZU3dXbR1BZtBbbPuRGxz53","sortOrder":3,"_type":"mainNavigation","_id":"a006d0df-0cc9-4386-abfb-b1931a3918d4","url":"/post-conference-perspectives","is_active":true,"name":"Post Conference Perspectives","_updatedAt":"2024-07-03T19:00:13Z","navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"}}],"name":"Conferences"},{"navParent":null,"_type":"mainNavigation","_id":"94f13109-c3cc-47b5-bf49-96ed727c8150","_createdAt":"2020-04-14T13:27:20Z","subQuery":[{"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-05-04T21:06:00Z","sortOrder":1,"_updatedAt":"2024-05-24T16:42:23Z","_rev":"rcwwj6TiN2Q0ymhqDzIVyQ","_type":"mainNavigation","_id":"48193abd-ecf4-4c90-b0ae-984ca2be88c9","children":[],"is_active":true,"name":"All Journals","url":"/publications"},{"url":"/publications/issue","_rev":"rcwwj6TiN2Q0ymhqDzIWug","name":"The American Journal of Managed Care","_id":"08081ddf-ffd8-4b17-a2ff-dfe6a0ac64a3","is_active":true,"_createdAt":"2020-04-14T13:55:29Z","children":[],"sortOrder":2,"_updatedAt":"2024-05-24T16:42:39Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_type":"mainNavigation"},{"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:01Z","_type":"mainNavigation","_id":"47782239-2714-4bd1-99e6-750443bd39ea","_updatedAt":"2024-09-16T13:23:11Z","name":"Population Health, Equity \u0026 Outcomes","sortOrder":3,"_rev":"4fso9RuTzczLhlxmnMQ1bu","children":[],"url":"/publications/ajac"},{"is_active":true,"url":"/publications/evidence-based-oncology","children":[],"_type":"mainNavigation","_rev":"uJbbwQWkLESsncBrcLL4uf","_id":"b99cc54f-5801-46e9-bd20-e690623ed12c","_updatedAt":"2024-05-24T16:43:12Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:21Z","sortOrder":4,"name":"Evidence-Based Oncology"},{"_type":"mainNavigation","_id":"6e7e3485-ef8b-40e3-8320-3c434df6bbb5","_createdAt":"2024-05-23T20:59:41Z","sortOrder":5,"_updatedAt":"2024-05-24T16:43:26Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"name":"About Supplements and Featured Publications","children":[],"is_active":true,"url":"/supplement","_rev":"rcwwj6TiN2Q0ymhqDzIY1L"},{"_updatedAt":"2024-05-24T16:43:32Z","is_active":true,"children":[],"sortOrder":6,"_rev":"uJbbwQWkLESsncBrcLL5w0","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:51Z","url":"/publications/supplement","_type":"mainNavigation","name":"Supplements and Featured Publications Issues","_id":"a2112c87-8e92-4b64-b42d-3117117f67a3"},{"is_active":true,"_createdAt":"2023-03-14T13:29:11Z","_type":"mainNavigation","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"sortOrder":7,"url":"/submit-a-manuscript","_rev":"rcwwj6TiN2Q0ymhqDzIYDp","children":[],"name":"Submit a Manuscript","_id":"fa8c9edc-3d32-4e9e-b68b-47d5c15694a5","_updatedAt":"2024-05-24T16:43:38Z"}],"_rev":"uJbbwQWkLESsncBrcLL0hr","name":"Journals","is_active":true,"_updatedAt":"2024-05-24T16:41:49Z","sortOrder":5},{"_type":"mainNavigation","name":"Events","_createdAt":"2020-04-14T13:27:17Z","is_active":true,"subQuery":[{"_createdAt":"2024-05-24T16:44:43Z","_type":"mainNavigation","name":"Institute for Value-Based Medicine","_id":"de4fe195-3db9-4d12-842d-f26100fbea5b","_updatedAt":"2024-05-24T18:26:23Z","children":[],"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHgA4Yf","url":"/ivbmevents","navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"}},{"_updatedAt":"2024-05-24T18:26:42Z","url":"https://pcoc.ajmc.com/","is_active":true,"navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"name":"Patient-Centered Oncology Care","_createdAt":"2024-05-24T16:45:02Z","_type":"mainNavigation","children":[],"_id":"dddfc37d-8958-4e0a-91e3-0634bb6502a3","_rev":"Jz2W7keLhiw1UYkGHgA4eP"}],"sortOrder":6,"_id":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_updatedAt":"2020-05-08T20:03:10Z","_rev":"8ZvheBjSwe5Dc4gCmgsR0M","url":"/events","navParent":null},{"_rev":"rcwwj6TiN2Q0ymhqDzIdco","subQuery":[{"is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"sortOrder":1,"_rev":"rcwwj6TiN2Q0ymhqDzIfXP","_type":"mainNavigation","_updatedAt":"2024-05-24T16:46:13Z","children":[],"name":"Interactive Tools","_id":"4a08b5fc-379c-4952-bec1-0d9dacb11170","url":"/interactive-tools","_createdAt":"2020-04-14T13:51:39Z"},{"is_active":true,"sortOrder":3,"name":"Formulary Central","_id":"db1214fd-aa4d-4f12-a6f5-72d7e3927ce9","_updatedAt":"2025-02-14T19:42:02Z","_rev":"4IWvQAHLC63503PAHcJhJi","children":[],"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_createdAt":"2025-02-14T19:41:37Z","_type":"mainNavigation","url":"/formulary"},{"_updatedAt":"2024-05-23T20:32:07Z","_createdAt":"2020-10-16T13:03:47Z","_rev":"rcwwj6TiN2Q0ymhqDyFVrf","url":"/clinical-spotlight","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_id":"43960f88-0c8d-404b-b9d9-d90432c2c516","_type":"mainNavigation","name":"Clinical Spotlight","is_active":true,"children":[]},{"name":"Microsites","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_id":"38aa3af0-8a34-4ae6-898c-37214580d384","url":"/custom-email","_updatedAt":"2024-05-24T16:46:44Z","children":[],"is_active":true,"_createdAt":"2024-05-24T16:46:44Z","_type":"mainNavigation","_rev":"rcwwj6TiN2Q0ymhqDzIhDR"},{"name":"Sponsored Content","children":[],"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDzIiDr","_id":"d0b0683f-18e1-4e75-89fd-fb4e578a562f","_updatedAt":"2024-05-24T16:47:05Z","_type":"mainNavigation","url":"/sponsored","is_active":true,"_createdAt":"2024-05-24T16:47:05Z"}],"name":"Resources","_id":"86b03e38-f3d2-41d1-89e7-c3175c571a55","is_active":true,"navParent":null,"_type":"mainNavigation","_createdAt":"2020-04-14T13:29:34Z","sortOrder":7,"_updatedAt":"2024-05-24T16:45:37Z"},{"_rev":"LtkInV1jlQdtEIFjVpi9sG","_id":"621fccf5-dcdb-40a9-af70-9bf3ccf79278","_updatedAt":"2024-08-27T15:31:04Z","navParent":null,"subQuery":[],"url":"/continuing-education","_createdAt":"2020-04-14T14:00:08Z","sortOrder":8,"_type":"mainNavigation","name":"CE","is_active":true},{"navParent":null,"_updatedAt":"2024-05-24T16:48:11Z","sortOrder":9,"_type":"mainNavigation","name":"About AJMC","is_active":true,"subQuery":[{"_rev":"Jz2W7keLhiw1UYkGHgBp6D","_type":"mainNavigation","_id":"be637b3b-f72a-4049-91b8-409809b2d815","name":"AJMC Staff","url":"/editorial","_updatedAt":"2024-05-24T19:05:57Z","children":[],"is_active":true,"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_createdAt":"2024-05-24T19:05:57Z"},{"is_active":true,"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDzIn5Y","_id":"5298152f-5135-4c2c-a46e-a14ad0300bf4","_updatedAt":"2024-05-24T16:48:30Z","url":"/anniversary","_createdAt":"2024-05-24T16:48:30Z","_type":"mainNavigation","name":"Anniversary","children":[]},{"_rev":"AGf4LvcO2r7q1La1cjR7dD","name":"Seema Sonnad Award","_updatedAt":"2024-07-23T13:38:48Z","_createdAt":"2024-05-24T18:24:23Z","children":[],"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_id":"28d33143-d9a9-45bd-af63-bed8d2198118","is_active":true,"_type":"mainNavigation","url":"/about/seema-sonnad-nomination"},{"children":[],"name":"Strategic Alliance Partners","url":"/partners","_createdAt":"2024-05-24T16:49:00Z","is_active":true,"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_rev":"uJbbwQWkLESsncBrcLLVEZ","_type":"mainNavigation","_updatedAt":"2024-05-24T16:49:00Z","_id":"acb7dc53-dfab-462a-b2e9-b0cfc8675da4"}],"_createdAt":"2024-05-24T16:48:11Z","_rev":"rcwwj6TiN2Q0ymhqDzIlc0","_id":"c14e4637-909c-4bf6-bf81-64eeb6005352"},{"name":"Subscribe","navParent":null,"subQuery":[],"url":"https://one.ajmc.com/subscribe","blank":true,"is_active":true,"sortOrder":9,"_rev":"gFXie0Ldruy1o91XppbLLd","_id":"1e279576-0b33-4e57-8782-b6b1edbf68da","_type":"mainNavigation","_updatedAt":"2024-03-11T14:58:15Z","_createdAt":"2020-06-22T20:56:33Z"}],"sub_menu":[{"navParent":null,"name":"Specialty Area","_updatedAt":"2024-05-24T05:08:37Z","url":"/compendium","_createdAt":"2020-04-14T14:04:25Z","subQuery":[{"_type":"subNavigation","name":"Biosimilars","_id":"aa3904f3-c0d8-495d-a77f-afcc41f27045","is_active":true,"_updatedAt":"2024-05-24T05:06:44Z","navParent":{"_type":"reference","_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e"},"_rev":"Jz2W7keLhiw1UYkGHfbM3A","url":"/compendium/biosimilars","_createdAt":"2024-05-24T05:06:44Z","children":[]},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:30:27Z","_type":"subNavigation","name":"Cardiorenalmetabolic","_id":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_updatedAt":"2025-01-17T17:17:34Z","is_active":true,"children":[{"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"is_active":true,"_createdAt":"2024-05-24T05:30:54Z","_rev":"Jz2W7keLhiw1UYkGHfbquf","_type":"subNavigation","name":"Cardiovascular","_id":"c3566f20-e7c6-4b38-bf9f-7d52055698b1","_updatedAt":"2024-05-24T05:30:54Z","url":"/compendium/cardiovascular"},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbumO","_type":"subNavigation","url":"/compendium/ckd","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:32:42Z","name":"Chronic Kidney Disease","_id":"f3a69e16-dc38-4135-886e-d70e18532bf4","_updatedAt":"2024-05-24T05:32:42Z"},{"name":"Diabetes","_id":"79c02dc8-3c2d-451b-9797-008b25d61d4d","url":"/compendium/diabetes","is_active":true,"navParent":{"_type":"reference","_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab"},"_createdAt":"2024-05-24T05:31:14Z","_rev":"Jz2W7keLhiw1UYkGHfbrEl","_updatedAt":"2024-05-24T05:31:14Z","_type":"subNavigation"},{"is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:31:38Z","_type":"subNavigation","url":"/compendium/heart-failure","_rev":"Jz2W7keLhiw1UYkGHfbrQF","name":"Heart Failure","_id":"84c7dd54-fb21-4bc5-86bc-9bbf39a7f836","_updatedAt":"2024-05-24T05:31:38Z"},{"url":"/compendium/type1diabetes","is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_type":"subNavigation","_id":"aadd9bdc-4dd1-4ac1-be4f-2afb4315b6cb","_updatedAt":"2024-05-24T05:32:00Z","_createdAt":"2024-05-24T05:32:00Z","_rev":"Jz2W7keLhiw1UYkGHfbsbS","name":"Type 1 Diabetes"}],"_rev":"aW9ZvtW6d5z6x1Negj6Jxc","url":"/compendium/cardiorenalmetabolic"},{"_updatedAt":"2024-05-24T05:10:35Z","url":"/compendium/dermatology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"is_active":true,"_createdAt":"2024-05-24T05:10:35Z","_type":"subNavigation","children":[{"_id":"04523862-a8a1-4626-b288-95b3d4114267","_updatedAt":"2024-05-24T05:12:43Z","_createdAt":"2024-05-23T21:42:49Z","_rev":"Jz2W7keLhiw1UYkGHfbTPe","url":"/compendium/alopecia","is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_type":"subNavigation","name":"Alopecia"},{"is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:02Z","_rev":"Jz2W7keLhiw1UYkGHfbSvV","_type":"subNavigation","name":"Atopic Dermatitis","_id":"637a0b1e-1b12-42bf-81a3-e6db5a997021","_updatedAt":"2024-05-24T05:12:02Z","url":"/compendium/atopic-dermatitis"},{"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:30Z","_rev":"Jz2W7keLhiw1UYkGHfbTJu","_type":"subNavigation","name":"Psoriasis","_updatedAt":"2024-05-24T05:12:36Z","url":"/compendium/psoriasis","is_active":true,"_id":"a9dcce80-4f29-488e-b7ef-51f0fb562a5a"}],"_id":"7599f50b-36ff-42a5-8d72-82814db9b988","_rev":"Jz2W7keLhiw1UYkGHfbSVf","name":"Dermatology"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Gastroenterology","_updatedAt":"2024-11-25T15:12:43Z","_createdAt":"2024-11-25T15:12:24Z","url":"/compendium/gastroenterology","children":[],"_rev":"I64rexdokWxpEDPZsg5Lox","_type":"subNavigation","_id":"3c425964-bf72-4f93-bfbc-4d44d42dc2fe","is_active":true},{"_id":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","url":"/compendium/hematology","_type":"subNavigation","_updatedAt":"2024-05-24T05:13:48Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:13:48Z","name":"Hematology","children":[{"name":"ALL/AML","url":"/compendium/all","_rev":"Iat2IZiT321TmGHwkF66wB","_id":"d79f2b30-e7f2-4915-bef8-1a73a9190a91","_updatedAt":"2024-05-29T15:28:26Z","is_active":true,"navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"},"_createdAt":"2024-05-29T15:28:26Z","_type":"subNavigation"},{"_id":"664a6ece-64dd-41f8-87a0-7f5a47323c3b","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_type":"subNavigation","_updatedAt":"2024-05-29T15:27:46Z","url":"/compendium/cll","is_active":true,"_createdAt":"2024-05-29T15:26:57Z","_rev":"Iat2IZiT321TmGHwkF65Md","name":"CLL/SLL"},{"name":"GVHD","_id":"32cf626c-1ce6-4fb5-9dd7-088522dc46e6","_updatedAt":"2024-05-29T15:28:51Z","url":"/compendium/gvhd","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Iat2IZiT321TmGHwkF67tn","is_active":true,"_createdAt":"2024-05-29T15:28:51Z","_type":"subNavigation"},{"_rev":"Jz2W7keLhiw1UYkGHfbUDt","_type":"subNavigation","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:14:15Z","name":"Hemophilia","_id":"4dd2ce64-8f4d-4285-bc1a-ec40ffc99b51","_updatedAt":"2024-05-24T05:14:15Z","url":"/compendium/hemophilia"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:45:17Z","_rev":"Iat2IZiT321TmGHwkF6NtX","name":"Multiple Myeloma","_updatedAt":"2024-05-29T15:35:07Z","_type":"subNavigation","_id":"84e2d674-0fe1-4bd1-9d97-2f8bc8589ba0","url":"/compendium/multiple-myeloma","is_active":true},{"is_active":true,"_rev":"Iat2IZiT321TmGHwkF6a5X","_type":"subNavigation","name":"Myelodysplastic Syndromes","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:45:36Z","_id":"3a327f90-a5fc-4d87-9a18-02f54cb40b8e","_updatedAt":"2024-05-29T15:35:22Z","url":"/compendium/myelodysplastic-syndromes"},{"_type":"subNavigation","name":"Myeloproliferative Neoplasms","_id":"a6003c4f-e7f0-422a-8129-49a2d78eb113","_updatedAt":"2024-06-05T20:02:27Z","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"url":"/compendium/mpn","is_active":true,"_createdAt":"2024-05-29T15:29:21Z","_rev":"Up1TL5YPo1fhI8V2tpNnMb"},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"rmdpbbz4U7GL9ExaGp96DY","_id":"fc247a6b-0b33-4e18-ae78-56e677c6bb18","url":"/compendium/nhl","is_active":true,"_createdAt":"2024-05-24T05:43:54Z","_type":"subNavigation","name":"Non-Hodgkin Lymphoma","_updatedAt":"2024-06-25T17:42:12Z"},{"_type":"subNavigation","url":"/compendium/rareblood","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbUPN","name":"Rare Blood","_id":"85e2fc3e-ac5c-4b47-8b14-411d730d20d9","_updatedAt":"2024-05-24T05:14:40Z","is_active":true,"_createdAt":"2024-05-24T05:14:40Z"}],"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbU3q"},{"_type":"subNavigation","_id":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","name":"Hepatology","children":[{"_createdAt":"2024-05-24T05:34:54Z","_rev":"Jz2W7keLhiw1UYkGHfbwkP","_type":"subNavigation","_updatedAt":"2024-05-24T05:34:54Z","url":"/compendium/liver-cancer","navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"},"name":"Liver","_id":"2aefee8c-db97-4e7d-b600-efb48e6bcb6c","is_active":true}],"url":"/compendium/hepatology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"IZ4ZA8avncRcTDvyuUbX0o","_updatedAt":"2025-01-17T17:19:10Z","is_active":true,"_createdAt":"2024-05-24T05:34:29Z"},{"name":"Immunology","_updatedAt":"2024-05-24T05:23:19Z","children":[{"is_active":true,"_createdAt":"2024-05-24T05:23:39Z","_rev":"Jz2W7keLhiw1UYkGHfbkp8","name":"Autoimmune","url":"/compendium/autoimmune","navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_type":"subNavigation","_id":"b3daefd0-0ac3-4be2-ad23-f9c3fa37cf37","_updatedAt":"2024-05-24T05:23:39Z"},{"name":"Inflammation","_updatedAt":"2024-05-24T05:23:59Z","url":"/compendium/Inflammation","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:23:59Z","_type":"subNavigation","_id":"6016d41d-9d43-49fa-99b6-7caca304f30d","_rev":"Jz2W7keLhiw1UYkGHfbkzB"},{"_updatedAt":"2024-05-24T05:24:47Z","url":"/compendium/lupus","_createdAt":"2024-05-24T05:24:47Z","_type":"subNavigation","name":"Lupus","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbmd6","_id":"b537fcea-aea3-40ca-83c1-0907fdc9ccb5"},{"_id":"ef6c4efc-5932-4148-b626-cbf42e1c49c3","_updatedAt":"2024-05-24T05:25:23Z","navParent":{"_type":"reference","_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797"},"_rev":"Jz2W7keLhiw1UYkGHfbn7F","name":"Myasthenia Gravis","url":"/compendium/myasthenia-gravis","is_active":true,"_createdAt":"2024-05-24T05:25:23Z","_type":"subNavigation"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","url":"/compendium/immunology","_createdAt":"2024-05-24T05:23:19Z","_id":"1b1e3727-8b82-42da-9a62-b20472b9c797","_rev":"Jz2W7keLhiw1UYkGHfbkam","is_active":true},{"url":"/compendium/infectious-disease","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","name":"Infectious Disease","_id":"b62af616-818b-4bda-b606-bd64287f9a85","_updatedAt":"2024-05-24T05:35:38Z","_createdAt":"2024-05-24T05:35:38Z","_rev":"Jz2W7keLhiw1UYkGHfcA9Y","children":[{"is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyeyP3","_type":"subNavigation","name":"COVID-19","_updatedAt":"2024-05-24T05:36:03Z","url":"/compendium/covid-19","_createdAt":"2024-05-24T05:36:03Z","_id":"ffcd30d0-169f-4a8f-9f01-616142f33712"},{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcAxn","_type":"subNavigation","name":"HIV","is_active":true,"_createdAt":"2024-05-24T05:36:22Z","_id":"a53004c6-9fe2-4b9c-a86a-ad74f9204b3a","_updatedAt":"2024-05-24T05:36:29Z","url":"/compendium/hiv"},{"_id":"ca70e9ab-a981-4629-a766-81f7890b3977","url":"/compendium/rsv","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:37:06Z","_type":"subNavigation","name":"RSV","_updatedAt":"2024-05-24T05:37:06Z","_rev":"rcwwj6TiN2Q0ymhqDyezNO"},{"_createdAt":"2024-05-24T05:37:53Z","_type":"subNavigation","_id":"a0ec0591-b4a1-4723-b984-b681c957523f","_updatedAt":"2024-05-24T05:37:53Z","url":"/compendium/vaccines","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcFFM","name":"Vaccines"}]},{"is_active":true,"_rev":"aW9ZvtW6d5z6x1Negj3Mh7","_id":"28c2b871-3034-43e1-b2b3-613ceefea3f1","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"MASH","_updatedAt":"2025-01-17T17:02:58Z","url":"/compendium/mash","children":[],"_createdAt":"2025-01-15T14:59:47Z","_type":"subNavigation"},{"children":[{"_updatedAt":"2024-05-24T05:38:58Z","_id":"efcab5a8-97d8-4f5a-ba99-0a0555531f5a","url":"/compendium/mdd","is_active":true,"navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_createdAt":"2024-05-24T05:38:58Z","_rev":"rcwwj6TiN2Q0ymhqDyf7Qk","_type":"subNavigation","name":"Major Depressive Disorder"},{"_rev":"rcwwj6TiN2Q0ymhqDyf96m","_type":"subNavigation","name":"Sleep","_id":"f52dbfa9-aefe-4d21-b432-7052a136ae98","url":"/compendium/sleep","is_active":true,"navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_createdAt":"2024-05-24T05:39:18Z","_updatedAt":"2024-05-24T05:39:18Z"}],"name":"Mental Health","url":"/compendium/mental-health","_type":"subNavigation","_createdAt":"2024-05-24T05:38:33Z","_id":"db67ff69-2c58-4931-ad3d-767a636e38b0","_rev":"rcwwj6TiN2Q0ymhqDyf4PU","_updatedAt":"2024-05-24T05:38:33Z","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"is_active":true,"_createdAt":"2024-05-24T05:39:38Z","_type":"subNavigation","_id":"bafe1c52-a8b5-4786-bcee-668409d14a11","_updatedAt":"2025-01-17T17:18:32Z","_rev":"wsljz10lCZachwUMK3D8Fg","name":"Neurology","url":"/compendium/neurology","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfERb","_type":"subNavigation","_updatedAt":"2024-05-24T05:40:18Z","url":"/compendium/dmd","_createdAt":"2024-05-24T05:40:18Z","name":"Duchenne Muscular Dystrophy","_id":"3e24f5af-027e-4f0b-a7e2-a3ffaf756a35"},{"_updatedAt":"2024-05-24T05:40:38Z","url":"/compendium/epilepsy","is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:40:30Z","_rev":"rcwwj6TiN2Q0ymhqDyfIhq","_type":"subNavigation","name":"Epilepsy","_id":"d4e270df-2a59-4109-a7be-9c10f80722a7"},{"_type":"subNavigation","_id":"7539f9b5-8f2a-4e1b-a10f-8cc748cd1489","_updatedAt":"2024-05-24T05:41:07Z","url":"/compendium/multiple-sclerosis","is_active":true,"name":"Multiple Sclerosis","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:07Z","_rev":"rcwwj6TiN2Q0ymhqDyfJRc"},{"is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:29Z","name":"Parkinson Disease","_rev":"rcwwj6TiN2Q0ymhqDyfJiG","_type":"subNavigation","_id":"90ebd8e7-e6d1-4128-8010-0b205fedb430","_updatedAt":"2024-05-24T05:41:29Z","url":"/compendium/parkinson"}]},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","name":"Obesity","children":[],"_createdAt":"2024-09-04T14:25:34Z","url":"/compendium/obesity","_rev":"B2kOGngERQtEUh1WG5WXvd","_updatedAt":"2024-09-04T14:25:34Z","is_active":true,"_id":"fe48de19-78d2-4ed0-83fa-8884fb340de2"},{"url":"/compendium/oncology","is_active":true,"_createdAt":"2024-05-24T05:41:55Z","_rev":"rcwwj6TiN2Q0ymhqDyfKov","name":"Oncology","children":[{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfMpl","_type":"subNavigation","name":"Breast Cancer","_id":"03ea9371-55cd-42e2-b300-7078b94ff467","url":"/compendium/breast-cancer","_createdAt":"2024-05-24T05:42:17Z","_updatedAt":"2024-05-24T05:42:17Z"},{"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfatY","_type":"subNavigation","name":"Cholangiocarcinoma","_updatedAt":"2024-05-24T05:42:35Z","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:42:35Z","_id":"8b57fc91-4191-420c-a224-cb869f8fa0d7","url":"/compendium/cholangiocarcinoma"},{"is_active":true,"_createdAt":"2024-05-24T05:43:23Z","_rev":"Jz2W7keLhiw1UYkGHfcTh6","_type":"subNavigation","name":"Colorectal Cancer","_updatedAt":"2024-05-24T05:43:23Z","url":"/compendium/colorectal-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_id":"e45ff858-e1bc-4b4a-9398-e12877b61607"},{"is_active":true,"_createdAt":"2024-05-24T05:44:17Z","name":"Immuno-Oncology","_id":"289f747b-dffd-4006-a27d-4933a46fd7c1","_updatedAt":"2024-05-24T13:25:09Z","url":"/compendium/immuno-oncology","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfsKT5","_type":"subNavigation"},{"_id":"9d17bccc-3f33-4793-90e3-0adecfa71fa1","url":"/compendium/liver-cancer","is_active":true,"_rev":"Iat2IZiT321TmGHwkF6F4B","_type":"subNavigation","name":"Liver Cancer","_updatedAt":"2024-05-29T15:32:02Z","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-29T15:32:02Z"},{"url":"/compendium/nsclc","_rev":"Jz2W7keLhiw1UYkGHfsIwL","_type":"subNavigation","name":"Non–Small Cell Lung Cancer","_id":"85d30c37-d6a1-4028-9c0f-ecdf36de220d","_updatedAt":"2024-05-24T13:24:22Z","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:45:56Z"},{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:46:17Z","_rev":"Jz2W7keLhiw1UYkGHfcbF4","_type":"subNavigation","_updatedAt":"2024-05-24T05:46:17Z","url":"/compendium/ovarian-cancer","name":"Ovarian Cancer","_id":"5a67adcb-11d8-48a6-8c39-b2956f5f3e86"},{"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"_createdAt":"2024-05-24T05:47:42Z","_rev":"rcwwj6TiN2Q0ymhqDyfmoB","_type":"subNavigation","name":"Prostate Cancer","_updatedAt":"2024-05-24T05:47:42Z","is_active":true,"_id":"bcfe0d88-7498-4268-95e6-875c94a2dab5","url":"/compendium/prostate-cancer"},{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfpKE","_type":"subNavigation","_id":"a3a04e72-c707-450d-b9d3-f9ebacc9f997","_updatedAt":"2024-05-24T05:48:18Z","url":"/compendium/skincancer","_createdAt":"2024-05-24T05:48:18Z","name":"Skin Cancer"},{"_id":"89f99f56-72a9-4dcd-9d8c-3d717d66a5f0","_updatedAt":"2025-01-14T18:47:45Z","url":"/compendium/lung-cancer","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:44:58Z","_rev":"36ELbxF4To1FbIa7xZVI3e","_type":"subNavigation","name":"Small Cell Lung Cancer"},{"_createdAt":"2024-05-29T15:30:06Z","_rev":"Iat2IZiT321TmGHwkF69Qd","_type":"subNavigation","_updatedAt":"2024-05-29T15:30:06Z","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"name":"Soft Tissue Sarcoma","_id":"6d1dc4b4-1be8-41ee-9bba-90ad4ce546b3","url":"/compendium/soft-tissue-sarcoma"}],"_id":"90b398eb-3349-4b6a-b205-780a34cb4717","_updatedAt":"2024-05-24T05:41:55Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_updatedAt":"2024-05-24T05:48:54Z","_rev":"Jz2W7keLhiw1UYkGHfcePj","name":"Ophthalmology","_id":"eee19078-eb50-46e7-a97c-8f16d79eea97","url":"/compendium/ophthalmology","is_active":true,"_createdAt":"2024-05-24T05:48:54Z","children":[]},{"is_active":true,"_createdAt":"2024-05-24T05:49:11Z","_rev":"IZ4ZA8avncRcTDvyuUbYi3","_type":"subNavigation","name":"Pulmonology","_id":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","children":[{"navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_type":"subNavigation","name":"COPD","_id":"3a19d535-d61e-43b1-bf6a-d6ced486a0b9","_updatedAt":"2024-05-24T05:49:28Z","url":"/compendium/copd","is_active":true,"_createdAt":"2024-05-24T05:49:28Z","_rev":"rcwwj6TiN2Q0ymhqDyfrwW"},{"navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:52Z","_type":"subNavigation","_id":"474080cd-4295-4a70-907d-e1fc93c435cc","_updatedAt":"2024-05-24T05:49:52Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfuBv","name":"Pulmonary Arterial Hypertension","url":"/compendium/pah"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_updatedAt":"2025-01-17T17:19:27Z","url":"/compendium/pulmonology"},{"url":"/compendium/raredisease","_rev":"rcwwj6TiN2Q0ymhqDyg1Ah","_id":"de690920-3cdc-4c43-a27e-ba4e38a62059","children":[{"navParent":{"_ref":"de690920-3cdc-4c43-a27e-ba4e38a62059","_type":"reference"},"_type":"subNavigation","_id":"9e780f76-2008-441b-ab5f-00d3a6d1a5b0","_updatedAt":"2024-05-24T05:51:19Z","is_active":true,"_createdAt":"2024-05-24T05:51:19Z","_rev":"rcwwj6TiN2Q0ymhqDyg1k4","name":"Spinal Muscular Atrophy","url":"/compendium/sma"}],"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Rare Disease","_createdAt":"2024-05-24T05:50:50Z","_type":"subNavigation","_updatedAt":"2024-05-24T05:50:50Z"},{"_rev":"Jz2W7keLhiw1UYkGHfcjSf","_updatedAt":"2024-05-24T05:50:22Z","is_active":true,"_id":"f2a34114-0396-44cb-b241-11ef7b175500","url":"/compendium/respiratory","children":[{"navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyg2wy","name":"Asthma","_id":"b2b2802f-2918-4431-8f4f-3bc7e6e6042f","_updatedAt":"2024-05-24T05:52:02Z","url":"/compendium/asthma","is_active":true,"_createdAt":"2024-05-24T05:52:02Z","_type":"subNavigation"},{"is_active":true,"_createdAt":"2024-06-03T18:31:07Z","_type":"subNavigation","name":"Idiopathic Pulmonary Fibrosis","url":"/compendium/ipf","navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_rev":"5DUHcaiKRKj5c8wHOPKtuf","_id":"4dac47d5-8dd1-4e90-b4be-b6b5e605f6f5","_updatedAt":"2024-06-03T18:31:07Z"}],"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:50:22Z","_type":"subNavigation","name":"Respiratory"},{"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcm6J","name":"Rheumatology","_updatedAt":"2024-05-24T05:52:28Z","url":"/compendium/rheumatology","children":[],"_type":"subNavigation","_id":"3ecb2952-6710-46b1-ab05-36997bfb4a33","_createdAt":"2024-05-24T05:52:28Z"},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_updatedAt":"2024-05-24T05:52:51Z","is_active":true,"_createdAt":"2024-05-24T05:52:51Z","name":"Women's Health","_id":"ead467ba-7c17-4a1b-9deb-a7af56a7366e","_rev":"Jz2W7keLhiw1UYkGHfcmDU","url":"/compendium/womens-health","children":[]}],"is_active":true,"sortOrder":1,"_type":"subNavigation","_id":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_rev":"Jz2W7keLhiw1UYkGHfbRHa"},{"navParent":null,"subQuery":[{"_rev":"uJbbwQWkLESsncBrcJSd1N","_type":"subNavigation","_id":"f5b2c97b-d6d4-468b-8a9a-4814364994c8","_updatedAt":"2024-05-23T21:05:49Z","url":"/ivbmevents?display=home","name":"Free In-Person Regional Events Focused on Oncology and Population Health","children":[],"is_active":true,"navParent":{"_ref":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_type":"reference"},"_createdAt":"2024-05-23T21:04:56Z"}],"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyHDJ3","_updatedAt":"2024-05-23T21:04:52Z","_type":"subNavigation","name":"Spotlight","_createdAt":"2024-05-23T20:47:34Z","_id":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","sortOrder":2},{"name":"Topics","_id":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","subQuery":[{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbHQ4","_updatedAt":"2024-05-24T05:05:19Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"sortOrder":1,"_type":"subNavigation","_id":"43207521-4e5f-42d2-b013-34763a4d964c","url":"/compendium/biosimilars","_createdAt":"2024-05-24T05:05:19Z","children":[],"name":"Biosimilars"},{"_id":"4161ff97-2901-4526-80ee-3749b6dc6345","is_active":true,"_createdAt":"2022-12-23T21:04:41Z","_rev":"N7mKycgLbGtEq6btkPIW3d","name":"Center on Health Equity \u0026 Access","children":[],"_updatedAt":"2024-06-12T13:58:35Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"url":"/topic/center-on-health-equity-and-access","_type":"subNavigation"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:56:42Z","_rev":"rcwwj6TiN2Q0ymhqDygl51","_type":"subNavigation","_id":"232e30a0-2f7d-4ce1-9e4d-cc0cee73b20a","url":"/compendium/digital-health","children":[],"is_active":true,"_updatedAt":"2024-05-24T05:56:42Z","name":"Digital Health"},{"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","name":"Formulary","_updatedAt":"2024-05-24T05:57:01Z","_id":"3887cee2-5461-4cb3-b54f-297fcceb11ee","_createdAt":"2024-05-24T05:57:01Z","_rev":"Jz2W7keLhiw1UYkGHfdAmX","url":"/formulary","children":[]},{"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDygmDl","_updatedAt":"2024-05-24T05:57:41Z","_type":"subNavigation","name":"Gene Therapy","url":"/compendium/gene-therapy","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:57:41Z","_id":"56aff93b-4f24-48fc-9dda-2d394397f956","children":[]},{"name":"Guidelines","_id":"69723346-76b2-4896-b2d9-2db53ed5da96","children":[],"_type":"subNavigation","url":"/guidelines","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDygv9D","_updatedAt":"2024-05-24T06:00:55Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T06:00:55Z"},{"url":"/","_rev":"rcwwj6TiN2Q0ymhqDz7eaC","_type":"subNavigation","name":"Health Care Administration","_updatedAt":"2024-05-24T14:10:39Z","is_active":true,"_createdAt":"2024-05-24T13:53:24Z","children":[{"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDz6EMB","_type":"subNavigation","name":"Employers","_updatedAt":"2024-05-24T13:53:42Z","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:26Z","_id":"83fca4ec-4ff0-4766-9e49-0376d44179e8","url":"/compendium/employers"},{"name":"Medicare","_updatedAt":"2024-05-24T13:53:53Z","is_active":true,"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:44Z","_type":"subNavigation","_id":"5647b438-aca9-4b57-9d4d-2df660b5a6ce","url":"/compendium/medicare","_rev":"rcwwj6TiN2Q0ymhqDz6F3s"},{"is_active":true,"_createdAt":"2024-05-24T05:59:16Z","_rev":"rcwwj6TiN2Q0ymhqDz6G8S","_id":"2c8ff713-9c43-4afc-aaca-e33ceb98f00c","_updatedAt":"2024-05-24T13:54:23Z","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_type":"subNavigation","name":"Reimbursement","url":"/compendium/reimbursement"}],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"cd6edcff-faa3-4bee-9071-042f8186052d"},{"_createdAt":"2020-04-14T14:06:29Z","_type":"subNavigation","_id":"c9a8f6fd-0ad0-4a82-a385-13c03fe688d0","children":[],"is_active":true,"name":"Health Care Cost","_updatedAt":"2021-02-25T17:30:59Z","_rev":"wx7I38TXtYeZdHCfn60Syn","url":"/topic/healthcare-cost","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"}},{"_id":"d01b9875-6e51-42d1-bdf5-93fd8771855c","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"YN5IiYQkhJ3hq0R7jM8DQW","url":"/topic/healthcare-delivery","is_active":true,"_type":"subNavigation","name":"Health Care Delivery","_createdAt":"2020-04-14T14:06:43Z","children":[],"_updatedAt":"2021-02-25T17:29:58Z"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"lslStCipHxtG437RQOGJ7p","children":[],"_updatedAt":"2022-12-21T19:05:52Z","is_active":true,"_type":"subNavigation","_id":"d8eab058-f5ec-4c42-a95a-941c0a506543","_createdAt":"2020-04-14T14:07:01Z","name":"Insurance","url":"/topic/insurance"},{"name":"Policy","children":[],"_id":"fd066f36-78ee-4112-a121-4e02f8e45b0b","url":"/topic/policy","_createdAt":"2020-04-14T14:07:15Z","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","_updatedAt":"2020-04-14T14:07:15Z","_rev":"T035zdq5xruIFPyK3OzgdQ"},{"_rev":"rcwwj6TiN2Q0ymhqDygvgV","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:59:24Z","children":[],"url":"/compendium/population","_type":"subNavigation","name":"Population Health","_id":"d7893fef-5eb0-4b2d-b13d-a0bec73b2c14","_updatedAt":"2024-05-24T06:01:29Z"},{"_id":"6188ac2f-7ec8-4cbb-a154-5822f606f3fa","url":"/approvals-launches","name":"Product Approvals and Launches","_updatedAt":"2024-05-24T13:24:58Z","children":[],"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfsKLu","is_active":true,"_createdAt":"2024-05-24T06:01:51Z","_type":"subNavigation"},{"_updatedAt":"2020-04-14T14:07:28Z","url":"/topic/technology","_createdAt":"2020-04-14T14:07:28Z","children":[],"_rev":"QxOJBWa4XErmibN6Cb5bN0","_type":"subNavigation","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Technology","_id":"4e2fe99b-3ac4-4b48-89ed-774dd51675df"},{"_createdAt":"2020-04-14T14:07:42Z","_id":"22bd1bd6-88a6-4278-a846-e086cf30b141","url":"/topic/value-based-care","name":"Value-Based Care","_updatedAt":"2020-04-14T14:07:42Z","children":[],"is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_rev":"T035zdq5xruIFPyK3OzhkC","_type":"subNavigation"}],"_updatedAt":"2020-08-21T22:11:57Z","url":"/topic","sortOrder":2,"is_active":true,"_createdAt":"2020-04-14T14:05:54Z","_rev":"iEeBpgQLYwZXMeCflboLMu","_type":"subNavigation","navParent":null},{"subQuery":[{"is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_type":"subNavigation","children":[],"_rev":"cyKVTGb2fpu5E4X0UMrv4p","name":"All Coverage","_updatedAt":"2020-05-06T13:11:16Z","_createdAt":"2020-05-06T13:11:16Z","_id":"f7379c68-40be-45e4-9747-484dcec584d3","url":"/ivbm"},{"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_createdAt":"2020-04-27T18:49:41Z","_rev":"k2D4PisPM2pBS5NIl95QbN","name":"Event Coverage","is_active":true,"children":[],"_type":"subNavigation","_id":"cc8a827f-3e94-413a-aa0c-0d8b40eb5f18","_updatedAt":"2020-04-27T18:49:41Z","url":"/ivbm/event-coverage"},{"url":"/ivbm/interviews","_createdAt":"2020-04-27T18:50:03Z","_type":"subNavigation","_id":"aa3f3bb8-9e8c-457d-aeb6-7b94b968395a","children":[],"_rev":"k2D4PisPM2pBS5NIl95RlO","name":"Interviews","_updatedAt":"2020-04-27T18:50:03Z","is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"}},{"is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_id":"1be7e99c-8d37-4d70-a009-67eb03fae5ba","url":"/ivbm/news","_createdAt":"2020-04-27T18:50:34Z","name":"News","_updatedAt":"2020-04-27T18:50:34Z","_rev":"XtnP0djhkej33kSTbdUgmN","_type":"subNavigation","children":[]}],"_createdAt":"2020-04-27T18:48:09Z","sortOrder":3,"_updatedAt":"2020-04-27T18:48:23Z","name":"Institute for Value-Based Medicine","_id":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","is_active":true,"navParent":null,"_rev":"N0LuVAjtHhQSyVgQyS0Kyv","url":"/ivbm","_type":"subNavigation"},{"subQuery":[{"_type":"subNavigation","_id":"4e10ead3-6a42-43df-b251-b93b912a24cb","_createdAt":"2020-05-07T17:05:52Z","_updatedAt":"2020-05-07T17:05:52Z","is_active":true,"name":"AJMC Journals","url":"/about","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_rev":"NGYpFwzJghlKjBIAt48VzS","children":[]},{"_createdAt":"2020-04-14T14:09:38Z","_rev":"rHX8vIEJKWyjgUO02y82fe","url":"/anniversary","is_active":true,"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"children":[],"_type":"subNavigation","name":"Anniversary","_id":"4451f4fa-a919-45b4-b6e5-282668cd792e","_updatedAt":"2020-04-14T14:09:38Z"},{"children":[],"name":"Author Forms","url":"/authorshipforms","is_active":true,"_rev":"VmKMEDy0rHs5jzhO3eZVVM","_updatedAt":"2020-06-09T11:44:06Z","_type":"subNavigation","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2020-04-14T14:10:37Z","_id":"99bccc8e-9329-496f-b588-ec3d080f0859"},{"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_updatedAt":"2020-05-06T12:53:11Z","_createdAt":"2020-04-14T14:10:19Z","children":[],"_type":"subNavigation","url":"/authors","_rev":"0JTsteyxJPdyCvciQ9yBPv","name":"Authors","_id":"518317a5-297f-4c4f-9d2a-6da7b8c98d9c","is_active":true},{"is_active":true,"name":"Nominate a Rising Leader","_updatedAt":"2020-06-15T17:13:51Z","url":"/seema-sonnad-nomination","_rev":"m6BzyPIGe9IGx2bV3pSCbq","_id":"a96a44c9-4d51-47c6-8f81-4263bd2f58b4","children":[],"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2020-06-15T17:13:51Z","_type":"subNavigation"},{"is_active":true,"_rev":"TctAtfg0qER1kILh39bPC4","_type":"subNavigation","_updatedAt":"2023-03-14T13:29:28Z","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_createdAt":"2023-03-14T13:29:28Z","children":[],"name":"Submit a Manuscript","_id":"4420e458-acb4-4edb-9f33-c4fc4504ff41","url":"/submit-a-manuscript"}],"_createdAt":"2020-04-14T14:09:11Z","_rev":"lsW1cEPdRFwwIdupAS8Stb","navParent":null,"_updatedAt":"2020-04-27T18:48:27Z","_type":"subNavigation","name":"About AJMC","_id":"9a07b754-3383-43ac-9d2d-a370d44406d1","is_active":true,"sortOrder":4}],"site_setting":{"description":"The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.","salesforceDMPId":"tr3xsudox","siteURL":"www.ajmc.com","creativeLayoutLatestNews":null,"_createdAt":"2020-04-14T14:14:32Z","footerLinks":[{"_type":"urlArray","_key":"6170fdefc8129a5a7ef9dfdd78a2573e","title":"About","url":"/about-us"},{"_type":"urlArray","_key":"281c240875d5","title":"Contact","url":"/contactus"},{"_type":"urlArray","_key":"25e9e6fb7b4422cd0ac20e1a1d993228","title":"Editorial Boards","url":"/editorial-boards"},{"_type":"urlArray","_key":"20a44c137e8d","title":"Advertise","url":"/advertise"},{"url":"https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com","blank":true,"_type":"urlArray","_key":"21b84fcc9b6e","title":"Do Not Sell My Information"},{"title":"Terms \u0026 Conditions","url":"/terms","_type":"urlArray","_key":"2f35307aab1f"},{"_type":"urlArray","_key":"50ecd8627d01","title":"Privacy Policy","url":"/privacy"}],"_id":"siteSettings","_rev":"iBzEylCaJfBlbg7ZehwyvL","enableSanity2":true,"_type":"siteSettings","gaID":"UA-155582410-5,UA-11140057-3","creativeLayout":null,"copyRightText":"AJMC®","name":"AJMC - Managed Care News, Research, and Expert Insights","socialLinks":[{"_key":"5a09ae68c48c","title":"Facebook","url":"https://www.facebook.com/TheAmericanJournalOfManagedCare","blank":true,"_type":"urlArray"},{"_type":"urlArray","_key":"ad6b3d250e0b","title":"Twitter","url":"https://twitter.com/AJMC_Journal","blank":true},{"title":"LinkedIn","url":"https://www.linkedin.com/company/american-journal-of-managed-care/","blank":true,"_type":"urlArray","_key":"7d1e53fa7d09"},{"_type":"urlArray","_key":"2478204aa05c","title":"Instagram","url":"https://www.instagram.com/ajmcjournal/","blank":true},{"blank":true,"_type":"urlArray","_key":"0ba4cf990c2f","title":"RSS","url":"/rss"}],"alternateName":"The American Journal of Managed Care","orangizationName":"AJMC","_updatedAt":"2025-01-23T16:12:11Z","keywords":["American Journal of Managed Care","AJMC"]},"clinicalData":[{"_id":"4ee49086-e720-4a65-883e-4efc24de53bb","name":"Center on Health Equity \u0026 Access","identifier":"center-on-health-equity-and-access","sortOrder":null,"children":[]},{"sortOrder":null,"children":[],"_id":"topic_clinical","name":"Clinical","identifier":"clinical"},{"_id":"topic_healthcare-cost","name":"Health Care Cost","identifier":"healthcare-cost","sortOrder":null,"children":[]},{"_id":"topic_healthcare-delivery","name":"Health Care Delivery","identifier":"healthcare-delivery","sortOrder":null,"children":[]},{"identifier":"insurance","sortOrder":null,"children":[],"_id":"topic_insurance","name":"Insurance"},{"_id":"topic_policy","name":"Policy","identifier":"policy","sortOrder":null,"children":[]},{"children":[],"_id":"topic_technology","name":"Technology","identifier":"technology","sortOrder":null},{"_id":"topic_value-based-care","name":"Value-Based Care","identifier":"value-based-care","sortOrder":null,"children":[]}],"seo_data":[],"recent_news":[{"title":"Camden Coalition’s Complex Care Education Extends to Various Sectors","thumbnail":{"_type":"mainImage","alt":"Gladys Antelo-Allen, Camden Coalition","asset":{"_ref":"image-a03fc18154b8ea004ab3b23ce07752ea3dc6b1b3-1266x711-png","_type":"reference"}},"_id":"a0f41777-2f50-4dfe-80aa-fc27f5c85ff1","summary":"Gladys Antelo-Allen, Camden Coalition, shares the necessary skills to effectively equip supervisors to lead their teams and support individuals with complex health and social needs.","url":{"current":"camden-coalition-s-complex-care-education-extends-to-various-sectors","_type":"slug"},"published":"2025-02-22T14:20:00.000Z","authorMapping":{"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","caption":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","asset":{"_ref":"image-6ce94d112b3a5df5bd05dc2b689a0720adadcc62-400x400-jpg","_type":"reference"}},"_updatedAt":"2025-02-19T19:08:51Z","_createdAt":"2023-06-23T19:52:20Z","_rev":"itvkhwxEA2FOFySb8pBfxH","_type":"author","url":{"_type":"slug","current":"giuliana-grossi"},"firstName":"Giuliana","lastName":"Grossi","authorType":"author","displayName":"Giuliana Grossi","_id":"8e597e29-c3ad-470c-8174-00c81b563f81","biography":[{"children":[{"_type":"span","marks":[],"text":"Giuliana Grossi is an editor for ","_key":"0179b0541e0b"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"d7871694e50e"},{"_type":"span","marks":["sup"],"text":"®","_key":"3173808ea48d"},{"_key":"1c074ec7251f","_type":"span","marks":[],"text":", overseeing the publication's "},{"_type":"span","marks":["324bbc17fbcd"],"text":"Center on Health Equity \u0026 Access","_key":"e68159433236"},{"_type":"span","marks":[],"text":". Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.","_key":"c2e2da920bfb"}],"_type":"block","style":"normal","_key":"7644d0957596","markDefs":[{"_key":"324bbc17fbcd","nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/topic/center-on-health-equity-and-access"}]},{"_type":"block","style":"normal","_key":"cf123c823686","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Before Giuliana joined ","_key":"cd7292039254"},{"_key":"ad727be45f99","_type":"span","marks":["em"],"text":"AJMC"},{"marks":[],"text":", she delved into rare disease coverage at HCPLive","_key":"c140cf0f19d0","_type":"span"},{"_key":"39ac8edb75a8","_type":"span","marks":["sup"],"text":"®"},{"text":", a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in ","_key":"6a1265a483a0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"Population Health, Equity \u0026 Outcomes","_key":"cf2d12c38dca"},{"_type":"span","marks":["sup"],"text":"®","_key":"aa763d202117"},{"marks":[],"text":" (formerly ","_key":"61f88e04956e","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"17e5c52377f8"},{"text":"®","_key":"5504bfff7017","_type":"span","marks":["sup"]},{"_type":"span","marks":[],"text":"), ","_key":"19512dc0b299"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"3cb7d49a81f9"},{"_type":"span","marks":["sup"],"text":"®","_key":"22ab5aeaa59a"},{"_type":"span","marks":[],"text":",","_key":"b1d13339e368"},{"_type":"span","marks":["sup"],"text":" ","_key":"fcd8255a68b5"},{"_type":"span","marks":[],"text":"NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.","_key":"e4e8d0128520"}]},{"_type":"block","style":"normal","_key":"59a199fedfec","markDefs":[],"children":[{"_type":"span","marks":[],"text":"She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.","_key":"5f3ea2ee587e"}]},{"markDefs":[],"children":[{"marks":[],"text":"\n","_key":"e7fe8691814f","_type":"span"}],"_type":"block","style":"normal","_key":"cd682b512e51"}]},"factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"}},{"summary":"Both drugs showed significant improvements, with higher response observed for bimekizumab, study finds. ","url":{"current":"bimekizumab-brodalumab-safe-effective-up-to-36-weeks-for-psoriasis","_type":"slug"},"authorMapping":{"_createdAt":"2022-10-05T15:22:49Z","profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}},"lastName":"Steinzor","authorType":"author","displayName":"Pearl Steinzor","_rev":"DctwwV37cP5NCi4QxZhRK8","_type":"author","_id":"8f51e09f-2c76-4ef0-83e7-d577a5dfcdd1","_updatedAt":"2025-01-08T16:39:17Z","url":{"current":"pearl-steinzor","_type":"slug"},"firstName":"Pearl "},"factCheckAuthorMapping":null,"_id":"96ba80f4-6163-4a8d-bfa4-d474d3beabde","title":"Bimekizumab, Brodalumab Safe, Effective Up to 36 Weeks for Psoriasis","thumbnail":{"asset":{"_type":"reference","_ref":"image-ea59b0a821081df7e1f5c7978458e3ca7897bb92-1111x741-png"},"_type":"mainImage","alt":"Psoriasis | Image credit: SergeVo - stock.adobe.com"},"published":"2025-02-21T21:46:37.432Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"_id":"c2fa898f-1aca-4c91-bb5c-89907ed3ed59","title":"Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case","summary":"The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.","thumbnail":{"asset":{"_ref":"image-76ac2d8e0ea70215869755af5b941159c8b2024a-6000x4000-jpg","_type":"reference"},"_type":"mainImage","alt":"Health law | Image credit: yavdat - stock.adobe.com","caption":"Health law | Image credit: yavdat - stock.adobe.com"},"url":{"current":"trump-administration-s-message-to-supreme-court-puts-new-wrinkle-in-braidwood-case","_type":"slug"},"published":"2025-02-21T21:33:08.407Z","authorMapping":{"url":{"current":"julia-bonavitacola","_type":"slug"},"lastName":"Bonavitacola","_rev":"sgy4yN0CjmArmRDnE2Khrz","profileImage":{"_type":"mainImage","alt":"Julia Bonavitacola","asset":{"_type":"reference","_ref":"image-fa6d7df41e3dda6f2ed66b65f3313ff5869748c2-430x430-png"}},"firstName":"Julia","displayName":"Julia Bonavitacola","_createdAt":"2022-02-23T21:42:42Z","_type":"author","_id":"15b1de57-6a71-4655-ba17-eeaa1c733634","biography":[{"_key":"106fd454900b","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"_type":"span","marks":[],"text":"Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.","_key":"8a55e07516550"}],"_type":"block","style":"normal"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/julia-bonavitacola-b5aa63171/","_key":"d45285824c6f"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English language and literature from Rutgers University. You can connect with Julia on ","_key":"c2ef3167786d"},{"_key":"8a55e07516551","_type":"span","marks":["d45285824c6f"],"text":"LinkedIn"},{"_type":"span","marks":[],"text":".","_key":"8a55e07516552"}],"_type":"block","style":"normal","_key":"769839c11518"}],"_updatedAt":"2024-05-20T19:27:55Z"},"factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"title":"Specialists Boost Patient Acceptance of Longer Colonoscopy Intervals","thumbnail":{"asset":{"_ref":"image-5e9a452419c115c07713fe14e371d40eee0e1c61-5376x3072-jpg","_type":"reference"},"_type":"mainImage","alt":"CRC detection | Image credit: Ahmet Aglamaz - stock.adobe.com"},"published":"2025-02-21T20:42:35.859Z","authorMapping":{"lastName":"Steinzor","authorType":"author","displayName":"Pearl Steinzor","_rev":"DctwwV37cP5NCi4QxZhRK8","_type":"author","_id":"8f51e09f-2c76-4ef0-83e7-d577a5dfcdd1","_updatedAt":"2025-01-08T16:39:17Z","url":{"current":"pearl-steinzor","_type":"slug"},"firstName":"Pearl ","_createdAt":"2022-10-05T15:22:49Z","profileImage":{"_type":"mainImage","alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"}}},"factCheckAuthorMapping":null,"_id":"cc9024b8-3fb0-4bb1-b229-be07b4f100c7","summary":"Study results show most patients prefer more frequent colonoscopies, but specialist recommendations drive acceptance of extended intervals.","url":{"current":"specialists-boost-patient-acceptance-of-longer-colonoscopy-intervals-study-finds","_type":"slug"},"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"}}],"latest_publications":[{"title":"Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP","summary":"To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.","authorDetails":[{"url":{"current":"richard-j-gilfillan-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Richard J. Gilfillan, MD","firstName":"Richard","lastName":"Gilfillan"},{"biography":null,"showSocialShare":null,"displayName":"Donald M. Berwick, MD, MPP","firstName":"Donald","lastName":"Berwick","url":{"current":"donald-m-berwick-md-mpp","_type":"slug"},"profileImage":null}],"_id":"9aad20b6-a311-4652-8fa6-7991baa92ef1","issueGroup":{"_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"}},"hasAlpha":true},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png"}},"url":"managed-care-reflections-insights-from-richard-j-gilfillan-md-and-donald-m-berwick-md-mpp","published":"2025-02-20T17:15:00.000Z","factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Richard J. Gilfillan, MD","firstName":"Richard","lastName":"Gilfillan","url":{"current":"richard-j-gilfillan-md","_type":"slug"}},{"displayName":"Donald M. Berwick, MD, MPP","firstName":"Donald","lastName":"Berwick","url":{"current":"donald-m-berwick-md-mpp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"issueGroup":{"_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68","_type":"reference"},"title":"Clinical Trials Must Represent Those Who Will Receive Therapy","summary":null,"thumbnail":{"_type":"mainImage","alt":"Ander Hertler, MD | Image credit: Evolent","caption":"Ander Hertler, MD | Image credit: Evolent","asset":{"uploadId":"EmJHssAXy9Ob2FKR4o6xFVLIGtMA0NLu","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800.jpg","_id":"image-804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800-jpg","extension":"jpg","path":"images/0vv8moc6/ajmc/804cdb34aa88272063b6af54a7ef72eaf4f8fa92-1800x1800.jpg","_updatedAt":"2024-02-14T21:29:57Z","_type":"sanity.imageAsset","mimeType":"image/jpeg","size":2044952,"_rev":"VsPixfEw6DNbTy7utCEJN0","sha1hash":"804cdb34aa88272063b6af54a7ef72eaf4f8fa92","assetId":"804cdb34aa88272063b6af54a7ef72eaf4f8fa92","_createdAt":"2024-02-14T21:29:57Z","originalFilename":"Andrew Hertler Head Shot High Res.jpg","metadata":{"dimensions":{"aspectRatio":1,"height":1800,"_type":"sanity.imageDimensions","width":1800},"isOpaque":true,"blurHash":"eeJa{3juOskD$$~Tf6tlogRQS5a|RPj[kDS6ayadayt7odj[t7jsRj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#f1cbc0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":3.86},"darkVibrant":{"background":"#28385c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"background":"#d2b6af","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.54},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#7890c4"},"dominant":{"background":"#495c7e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":12.37},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":12.37,"background":"#495c7e","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"title":"#fff","population":9.64,"background":"#5c759f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"}}},"url":"clinical-trials-must-represent-those-who-will-receive-therapy","published":"2025-02-19T17:53:00.000Z","authorDetails":[{"displayName":"Andrew Hertler, MD, FACP","firstName":"Andrew","lastName":"Hertler","url":{"current":"andrew-hertler-md-facp","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Andrew Hertler, MD, FACP","firstName":"Andrew","lastName":"Hertler","url":{"current":"andrew-hertler-md-facp","_type":"slug"}}],"_id":"4032e831-2748-4d94-b3ba-10b9c74e53aa"},{"_id":"071d815c-00f4-43f8-a143-a5179ccc1ffb","published":"2025-02-19T14:07:00.000Z","authorDetails":[{"biography":[{"_type":"block","style":"normal","_key":"f73a10e9267d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0"}]},{"style":"normal","_key":"95aad26356ef","markDefs":[{"href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"text":".","_key":"6fba991875ae2","_type":"span","marks":[]}],"_type":"block"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}}}],"factCheckBy":[{"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span"}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal","_key":"95aad26356ef"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null}],"issueGroup":{"_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68","_type":"reference"},"title":"A New Horizon: Precision Medicine and Value-Based Care in Lung, Gastric, and Sarcoma Cancers","summary":null,"thumbnail":{"_type":"mainImage","alt":"Tampa city scene | Image: Getty Images","asset":{"metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"height":844,"_type":"sanity.imageDimensions","width":1500,"aspectRatio":1.7772511848341233},"isOpaque":true,"blurHash":"MZI4^%%MXUnMXRgladNGsAs.IyV@Wraeod","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.3,"background":"#aab8d3"},"vibrant":{"population":1.26,"background":"#d7822e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#e69f81","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.31},"_type":"sanity.imagePalette","darkMuted":{"background":"#504f31","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.89},"muted":{"title":"#fff","population":0.83,"background":"#81629b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#e69f81","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.31},"darkVibrant":{"background":"#6a5b06","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.7}}},"_rev":"qHhNQIW6XHipcCVoq0ny6L","sha1hash":"c48a99a97eeca7818a5d28fa95603c5fecc29285","path":"images/0vv8moc6/ajmc/c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844.jpg","_createdAt":"2025-02-19T15:13:04Z","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844.jpg","_id":"image-c48a99a97eeca7818a5d28fa95603c5fecc29285-1500x844-jpg","originalFilename":"Tampa Getty images.jpg","uploadId":"pWFsyFLETHHSrtJzCJTHxmWraWX5bKRu","extension":"jpg","_type":"sanity.imageAsset","size":142962,"assetId":"c48a99a97eeca7818a5d28fa95603c5fecc29285","_updatedAt":"2025-02-19T15:13:04Z"}},"url":"a-new-horizon-precision-medicine-and-value-based-care-in-lung-gastric-and-sarcoma-cancers"},{"_id":"e4a32dfb-8008-41b9-82e8-569d97a87e7f","summary":"Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.","url":"what-recent-evidence-is-telling-us-about-alcohol-and-cancer","factCheckBy":[{"lastName":"Caffrey","url":{"current":"produced-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Produced by Mary Caffrey","firstName":"Mary "}],"issueGroup":{"_ref":"6d917ea7-7e09-4a04-9a3f-85d7c6439c68","_type":"reference"},"title":"What Recent Evidence Is Telling Us About Alcohol and Cancer","thumbnail":{"_type":"mainImage","alt":"Noelle LoConte, MD | Image credit: University of Wisconsin","caption":"Noelle LoConte, MD | Image credit: University of Wisconsin","asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c0ffc966125542010d43006654c25de2d5a8b433-141x118.jpg","size":5645,"originalFilename":"LoConte.jpg","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/c0ffc966125542010d43006654c25de2d5a8b433-141x118.jpg","sha1hash":"c0ffc966125542010d43006654c25de2d5a8b433","_createdAt":"2025-02-19T11:50:21Z","_id":"image-c0ffc966125542010d43006654c25de2d5a8b433-141x118-jpg","_updatedAt":"2025-02-19T11:50:21Z","extension":"jpg","uploadId":"zaGG18ur2Y8oBLhkaUfqqJLNWVWbGZUE","_rev":"itvkhwxEA2FOFySb8jc0KF","mimeType":"image/jpeg","assetId":"c0ffc966125542010d43006654c25de2d5a8b433","metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":141,"aspectRatio":1.194915254237288,"height":118},"isOpaque":true,"blurHash":"eGD[@GkD0h-p}@bws:s.NGNF57t7={RjIptRoft7s.RkNHs:xZWCNG","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.39,"background":"#51382f"},"muted":{"foreground":"#fff","title":"#fff","population":6.74,"background":"#9b7161","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#edb8a5","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.3},"darkVibrant":{"background":"#602424","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"population":2.31,"background":"#d9c3ba","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"vibrant":{"background":"#b44444","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"title":"#fff","population":6.74,"background":"#9b7161","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false}},"crop":{"right":0,"top":0.05084745762711864,"left":0,"bottom":0,"_type":"sanity.imageCrop"},"hotspot":{"y":0.5254237288135594,"height":0.9491525423728814,"_type":"sanity.imageHotspot","width":1,"x":0.5}},"published":"2025-02-19T03:49:00.000Z","authorDetails":[{"firstName":"Mary ","lastName":"Caffrey","url":{"current":"produced-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Produced by Mary Caffrey"}]},{"published":"2025-02-11T14:00:00.000Z","authorDetails":[{"displayName":"Hinpetch Daungsupawong, PhD","firstName":"Hinpetch","lastName":"Daungsupawong","url":{"current":"hinpetch-daungsupawong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj","lastName":"Wiwanitkit","url":{"current":"viroj-wiwanitkit-md","_type":"slug"},"profileImage":null,"biography":null}],"_id":"029c0e16-5487-4d46-8669-9c80e6c775d2","issueGroup":{"_type":"reference","_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64"},"title":"KAP Regarding ChatGPT Among Health Care Professionals: Correspondence","factCheckBy":[{"firstName":"Hinpetch","lastName":"Daungsupawong","url":{"current":"hinpetch-daungsupawong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Hinpetch Daungsupawong, PhD"},{"showSocialShare":null,"displayName":"Viroj Wiwanitkit, MD","firstName":"Viroj","lastName":"Wiwanitkit","url":{"_type":"slug","current":"viroj-wiwanitkit-md"},"profileImage":null,"biography":null}],"summary":"This letter discusses previously published research that paves the way for deeper exploration of the ethical and human aspects of artificial intelligence in health care.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382}},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z"}},"url":"kap-regarding-chatgpt-among-health-care-professionals-correspondence"},{"_id":"90b5927a-b28a-40cd-a19e-2ad54b3a4de3","issueGroup":{"_type":"reference","_ref":"cfc4ad72-548d-4101-af2d-9fff7f70ed64"},"summary":"This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2"},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj"},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"authorDetails":[{"biography":null,"showSocialShare":null,"displayName":"Jai N. Patel, PharmD","firstName":"Jai","lastName":"Patel","url":{"_type":"slug","current":"jai-n-patel-pharmd"},"profileImage":null},{"showSocialShare":null,"displayName":"Lena Chaihorsky, BS","firstName":"Lena","lastName":"Chaihorsky","url":{"_type":"slug","current":"lena-chaihorsky-bs"},"profileImage":null,"biography":null},{"displayName":"Olivia M. Dong, PhD","firstName":"Olivia","lastName":"Dong","url":{"current":"olivia-m-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Christine Y. Lu, PhD","firstName":"Christine","lastName":"Lu","url":{"current":"christine-y-lu-phd","_type":"slug"},"profileImage":null},{"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz","url":{"_type":"slug","current":"chad-moretz-scd"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Emily","lastName":"Reese","url":{"_type":"slug","current":"emily-reese-phd-mph"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Emily Reese, PhD, MPH"},{"firstName":"Wrenda","lastName":"Teeple","url":{"current":"wrenda-teeple-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Wrenda Teeple, PharmD"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"_type":"slug","current":"benjamin-brown-bs"}},{"lastName":"Rogers","url":{"_type":"slug","current":"sara-rogers-pharmd"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sara Rogers, PharmD","firstName":"Sara"}],"title":"Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans","url":"medical-policy-determinations-for-pharmacogenetic-tests-among-us-health-plans","published":"2025-02-10T14:00:00.000Z","factCheckBy":[{"lastName":"Patel","url":{"current":"jai-n-patel-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jai N. Patel, PharmD","firstName":"Jai"},{"displayName":"Lena Chaihorsky, BS","firstName":"Lena","lastName":"Chaihorsky","url":{"current":"lena-chaihorsky-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Olivia M. Dong, PhD","firstName":"Olivia","lastName":"Dong","url":{"current":"olivia-m-dong-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Christine","lastName":"Lu","url":{"current":"christine-y-lu-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Christine Y. Lu, PhD"},{"displayName":"Chad Moretz, ScD","firstName":"Chad","lastName":"Moretz","url":{"_type":"slug","current":"chad-moretz-scd"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Emily Reese, PhD, MPH","firstName":"Emily","lastName":"Reese","url":{"_type":"slug","current":"emily-reese-phd-mph"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Wrenda Teeple, PharmD","firstName":"Wrenda","lastName":"Teeple","url":{"current":"wrenda-teeple-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Benjamin Brown, BS","firstName":"Benjamin ","lastName":"Brown","url":{"current":"benjamin-brown-bs","_type":"slug"}},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sara Rogers, PharmD","firstName":"Sara","lastName":"Rogers","url":{"current":"sara-rogers-pharmd","_type":"slug"}}]},{"_id":"a74e0c61-1db8-4176-a3ff-356818f8f1bc","issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"thumbnail":{"caption":"Elias Jabbour, MD | Image credit: MD Anderson","asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","size":8344,"extension":"jpg","mimeType":"image/jpeg","_createdAt":"2025-01-22T01:39:28Z","_id":"image-d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202-jpg","uploadId":"AI9UWYzlKUzpNZoSkOg0eaGj37ri4uGg","sha1hash":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","path":"images/0vv8moc6/ajmc/d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2-360x202.jpg","assetId":"d7b07ba2f95a91eead9b2ff8ea1eab8b3e1e9ff2","originalFilename":"Elias Jabbour MD.jpg","metadata":{"palette":{"lightVibrant":{"foreground":"#000","title":"#000","population":0.02,"background":"#ececfc","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"title":"#fff","population":0,"background":"#5d3626","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.2,"background":"#c6b8b8"},"vibrant":{"background":"#c78e77","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.25},"dominant":{"population":5.59,"background":"#563d35","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#563d35","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.59},"muted":{"foreground":"#fff","title":"#fff","population":1.13,"background":"#8d624f","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAYHBAX/xAAjEAABBAIBAwUAAAAAAAAAAAABAAIDBAURBhITIjEyQXGR/8QAFQEBAQAAAAAAAAAAAAAAAAAAAAH/xAAZEQACAwEAAAAAAAAAAAAAAAAAAQIREjL/2gAMAwEAAhEDEQA/AKrfz9jIYi9Xp9feMTg0s9QuJxKTKYziUZtwvY17yQCdkLThR2pnGPxJ0Dr7TFaAdMyIjcfT7fhXC6G6TiJsj7Uzy8MdooVHr1YBEAImfiFAf//Z","dimensions":{"aspectRatio":1.7821782178217822,"height":202,"_type":"sanity.imageDimensions","width":360},"isOpaque":true,"blurHash":"MKL;jYxvNZ%MMw%0?a%g-;IA~qWBs:aeWB","_type":"sanity.imageMetadata"},"_rev":"03H5IWZJxxErG40FSFrSh1","_type":"sanity.imageAsset","_updatedAt":"2025-01-22T01:39:28Z"},"_type":"mainImage","alt":"Elias Jabbour, MD | Image credit: MD Anderson"},"published":"2025-01-22T01:20:00.000Z","authorDetails":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"_type":"slug","current":"mary-caffrey"},"profileImage":null,"biography":[{"children":[{"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span","marks":[]},{"marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc","_type":"span"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span"},{"marks":["em"],"text":"AJMC","_key":"3c5f9805f644","_type":"span"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"_key":"a03d32973d6e","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_key":"9737335da1ed1","_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn"},{"_key":"9737335da1ed2","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal"}],"showSocialShare":null},{"lastName":null,"url":{"current":"elias-j-jabbour-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elias J. Jabbour, MD","firstName":null}],"title":"MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL","url":"mrd-and-other-predictors-from-felix-for-obe-cel-success-in-r-r-b-all","factCheckBy":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"_type":"slug","current":"mary-caffrey"},"profileImage":null,"biography":[{"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962","_type":"span","marks":["em"]},{"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3","_type":"span","marks":[]},{"_key":"3c5f9805f644","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"_key":"c2027cf5a357","_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on "},{"marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elias J. Jabbour, MD","firstName":null,"lastName":null,"url":{"current":"elias-j-jabbour-md","_type":"slug"}}]},{"_id":"83a8ce9d-6abb-4501-81a9-077d46c26bf1","summary":"A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382}},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6"}},"authorDetails":[{"displayName":"Denise Tran, PharmD","firstName":"Denise","lastName":"Tran","url":{"current":"denise-tran-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Park","url":{"current":"haesuk-park-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Haesuk Park, PhD","firstName":"Haesuk"},{"displayName":"Jordon Rabey, MS","firstName":"Jordon","lastName":"Rabey","url":{"current":"jordon-rabey-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Seth","lastName":"Killion","url":{"current":"seth-killion-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Seth Killion, BS"},{"showSocialShare":null,"displayName":"S. Bobby Arelli, MD","firstName":"S.","lastName":"Arelli","url":{"current":"s-bobby-arelli-md","_type":"slug"},"profileImage":null,"biography":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elaine Murphy, BS","firstName":"Elaine","lastName":"Murphy","url":{"_type":"slug","current":"elaine-murphy-bs"}},{"profileImage":null,"biography":[{"markDefs":[{"href":"https://www.arine.io/?utm_campaign=Public%20Relations\u0026utm_source=Bylined%20Article\u0026utm_medium=AJMC\u0026utm_content=Optimizing%20Medication%20Outcomes","_key":"531fb76b610f","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_key":"f5c43b0094150","_type":"span","marks":[],"text":"Yoona Kim, PharmD, PhD, is the CEO and co-founder of "},{"marks":["531fb76b610f"],"text":"Arine","_key":"1e6470ee49ca","_type":"span"},{"_type":"span","marks":[],"text":", a next-generation medication intelligence company with a mission to solve medication mismanagement across the health care continuum. Arine’s proprietary platform pulls insights from a complex ecosystem of clinical, socioeconomic, and behavioral data to optimize patient outcomes and deliver value-based care. The technology uses predictive analytics to target care to at-risk members, develops artificial intelligence (AI)-driven personalized care plans for each patient, and uses machine learning to continuously optimize members’ medication therapy. Arine overcomes the limits of traditional, manually driven medication management approaches by making the practice scalable and allowing time-strapped health care providers to deliver care to large populations and with a far greater impact. Arine’s clients have achieved the highest quality ratings and have reduced hospital admissions by 40%.","_key":"2ad98b63e1fb"}],"_type":"block","style":"normal","_key":"bf797f939822"},{"_key":"816767524ea1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Arine’s AI-driven technology platform is powering successful interventions that navigate complexities discussed in this article. For example, Arine’s platform identified a 67-year-old Latinx male in Medicare Advantage with diabetes and an elevated hemoglobin A","_key":"ee58d5fd8fca0"},{"_key":"2886ba74f33e","_type":"span","marks":["subscript"],"text":"1C"},{"marks":[],"text":" at high risk for hyperglycemic crisis. He had a history of medication nonadherence and canceling appointments and expressed difficulty affording a branded diabetes medication. Arine’s platform identified a generic option, along with several other recommendations, to optimize the member’s array of medications for other comorbidities. The platform also flagged a pattern of underutilization of care, indicated by an absence of a primary care visit within the last year and connected the member to an appointment. These measures were supplemented by auto-generated Spanish-language educational materials on the importance of medications and lifestyle changes for diabetes management. Ultimately, the member was very receptive to the recommendations and started taking his medications more regularly.","_key":"00cebefaa126","_type":"span"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"88840c7d9452","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Prior to Arine, Yoona has held various roles at digital health, pharma, and consulting companies. She holds a bachelor’s degree from Stanford University; a PharmD with an emphasis in health policy and management from the University of California, San Francisco; and a PhD in health economics and outcomes from the University of Texas at Austin.","_key":"9db59a3d155d0"}]},{"markDefs":[],"children":[{"text":"","_key":"49f538df32460","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f9ff3fa5d2f5"}],"showSocialShare":null,"displayName":"Yoona Kim, PharmD, PhD","firstName":"Yoona","lastName":"Kim","url":{"current":"yoona-kim-pharmd-phd","_type":"slug"}}],"issueGroup":{"_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71","_type":"reference"},"title":"Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration","url":"effects-of-individualized-nurse-led-care-plans-on-olaparib-treatment-duration","published":"2025-01-20T17:00:00.000Z","factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Denise Tran, PharmD","firstName":"Denise","lastName":"Tran","url":{"current":"denise-tran-pharmd","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Haesuk Park, PhD","firstName":"Haesuk","lastName":"Park","url":{"current":"haesuk-park-phd","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Jordon Rabey, MS","firstName":"Jordon","lastName":"Rabey","url":{"current":"jordon-rabey-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Seth Killion, BS","firstName":"Seth","lastName":"Killion","url":{"current":"seth-killion-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"S. Bobby Arelli, MD","firstName":"S.","lastName":"Arelli","url":{"current":"s-bobby-arelli-md","_type":"slug"}},{"showSocialShare":null,"displayName":"Elaine Murphy, BS","firstName":"Elaine","lastName":"Murphy","url":{"current":"elaine-murphy-bs","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Yoona Kim, PharmD, PhD","firstName":"Yoona","lastName":"Kim","url":{"current":"yoona-kim-pharmd-phd","_type":"slug"},"profileImage":null,"biography":[{"_type":"block","style":"normal","_key":"bf797f939822","markDefs":[{"_key":"531fb76b610f","nofollow":true,"blank":true,"_type":"link","href":"https://www.arine.io/?utm_campaign=Public%20Relations\u0026utm_source=Bylined%20Article\u0026utm_medium=AJMC\u0026utm_content=Optimizing%20Medication%20Outcomes"}],"children":[{"marks":[],"text":"Yoona Kim, PharmD, PhD, is the CEO and co-founder of ","_key":"f5c43b0094150","_type":"span"},{"_type":"span","marks":["531fb76b610f"],"text":"Arine","_key":"1e6470ee49ca"},{"marks":[],"text":", a next-generation medication intelligence company with a mission to solve medication mismanagement across the health care continuum. Arine’s proprietary platform pulls insights from a complex ecosystem of clinical, socioeconomic, and behavioral data to optimize patient outcomes and deliver value-based care. The technology uses predictive analytics to target care to at-risk members, develops artificial intelligence (AI)-driven personalized care plans for each patient, and uses machine learning to continuously optimize members’ medication therapy. Arine overcomes the limits of traditional, manually driven medication management approaches by making the practice scalable and allowing time-strapped health care providers to deliver care to large populations and with a far greater impact. Arine’s clients have achieved the highest quality ratings and have reduced hospital admissions by 40%.","_key":"2ad98b63e1fb","_type":"span"}]},{"children":[{"_key":"ee58d5fd8fca0","_type":"span","marks":[],"text":"Arine’s AI-driven technology platform is powering successful interventions that navigate complexities discussed in this article. For example, Arine’s platform identified a 67-year-old Latinx male in Medicare Advantage with diabetes and an elevated hemoglobin A"},{"_key":"2886ba74f33e","_type":"span","marks":["subscript"],"text":"1C"},{"text":" at high risk for hyperglycemic crisis. He had a history of medication nonadherence and canceling appointments and expressed difficulty affording a branded diabetes medication. Arine’s platform identified a generic option, along with several other recommendations, to optimize the member’s array of medications for other comorbidities. The platform also flagged a pattern of underutilization of care, indicated by an absence of a primary care visit within the last year and connected the member to an appointment. These measures were supplemented by auto-generated Spanish-language educational materials on the importance of medications and lifestyle changes for diabetes management. Ultimately, the member was very receptive to the recommendations and started taking his medications more regularly.","_key":"00cebefaa126","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"816767524ea1","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"Prior to Arine, Yoona has held various roles at digital health, pharma, and consulting companies. She holds a bachelor’s degree from Stanford University; a PharmD with an emphasis in health policy and management from the University of California, San Francisco; and a PhD in health economics and outcomes from the University of Texas at Austin.","_key":"9db59a3d155d0"}],"_type":"block","style":"normal","_key":"88840c7d9452","markDefs":[]},{"markDefs":[],"children":[{"text":"","_key":"49f538df32460","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f9ff3fa5d2f5"}],"showSocialShare":null}]},{"issueGroup":{"_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71","_type":"reference"},"title":"Physiologic Insulin Resensitization Lowers Cost in Patients With Diabetes and Kidney Disease","summary":"Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382}},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png"}},"published":"2025-01-17T14:00:00.000Z","url":"physiologic-insulin-resensitization-lowers-cost-in-patients-with-diabetes-and-kidney-disease","authorDetails":[{"url":{"current":"zachary-villaverde-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Zachary Villaverde, BS","firstName":"Zachary","lastName":"Villaverde"},{"biography":null,"showSocialShare":null,"displayName":"Roy H. Hinman II, MD","firstName":"Roy","lastName":"Hinman","url":{"current":"roy-h-hinman-ii-md","_type":"slug"},"profileImage":null},{"url":{"current":"richard-m-grimes-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Richard M. Grimes, PhD","firstName":"Richard","lastName":"Grimes"}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Zachary Villaverde, BS","firstName":"Zachary","lastName":"Villaverde","url":{"current":"zachary-villaverde-bs","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Roy H. Hinman II, MD","firstName":"Roy","lastName":"Hinman","url":{"current":"roy-h-hinman-ii-md","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Richard M. Grimes, PhD","firstName":"Richard","lastName":"Grimes","url":{"current":"richard-m-grimes-phd","_type":"slug"},"profileImage":null,"biography":null}],"_id":"4f36a408-190c-4587-b6a4-404014c81e1f"},{"published":"2025-01-16T14:00:00.000Z","factCheckBy":[{"displayName":"Ann Haas, MS, MPH","firstName":"Ann","lastName":"Haas","url":{"current":"ann-haas-ms-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Quigley","url":{"current":"denise-d-quigley-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Denise D. Quigley, PhD","firstName":"Denise"},{"url":{"current":"amelia-m-haviland-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Amelia M. Haviland, PhD","firstName":"Amelia","lastName":"Haviland"},{"firstName":"Nate","lastName":"Orr","url":{"current":"nate-orr-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Nate Orr, MA"},{"displayName":"Julie Brown, BA","firstName":"Julie","lastName":"Brown","url":{"current":"julie-brown-ba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Gaillot","url":{"current":"sarah-gaillot-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sarah Gaillot, PhD","firstName":"Sarah"},{"lastName":"Elliott","url":{"current":"marc-n-elliott-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Marc N. Elliott, PhD","firstName":"Marc"}],"_id":"55d58c83-54a8-4ffd-83e6-7c1642cb2c0a","title":"Telephone Follow-Up on Medicare Patient Surveys Remains Critical","summary":"Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png"}},"url":"telephone-follow-up-on-medicare-patient-surveys-remains-critical","authorDetails":[{"firstName":"Ann","lastName":"Haas","url":{"_type":"slug","current":"ann-haas-ms-mph"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ann Haas, MS, MPH"},{"displayName":"Denise D. Quigley, PhD","firstName":"Denise","lastName":"Quigley","url":{"current":"denise-d-quigley-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Haviland","url":{"current":"amelia-m-haviland-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Amelia M. Haviland, PhD","firstName":"Amelia"},{"url":{"current":"nate-orr-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Nate Orr, MA","firstName":"Nate","lastName":"Orr"},{"firstName":"Julie","lastName":"Brown","url":{"current":"julie-brown-ba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Julie Brown, BA"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sarah Gaillot, PhD","firstName":"Sarah","lastName":"Gaillot","url":{"current":"sarah-gaillot-phd","_type":"slug"}},{"showSocialShare":null,"displayName":"Marc N. Elliott, PhD","firstName":"Marc","lastName":"Elliott","url":{"current":"marc-n-elliott-phd","_type":"slug"},"profileImage":null,"biography":null}],"issueGroup":{"_ref":"3be6d418-ebd1-4073-af15-1f73168f5c71","_type":"reference"}},{"title":"Spotlight on Access and Equity: Bispecifics for Multiple Myeloma in the Community Setting","thumbnail":{"_type":"mainImage","asset":{"metadata":{"blurHash":"e96IKkfxRiogRTWCf8fRayfP02e]t8WAt4t7fhfioeju_Lk6R$ogRn","_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#0c2c44","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":79.02},"_type":"sanity.imagePalette","darkMuted":{"background":"#334961","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.14},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.44,"background":"#697988"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0,"background":"#c4dc54"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":79.02,"background":"#0c2c44","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#c5d0da","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.14},"vibrant":{"background":"#bde428","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.02}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAUABQDASIAAhEBAxEB/8QAGAABAAMBAAAAAAAAAAAAAAAAAAEEBgf/xAAgEAACAQQDAAMAAAAAAAAAAAAAAQIDBAUREiExE1Fh/8QAGAEBAAMBAAAAAAAAAAAAAAAAAAEDBAX/xAAZEQEBAQADAAAAAAAAAAAAAAAAAhEBElH/2gAMAwEAAhEDEQA/AOBpN+EpN+Jmgo562pW8IQx1LnFLc2TSz9tDTdhBy72+u/w3xdVvacc7OPWfSf0wXchexua6nSp/FHilxQLEKOhoACUgAB//2Q==","dimensions":{"_type":"sanity.imageDimensions","width":200,"aspectRatio":1,"height":200},"isOpaque":true},"_rev":"z05Cxco1bGw7CBDJOjIZyP","mimeType":"image/jpeg","_createdAt":"2025-01-22T17:37:51Z","originalFilename":"ontada_logo.jpg","sha1hash":"d24a7ae4df61f95992f74a25b4d5666da68a6206","path":"images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg","_id":"image-d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200-jpg","_updatedAt":"2025-01-22T17:37:51Z","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d24a7ae4df61f95992f74a25b4d5666da68a6206-200x200.jpg","assetId":"d24a7ae4df61f95992f74a25b4d5666da68a6206","uploadId":"AJOmAkothnE9756fQQSjcbTCOOjl6EfV","_type":"sanity.imageAsset","size":4528}},"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Luke Halpern","firstName":null,"lastName":null,"url":{"current":"luke-halpern","_type":"slug"},"profileImage":null},{"lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_type":"reference","_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg"}},"biography":[{"style":"normal","_key":"4a950aea97b3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"3e92e7080a4e"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"_type":"span","marks":[],"text":" (","_key":"4fcef11aec7b"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"083d2efe5747"},{"text":"®","_key":"04c0192c7b85","_type":"span","marks":["sup"]},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_type":"span","marks":["sup"],"text":"®","_key":"5d07912e2fa4"},{"_type":"span","marks":[],"text":". She has been working on ","_key":"f8966f9273cf"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"ad2148a7aae1"},{"_type":"span","marks":[],"text":" since 2014 and has been with ","_key":"60560b0a7800"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3193684b48c2"},{"_type":"span","marks":[],"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50"},{"_key":"f08f3edc84e9","_type":"span","marks":["sup"],"text":"®"},{"marks":[],"text":", since 2011.","_key":"641e0208eef5","_type":"span"}],"_type":"block"},{"_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"text":" or ","_key":"67a67d3764f02","_type":"span","marks":[]},{"text":"Twitter","_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"]},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura"}],"_id":"de999a47-35fe-4e8d-8527-755d8e08ce93","issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"url":"spotlight-on-access-and-equity-bispecifics-for-multiple-myeloma-in-the-community-setting","published":"2025-01-11T17:28:00.000Z","authorDetails":[{"displayName":"Luke Halpern","firstName":null,"lastName":null,"url":{"current":"luke-halpern","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"_type":"slug","current":"laura-joszt"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"children":[{"marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"3e92e7080a4e"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"text":" (","_key":"4fcef11aec7b","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"083d2efe5747"},{"_key":"04c0192c7b85","_type":"span","marks":["sup"],"text":"®"},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_type":"span","marks":["sup"],"text":"®","_key":"5d07912e2fa4"},{"_type":"span","marks":[],"text":". She has been working on ","_key":"f8966f9273cf"},{"text":"AJMC","_key":"ad2148a7aae1","_type":"span","marks":["em"]},{"text":" since 2014 and has been with ","_key":"60560b0a7800","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3193684b48c2"},{"_type":"span","marks":[],"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50"},{"marks":["sup"],"text":"®","_key":"f08f3edc84e9","_type":"span"},{"marks":[],"text":", since 2011.","_key":"641e0208eef5","_type":"span"}],"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[]},{"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_key":"c419f18a7ffe","nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"text":".","_key":"67a67d3764f04","_type":"span","marks":[]}]}],"showSocialShare":true}]},{"title":"SPOTLIGHT: Cilta-Cel Shows Sustained MRD Negativity; Leads to Prolonged PFS in Multiple Myeloma","published":"2025-01-09T00:20:00.000Z","factCheckBy":[{"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage","alt":"Pearl Steinzor"},"biography":null}],"_id":"e7f1792f-598b-4b39-a6aa-40177d13717c","issueGroup":{"_ref":"5115f1e5-56a6-462e-9219-36c2ee74bc64","_type":"reference"},"summary":null,"thumbnail":{"_type":"mainImage","alt":"Yi Lin, MD, PhD ","asset":{"size":4599,"_updatedAt":"2025-01-22T00:31:10Z","originalFilename":"Yi Lin MD PhD.jpg","_rev":"0atQJUC04BTO87jLlB2QZm","sha1hash":"74682bc40139d223bd547d491e60f19bbf4a7a89","_type":"sanity.imageAsset","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","assetId":"74682bc40139d223bd547d491e60f19bbf4a7a89","_createdAt":"2025-01-22T00:31:10Z","extension":"jpg","metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":205,"aspectRatio":0.8333333333333334,"height":246},"isOpaque":true,"blurHash":"eAEoV-x^0#Iq=F~CX9.7xuNG0gxt=FV?Eg.8n~D%WqWA-UWCS2s:V[","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":1.92,"background":"#a9b5b9","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#000","title":"#fff","population":6.83,"background":"#d5a18e","_type":"sanity.imagePaletteSwatch"},"dominant":{"title":"#fff","population":6.83,"background":"#d5a18e","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#50343d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.02},"muted":{"background":"#a4505c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0,"background":"#dbae9e"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.18,"background":"#532f27"}}},"uploadId":"ow8Gv8Np3Nj1GOIUCHMbYvdmmOqXIgMk","path":"images/0vv8moc6/ajmc/74682bc40139d223bd547d491e60f19bbf4a7a89-205x246.jpg","_id":"image-74682bc40139d223bd547d491e60f19bbf4a7a89-205x246-jpg"}},"url":"spotlight-cilta-cel-shows-sustained-mrd-negativity-leads-to-prolonged-pfs-in-multiple-myeloma","authorDetails":[{"lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl "}]},{"_id":"261d60f2-d321-4f0c-b80a-b02f3f9da3ba","summary":null,"published":"2024-12-19T15:00:00.000Z","factCheckBy":[{"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"interview-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"issueGroup":{"_ref":"020f348b-83bc-4402-8a0e-56dfd206392b","_type":"reference"},"title":"The High Cost of Shortages of Low-Cost Chemotherapy","thumbnail":{"_type":"mainImage","alt":"chemotherapy | Image credit: Penn Medicine","asset":{"extension":"png","size":600696,"assetId":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","_updatedAt":"2024-12-19T20:25:38Z","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png","originalFilename":"CHEMO PENN MEDICINE.png","sha1hash":"fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4","_createdAt":"2024-12-19T20:25:38Z","_id":"image-fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658-png","metadata":{"isOpaque":true,"blurHash":"VIKnbqx^%M%Mx]_4?b%MIV-=tRogNGxtxaxst7kDozt6","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"background":"#84723e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.52},"lightMuted":{"population":2.17,"background":"#ccc3af","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"population":0.08,"background":"#cdbb65","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"dominant":{"background":"#3c3f48","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.26,"background":"#3c3f48"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.63,"background":"#a98a6a"},"lightVibrant":{"population":0.07,"background":"#c8b386","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/png;base64,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","dimensions":{"width":1000,"aspectRatio":1.5197568389057752,"height":658,"_type":"sanity.imageDimensions"}},"uploadId":"eCMXCsgcAvTQfUHoAFR5Dl14CWyEWapm","_rev":"bAl93RvH29PY4NpeP8EuRS","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/fc90c1bb74fbe4ee2cf001ef6f3c16b51ccacce4-1000x658.png"}},"url":"the-high-cost-of-shortages-of-low-cost-chemotherapy","authorDetails":[{"displayName":"Interview by Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"interview-by-mary-caffrey","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"title":"A Standardized Care Pathway Increases Optimal Dialysis Starts","published":"2024-12-17T14:00:00.000Z","authorDetails":[{"url":{"current":"roy-g-marcus-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Roy G. Marcus, MD","firstName":"Roy","lastName":"Marcus"},{"displayName":"David M. Miller, MBA","firstName":"David","lastName":"Miller","url":{"current":"david-m-miller-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Brian H. Nathanson, PhD","firstName":"Brian","lastName":"Nathanson","url":{"current":"brian-h-nathanson-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Douglas","lastName":"Eckhardt","url":{"current":"douglas-eckhardt-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Douglas Eckhardt, MBA"},{"displayName":"Steven Henry, PharmD","firstName":"Steven","lastName":"Henry","url":{"current":"steven-henry-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Kwon","url":{"current":"katherine-kwon-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Katherine Kwon, MD","firstName":"Katherine"},{"displayName":"Rohit Sharma, MD","firstName":"Rohit","lastName":"Sharma","url":{"_type":"slug","current":"rohit-sharma-md"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Vakharia","url":{"_type":"slug","current":"nirav-vakharia-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Nirav Vakharia, MD","firstName":"Nirav"}],"factCheckBy":[{"showSocialShare":null,"displayName":"Roy G. Marcus, MD","firstName":"Roy","lastName":"Marcus","url":{"current":"roy-g-marcus-md","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"David M. Miller, MBA","firstName":"David","lastName":"Miller","url":{"current":"david-m-miller-mba","_type":"slug"},"profileImage":null},{"displayName":"Brian H. Nathanson, PhD","firstName":"Brian","lastName":"Nathanson","url":{"current":"brian-h-nathanson-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Douglas","lastName":"Eckhardt","url":{"current":"douglas-eckhardt-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Douglas Eckhardt, MBA"},{"firstName":"Steven","lastName":"Henry","url":{"current":"steven-henry-pharmd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven Henry, PharmD"},{"biography":null,"showSocialShare":null,"displayName":"Katherine Kwon, MD","firstName":"Katherine","lastName":"Kwon","url":{"current":"katherine-kwon-md","_type":"slug"},"profileImage":null},{"url":{"current":"rohit-sharma-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rohit Sharma, MD","firstName":"Rohit","lastName":"Sharma"},{"displayName":"Nirav Vakharia, MD","firstName":"Nirav","lastName":"Vakharia","url":{"current":"nirav-vakharia-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"d38be53d-4528-46a4-bccc-0e2417cb289b","summary":"The authors observed a significant increase in optimal starts for dialysis and in peritoneal dialysis rates after implementing a standardized end-stage renal disease transition pathway.","thumbnail":{"alt":"AJMC","asset":{"_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"palette":{"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png"},"_type":"mainImage"},"url":"a-standardized-care-pathway-increases-optimal-dialysis-starts"},{"_id":"5a821cca-ecbc-492b-b96a-f79fac509885","issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"thumbnail":{"asset":{"_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette"},"hasAlpha":true},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT"},"_type":"mainImage","alt":"AJMC"},"url":"uptake-of-rituximab-biosimilars-in-medicare-and-medicaid-in-2019-2022","published":"2024-12-16T17:00:00.000Z","factCheckBy":[{"displayName":"Jingjing Qian, PhD","firstName":"Jingjing","lastName":"Qian","url":{"current":"jingjing-qian-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"title":"Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022","summary":"Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US.","authorDetails":[{"displayName":"Jingjing Qian, PhD","firstName":"Jingjing","lastName":"Qian","url":{"current":"jingjing-qian-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"_id":"a4a004f4-c13e-4e82-9b80-c57f6a1b3bfd","summary":"Medicaid and other managed care organizations could take several key steps to respond to the sexually transmitted infection (STI) epidemic in the US, including congenital syphilis.","url":"addressing-stis-through-managed-care-opportunities-in-medicaid-and-beyond","published":"2024-12-16T14:00:00.000Z","authorDetails":[{"lastName":"Seiler","url":{"current":"naomi-seiler-jd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Naomi Seiler, JD","firstName":"Naomi"},{"lastName":"Horton","url":{"current":"katie-horton-jd-rn-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Katie Horton, JD, RN, MPH","firstName":"Katie"},{"displayName":"Paige Organick-Lee, MPH","firstName":"Paige","lastName":"Organick-Lee","url":{"current":"paige-organick-lee-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Mekhi Washington, BS","firstName":"Mekhi","lastName":"Washington","url":{"current":"mekhi-washington-bs","_type":"slug"},"profileImage":null,"biography":null},{"lastName":"Turner","url":{"current":"taylor-turner-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Taylor Turner, MPH","firstName":"Taylor"},{"displayName":"William S. Pearson, PhD, MHA","firstName":"William","lastName":"Pearson","url":{"current":"william-s-pearson-phd-mha","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"issueGroup":{"_ref":"336c2bd9-8d6c-4558-8bd3-24df074cf426","_type":"reference"},"title":"Addressing STIs Through Managed Care: Opportunities in Medicaid and Beyond","thumbnail":{"_type":"mainImage","asset":{"_createdAt":"2023-07-11T20:45:56Z","_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","extension":"png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"_type":"sanity.imageExifMetadata","PixelXDimension":778,"PixelYDimension":382},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true},"sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","_updatedAt":"2023-07-11T20:45:56Z","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","_rev":"hiKH9HIKxNVM35TxYdonKh","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","size":203185,"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6"}},"factCheckBy":[{"url":{"current":"naomi-seiler-jd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Naomi Seiler, JD","firstName":"Naomi","lastName":"Seiler"},{"displayName":"Katie Horton, JD, RN, MPH","firstName":"Katie","lastName":"Horton","url":{"current":"katie-horton-jd-rn-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Paige","lastName":"Organick-Lee","url":{"current":"paige-organick-lee-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Paige Organick-Lee, MPH"},{"firstName":"Mekhi","lastName":"Washington","url":{"current":"mekhi-washington-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mekhi Washington, BS"},{"url":{"current":"taylor-turner-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Taylor Turner, MPH","firstName":"Taylor","lastName":"Turner"},{"biography":null,"showSocialShare":null,"displayName":"William S. Pearson, PhD, MHA","firstName":"William","lastName":"Pearson","url":{"current":"william-s-pearson-phd-mha","_type":"slug"},"profileImage":null}]},{"published":"2024-12-12T18:00:00.000Z","title":"Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models","thumbnail":{"alt":"Park City Utah | Image Credit: © SeanPavonePhoto - stock.adobe.com","asset":{"assetId":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","_id":"image-d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800-jpg","_updatedAt":"2024-12-09T16:14:43Z","_type":"sanity.imageAsset","sha1hash":"d79c993ad4d9e3983bc0d532aad3e304b33becd6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","path":"images/0vv8moc6/ajmc/d79c993ad4d9e3983bc0d532aad3e304b33becd6-1200x800.jpg","size":684667,"metadata":{"blurHash":"VbGt,K%NbvogW;-@o~s;xFofxbSiR*s9jvRjNIR*R*bI","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#531914","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"population":1.88,"background":"#baacda","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.86,"background":"#ce742b","_type":"sanity.imagePaletteSwatch"},"dominant":{"foreground":"#fff","title":"#fff","population":6.52,"background":"#55402b","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":6.52,"background":"#55402b","_type":"sanity.imagePaletteSwatch"},"muted":{"population":6.15,"background":"#8c7298","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.57,"background":"#db8a8b"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"SubSecTimeOriginal":"72","ExposureBiasValue":0,"FocalLengthIn35mmFormat":70,"SubjectDistanceRange":0,"DateTimeOriginal":"2019-09-30T07:53:48.000Z","SceneCaptureType":0,"FNumber":11,"ISO":64,"FocalPlaneYResolution":2301.324607329843,"SensingMethod":2,"ApertureValue":6.9188632619439865,"ColorSpace":1,"MeteringMode":5,"ExposureTime":72,"Saturation":0,"LightSource":9,"SubSecTimeDigitized":"72","ShutterSpeedValue":-6.169924996926103,"CustomRendered":0,"WhiteBalance":1,"LensSpecification":[70,200,2.8,2.8],"RecommendedExposureIndex":64,"LensModel":"70.0-200.0 mm f/2.8","ExposureMode":1,"FocalPlaneXResolution":2301.324607329843,"PixelXDimension":1200,"ExposureProgram":1,"GainControl":0,"BodySerialNumber":"3009697","Contrast":0,"PixelYDimension":800,"_type":"sanity.imageExifMetadata","Sharpness":1,"DateTimeDigitized":"2019-09-30T07:53:48.000Z","MaxApertureValue":2.9708536585365852,"FocalLength":70,"FocalPlaneResolutionUnit":3,"SensitivityType":2},"isOpaque":true},"extension":"jpg","uploadId":"HbuqVrHWM61ym51aODEQvln7RdZOo3Y9","_createdAt":"2024-12-09T16:14:43Z","originalFilename":"Park City Utah - SeanPavonePhoto - stock.adobe.com.jpeg","_rev":"NpDlOLwo2XgOWDaMKGnmaJ","mimeType":"image/jpeg"},"_type":"mainImage"},"authorDetails":[{"url":{"current":"kyle-munz","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Kyle Munz","asset":{"_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Kyle Munz","firstName":"Kyle","lastName":"Munz"}],"factCheckBy":[{"lastName":"Munz","url":{"current":"kyle-munz","_type":"slug"},"profileImage":{"alt":"Kyle Munz","asset":{"_ref":"image-afb5da0a933e7f6f632d76cd52a5bc1c1243fb36-430x430-png","_type":"reference"},"_type":"mainImage"},"biography":null,"showSocialShare":null,"displayName":"Kyle Munz","firstName":"Kyle"}],"_id":"1b2f775c-eb1e-4c9d-aab4-b9c0796cb0e2","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"summary":"Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes. ","url":"transforming-kidney-care-policy-risk-stratification-and-collaborative-models"},{"_id":"f802c956-5821-427f-8529-cd5ac1bf6b46","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"title":"From Approval to Practice: Addressing the Hurdles in Biosimilar Integration","summary":"Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.","authorDetails":[{"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0"}],"_type":"block","style":"normal","_key":"f73a10e9267d","markDefs":[]},{"style":"normal","_key":"95aad26356ef","markDefs":[{"href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"text":".","_key":"6fba991875ae2","_type":"span","marks":[]}],"_type":"block"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null,"url":{"current":"skylar-jeremias","_type":"slug"}}],"factCheckBy":[{"url":{"current":"skylar-jeremias","_type":"slug"},"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span"}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"_type":"span","marks":[],"text":".","_key":"6fba991875ae2"}],"_type":"block","style":"normal","_key":"95aad26356ef"}],"showSocialShare":null,"displayName":"Skylar Jeremias","firstName":null,"lastName":null}],"thumbnail":{"_type":"mainImage","alt":"Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com","asset":{"_rev":"Wk5bXdTaWvRA2U061yIUpH","mimeType":"image/jpeg","originalFilename":"Seattle Washington skyline - espiegle - stock.adobe.com.jpeg","_type":"sanity.imageAsset","_updatedAt":"2024-12-09T16:08:58Z","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","path":"images/0vv8moc6/ajmc/50d700b88aa9af2c75864177d43c5651d055284b-1200x697.jpg","size":691007,"assetId":"50d700b88aa9af2c75864177d43c5651d055284b","metadata":{"palette":{"dominant":{"foreground":"#fff","title":"#fff","population":8.35,"background":"#565e2e","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"population":8.35,"background":"#565e2e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"background":"#92ac4f","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.07,"background":"#8fb9e4"},"darkVibrant":{"background":"#53590e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.59},"lightMuted":{"title":"#fff","population":8.22,"background":"#d1c4b3","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.04,"background":"#1775d9"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"width":1200,"aspectRatio":1.721664275466284,"height":697,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"M%DAo?fkWBofWBTOj]j?WWj?IXa~oKayj[","_type":"sanity.imageMetadata"},"uploadId":"720OvtZqjd5bfGGG0HMUoxl39Z5gnaIE","sha1hash":"50d700b88aa9af2c75864177d43c5651d055284b","_createdAt":"2024-12-09T16:08:58Z","_id":"image-50d700b88aa9af2c75864177d43c5651d055284b-1200x697-jpg"}},"url":"from-approval-to-practice-addressing-the-hurdles-in-biosimilar-integration","published":"2024-12-12T17:00:00.000Z"},{"factCheckBy":[{"lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage","alt":"Pearl Steinzor"},"biography":null,"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl "}],"_id":"07739c7a-2ab2-4136-9387-b461d01ee7d6","issueGroup":{"_ref":"5c3d9b93-74e5-4e58-915c-ae8f5885c9b7","_type":"reference"},"title":"Navigating the Complexities of Neurological Drug Access","summary":"At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases. ","authorDetails":[{"showSocialShare":null,"displayName":"Pearl Steinzor","firstName":"Pearl ","lastName":"Steinzor","url":{"current":"pearl-steinzor","_type":"slug"},"profileImage":{"alt":"Pearl Steinzor","asset":{"_ref":"image-aaad3972f041cf080c4994a923d62017c74f0ac3-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":null}],"thumbnail":{"_type":"mainImage","alt":"Aurora Colorado aerial | Image Credit: © Jacob - stock.adobe.com","asset":{"metadata":{"isOpaque":true,"blurHash":"VtBzqmogR*a}aypMofaxa#ayS+j[jZj[ayRkfkj?fPjs","hasAlpha":false,"dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5018773466833542,"height":799},"_type":"sanity.imageMetadata","location":{"lng":-104.88007777777777,"_type":"geopoint","alt":1846,"lat":39.63568055555555},"exif":{"ShutterSpeedValue":6.643856143856143,"PixelXDimension":1200,"Saturation":0,"ExposureMode":1,"MeteringMode":2,"GainControl":0,"BodySerialNumber":"0K8TFB50024243","ExposureProgram":1,"FNumber":11,"MaxApertureValue":2.9708536585365852,"ExposureBiasValue":0,"ColorSpace":1,"ISO":100,"_type":"sanity.imageExifMetadata","DigitalZoomRatio":1,"DateTimeOriginal":"2021-10-22T12:38:25.000Z","ExposureTime":0.01,"LensSpecification":[28,28,2.8,11],"FocalLength":10.3,"PixelYDimension":799,"Flash":0,"SceneCaptureType":0,"LightSource":1,"FocalLengthIn35mmFormat":28,"WhiteBalance":0,"DateTimeDigitized":"2021-10-22T12:38:25.000Z","ApertureValue":6.9188632619439865,"Contrast":0,"Sharpness":0},"palette":{"lightMuted":{"population":0.11,"background":"#ada8bc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#0a71c4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.59},"dominant":{"background":"#938a66","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.03},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.95,"background":"#343f53","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"background":"#938a66","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.03},"lightVibrant":{"population":0.11,"background":"#7da9ec","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.03,"background":"#054cac"}},"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAQGBf/EACIQAAIBBAEEAwAAAAAAAAAAAAECAAMEBREhBhIUMUFRYv/EABYBAQEBAAAAAAAAAAAAAAAAAAMAAv/EABwRAAEFAAMAAAAAAAAAAAAAAAEAAgQFIRVRUv/aAAwDAQACEQMRAD8AWt+ocWQKb4s7+uIvd5XC1A2scQR+pBWV1UYM5PK+o75BentlBJ59ydcSmnChFfGcNat0nHVj3pbKoPwX1CStdy9ViCVA40DCMLmZ2scXG8r/2Q=="},"uploadId":"hDCo0dHvoUsJtwqc6XFChcP57mr0GYWo","path":"images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"e795e86678821e21c6aef5cf087bc961b2661488","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/e795e86678821e21c6aef5cf087bc961b2661488-1200x799.jpg","_updatedAt":"2024-12-09T16:01:02Z","originalFilename":"Aurora Colorado aerial - Jacob - stock.adobe.com.jpeg","extension":"jpg","_rev":"Wk5bXdTaWvRA2U061yEwr7","size":792084,"_id":"image-e795e86678821e21c6aef5cf087bc961b2661488-1200x799-jpg","assetId":"e795e86678821e21c6aef5cf087bc961b2661488","_createdAt":"2024-12-09T16:01:02Z"}},"url":"navigating-the-complexities-of-neurological-drug-access","published":"2024-12-12T16:00:00.000Z"},{"summary":"An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.","published":"2024-09-16T16:31:55.211Z","title":"Healthy State: Practicing What They Preach in Louisiana","thumbnail":{"asset":{"extension":"jpg","uploadId":"kH1bS8OTS7iWFNmOt3qixxFUDmuSmj11","title":null,"opt":{"media":{"tags":null}},"assetId":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","_createdAt":"2024-08-28T16:07:24Z","_id":"image-29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867-jpg","altText":null,"_rev":"LtkInV1jlQdtEIFjVqjDMg","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","size":4265557,"_updatedAt":"2024-08-28T16:07:46Z","metadata":{"blurHash":"VLKJoRB?^vPDoi765Ev|$*$x~W-poztRR-%#x]SxNyt7","_type":"sanity.imageMetadata","palette":{"darkMuted":{"title":"#fff","population":2.99,"background":"#2e3d58","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"title":"#fff","population":5.22,"background":"#976e64","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"title":"#000","population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":6.13,"background":"#935917","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":0.06,"background":"#b6a9cd","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.95,"background":"#efa11f"},"dominant":{"population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2800,"aspectRatio":1.4997321906802357,"height":1867},"exif":{"ColorSpace":1,"Sharpness":0,"Contrast":0,"MaxApertureValue":4,"RecommendedExposureIndex":100,"ISO":100,"_type":"sanity.imageExifMetadata","DateTimeOriginal":"2016-11-15T06:32:19.000Z","LensModel":"16-35mm F4 G SSM OSS","FocalPlaneResolutionUnit":3,"DateTimeDigitized":null,"WhiteBalance":0,"FocalPlaneYResolution":2164.4328018223237,"PixelXDimension":2800,"ExposureBiasValue":0,"ExposureTime":2,"SceneCaptureType":0,"ExposureMode":1,"PixelYDimension":1867,"ShutterSpeedValue":-1,"FocalLength":28,"Saturation":2,"DigitalZoomRatio":1,"BrightnessValue":-0.89296875,"CustomRendered":0,"SensitivityType":2,"FocalLengthIn35mmFormat":42,"MeteringMode":5,"FocalPlaneXResolution":2164.4328018223237,"FNumber":5.6,"ApertureValue":4.970853658536585,"LightSource":0,"ExposureProgram":1,"LensSpecification":[16,35,4,4]},"isOpaque":true},"mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","originalFilename":"New Orleans Bourbon Street - f11photo - AdobeStock_169182961.jpeg","description":null,"sha1hash":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707"},"_type":"mainImage","alt":"New Orleans Bourbon Street | Image Credit: © f11photo - stock.adobe.com"},"url":"healthy-state-practicing-what-they-preach-in-louisiana","authorDetails":[{"firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"},"default":false,"_type":"mainImage","alt":"Mary K. Caffrey"},"biography":null,"showSocialShare":null,"displayName":"Mary K. Caffrey"}],"factCheckBy":[{"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Mary K. Caffrey","firstName":null}],"_id":"04159ba8-44f9-40b5-b25f-0ae627881e39","issueGroup":{"_type":"reference","_ref":"73c988a3-a73b-49fa-af49-dce7e755e713"}},{"_id":"2a95bae0-0c9f-4bc1-8e7d-3602ac803646","issueGroup":{"_type":"reference","_ref":"73c988a3-a73b-49fa-af49-dce7e755e713"},"url":"multifaceted-approach-can-help-patients-benefit-from-the-expanded-lipid-lowering-toolbox","published":"2024-09-16T16:31:18.436Z","authorDetails":[{"lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"alt":"Christina Mattina","asset":{"_type":"reference","_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg"},"_type":"mainImage"},"biography":[{"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678","_type":"span"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"text":"AJMC","_key":"b773bee92455","_type":"span","marks":["em"]},{"marks":["superscript"],"text":"®","_key":"1f9bb13b24fa","_type":"span"},{"_key":"b9461d308bc8","_type":"span","marks":[],"text":") and "},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490"},{"text":"®","_key":"14118ee858d3","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45","markDefs":[]},{"style":"normal","_key":"a90d7ab4c801","markDefs":[{"href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_key":"6d8dca7834cc","_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on "},{"_key":"e23534b48658","_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn"},{"_key":"83d100c64d0e","_type":"span","marks":[],"text":"."}],"_type":"block"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina"}],"title":"Institute for Value-Based Medicine®: Multifaceted Approach Can Help Patients Benefit From the Expanded Lipid-Lowering Toolbox","summary":"Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.","thumbnail":{"_type":"mainImage","alt":"Denver Colorado | Image Credit: © f11photo - stock.adobe.com","asset":{"extension":"jpg","uploadId":"H7WTao1JKvhWv1JBicLCJENbGPV6jpQH","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","_createdAt":"2024-09-13T18:14:54Z","originalFilename":"Denver Colorado - f11photo - stock.adobe.com.jpeg","metadata":{"palette":{"dominant":{"population":6.64,"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64},"muted":{"title":"#fff","population":4.67,"background":"#50659b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.31,"background":"#e9cf8d","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":0.56,"background":"#544d07","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#a2a7c8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.42,"background":"#ca762d"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAcCBAX/xAAfEAACAgICAwEAAAAAAAAAAAABAgADBBEGEiExYQX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAwT/xAAdEQABBAIDAAAAAAAAAAAAAAADAAECEQQxBRJB/9oADAMBAAIRAxEAPwCeBhfnUkd7arNe+reptUZ/HVcV2voiKx8m2mtTWQCfgly3NtZEdhWWHgHqJI3InaVstA4C6aTkqyOIJWvfKRSRvREImxc7gMx8n5CBs83qLxhel//Z","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7142857142857142,"height":700},"exif":{"DateTimeDigitized":"2014-09-12T07:37:33.000Z","ColorSpace":1,"PixelXDimension":1200,"PixelYDimension":700,"_type":"sanity.imageExifMetadata"},"isOpaque":true,"blurHash":"MjHx1~IoS$S4oL%QRijZWrbH9vocWAoffP","_type":"sanity.imageMetadata"},"_rev":"WVB52uR738qojYGNKmrerb","_type":"sanity.imageAsset","_updatedAt":"2024-09-13T18:14:54Z","mimeType":"image/jpeg","sha1hash":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","path":"images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","size":584915,"assetId":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","_id":"image-c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700-jpg"}},"factCheckBy":[{"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"marks":["superscript"],"text":"®","_key":"b16316585120","_type":"span"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b773bee92455"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_key":"b9461d308bc8","_type":"span","marks":[],"text":") and "},{"text":"The American Journal of Accountable Care","_key":"f235dc7df490","_type":"span","marks":["em"]},{"text":"®","_key":"14118ee858d3","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_key":"6353c3a02e0f","_type":"span","marks":["em"],"text":"AJAC"},{"_type":"span","marks":[],"text":"), and joined ","_key":"7f777b20be12"},{"marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4","_type":"span"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal","_key":"9271b97a8f45"},{"children":[{"_key":"6d8dca7834cc","_type":"span","marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on "},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"text":".","_key":"83d100c64d0e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"a90d7ab4c801","markDefs":[{"href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d","nofollow":true,"blank":true,"_type":"link"}]}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"}}]},{"_id":"336a74f6-937d-40c6-a94c-b14c26f025f6","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"title":"Telehealth Insights From an Integrated Care System","summary":"Experiences from a large, integrated, value-based health system suggest that telehealth can be an effective care delivery approach. Public policies can improve telehealth access and care.","thumbnail":{"_type":"mainImage","alt":"telemedicine | Image Credit: © rh2010 - stock.adobe.com","asset":{"extension":"jpg","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":7360,"aspectRatio":1.498371335504886,"height":4912},"isOpaque":true,"blurHash":"VEDl=,D%4n?c-;_N%M-pD%xvM{-;_3DiWBt7xax]t7M{","_type":"sanity.imageMetadata","palette":{"dominant":{"title":"#fff","population":6.95,"background":"#bbbcbe","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#61553c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.82},"muted":{"foreground":"#fff","title":"#fff","population":0,"background":"#b4745c","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"background":"#e7d1c6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.05},"darkVibrant":{"population":6.07,"background":"#493a1a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.95,"background":"#bbbcbe"},"vibrant":{"title":"#fff","population":0.01,"background":"#ba825c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAYHA//EACUQAAIBAwMEAgMAAAAAAAAAAAECBAADBQYRIQcSE1EVQUNhgf/EABYBAQEBAAAAAAAAAAAAAAAAAAQCA//EABkRAQADAQEAAAAAAAAAAAAAAAEAAhEDgf/aAAwDAQACEQMRAD8ASY/UadK1hetXCiWHuEBtuV/dN+R0jjJcZs3aK5F9vI4tkgn+VF7LJ8mL5tguTuapOL1LLi6T8EcKnddKBgeQvoUY7BfGatdNJrG6kQcdZWNDe/ZtJ+MHbtP2KKQszhIs2e8hgyO/LBTwT7opEjyf/9k="},"uploadId":"ueKegQc9OLg07IP1riXXhgBAywYfiVMU","path":"images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","mimeType":"image/jpeg","sha1hash":"aa55cba013e542363db5e3021a7d049b005c0d44","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","size":10640408,"_createdAt":"2023-12-05T16:28:07Z","_id":"image-aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912-jpg","_type":"sanity.imageAsset","assetId":"aa55cba013e542363db5e3021a7d049b005c0d44","_updatedAt":"2023-12-05T16:28:07Z","_rev":"yLkPQ1Yunv4gUqVh5QBQaa","originalFilename":"telemedicine - rh2010.jpeg"}},"url":"telehealth-insights-from-an-integrated-care-system","authorDetails":[{"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null},{"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"published":"2024-09-16T16:29:41.215Z","factCheckBy":[{"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah"},{"firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elizabeth Moisan, MS"},{"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null}]},{"_id":"1472df1f-ab77-4b68-8ced-12ff81256022","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"title":"Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine","summary":"At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.","url":"cardiometabolic-interventions-focus-on-accessibility-evidence-based-medicine","factCheckBy":[{"firstName":"Giuliana","lastName":"Grossi","url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"caption":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","asset":{"_ref":"image-6ce94d112b3a5df5bd05dc2b689a0720adadcc62-400x400-jpg","_type":"reference"},"_type":"mainImage","alt":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC"},"biography":[{"_key":"7644d0957596","markDefs":[{"href":"https://www.ajmc.com/topic/center-on-health-equity-and-access","_key":"324bbc17fbcd","nofollow":false,"blank":true,"_type":"link"}],"children":[{"text":"Giuliana Grossi is an editor for ","_key":"0179b0541e0b","_type":"span","marks":[]},{"text":"The American Journal of Managed Care","_key":"d7871694e50e","_type":"span","marks":["em"]},{"marks":["sup"],"text":"®","_key":"3173808ea48d","_type":"span"},{"_type":"span","marks":[],"text":", overseeing the publication's ","_key":"1c074ec7251f"},{"_key":"e68159433236","_type":"span","marks":["324bbc17fbcd"],"text":"Center on Health Equity \u0026 Access"},{"_type":"span","marks":[],"text":". Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.","_key":"c2e2da920bfb"}],"_type":"block","style":"normal"},{"_key":"cf123c823686","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Before Giuliana joined ","_key":"cd7292039254"},{"text":"AJMC","_key":"ad727be45f99","_type":"span","marks":["em"]},{"text":", she delved into rare disease coverage at HCPLive","_key":"c140cf0f19d0","_type":"span","marks":[]},{"_type":"span","marks":["sup"],"text":"®","_key":"39ac8edb75a8"},{"text":", a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in ","_key":"6a1265a483a0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"Population Health, Equity \u0026 Outcomes","_key":"cf2d12c38dca"},{"_type":"span","marks":["sup"],"text":"®","_key":"aa763d202117"},{"_type":"span","marks":[],"text":" (formerly ","_key":"61f88e04956e"},{"marks":["em"],"text":"The American Journal of Accountable Care","_key":"17e5c52377f8","_type":"span"},{"_type":"span","marks":["sup"],"text":"®","_key":"5504bfff7017"},{"_type":"span","marks":[],"text":"), ","_key":"19512dc0b299"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"3cb7d49a81f9"},{"_type":"span","marks":["sup"],"text":"®","_key":"22ab5aeaa59a"},{"_type":"span","marks":[],"text":",","_key":"b1d13339e368"},{"_type":"span","marks":["sup"],"text":" ","_key":"fcd8255a68b5"},{"_key":"e4e8d0128520","_type":"span","marks":[],"text":"NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive."}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.","_key":"5f3ea2ee587e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"59a199fedfec"},{"style":"normal","_key":"cd682b512e51","markDefs":[],"children":[{"_type":"span","marks":[],"text":"\n","_key":"e7fe8691814f"}],"_type":"block"}],"showSocialShare":null,"displayName":"Giuliana Grossi"}],"thumbnail":{"alt":"San Francisco's Golden Gate Bridge | Image Credit: © phitha - stock.adobe.com","asset":{"metadata":{"exif":{"FNumber":11,"FocalPlaneYResolution":2164.4328018223237,"FocalLength":220,"DateTimeOriginal":"2016-06-04T04:25:41.000Z","Contrast":0,"ShutterSpeedValue":-1.6780719083366258,"ExposureProgram":3,"WhiteBalance":1,"RecommendedExposureIndex":200,"ColorSpace":1,"DigitalZoomRatio":1,"FocalPlaneXResolution":2164.4328018223237,"FocalPlaneResolutionUnit":3,"LensSpecification":[70,300,4.5,5.6],"PixelXDimension":1200,"ExposureBiasValue":0,"ISO":200,"SensitivityType":2,"_type":"sanity.imageExifMetadata","BrightnessValue":-0.44765625,"FocalLengthIn35mmFormat":220,"SceneCaptureType":0,"Sharpness":0,"LensModel":"FE 70-300mm F4.5-5.6 G OSS","ApertureValue":6.9188632619439865,"LightSource":14,"ExposureMode":0,"ExposureTime":3.2,"MaxApertureValue":4.970853658536585,"Saturation":0,"DateTimeDigitized":"2016-06-04T04:25:41.000Z","MeteringMode":5,"PixelYDimension":800,"CustomRendered":0},"isOpaque":true,"blurHash":"VuJ@2qs:WCjYbb}%soahbIjs-:R*WBoJW:I.W=WEoLj[","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"background":"#2e3250","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.93},"muted":{"background":"#9c5c58","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.47},"lightVibrant":{"background":"#fbe182","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":4.62},"darkVibrant":{"population":3.69,"background":"#6f2c2a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#fff","population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#f2a973","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":7.2},"dominant":{"background":"#9099c0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":8.5}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"height":800,"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5}},"_rev":"SWZtARO2mf3vRstToueLld","sha1hash":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","path":"images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","assetId":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","extension":"jpg","_type":"sanity.imageAsset","mimeType":"image/jpeg","_id":"image-1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800-jpg","uploadId":"O5nnIZFuz4knEBd9QmteN8nCCmR8xh2K","size":416089,"_createdAt":"2024-06-07T15:30:01Z","originalFilename":"San Francisco Golden Gate Bridge - phitha - stock.adobe.com.jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","_updatedAt":"2024-06-07T15:30:01Z"},"_type":"mainImage"},"published":"2024-06-14T13:00:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":"Giuliana","lastName":"Grossi","url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","caption":"Giuliana Grossi, Editor, Center on Health Equity \u0026 Access, AJMC","asset":{"_ref":"image-6ce94d112b3a5df5bd05dc2b689a0720adadcc62-400x400-jpg","_type":"reference"}},"biography":[{"markDefs":[{"_type":"link","href":"https://www.ajmc.com/topic/center-on-health-equity-and-access","_key":"324bbc17fbcd","nofollow":false,"blank":true}],"children":[{"marks":[],"text":"Giuliana Grossi is an editor for ","_key":"0179b0541e0b","_type":"span"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"d7871694e50e","_type":"span"},{"_key":"3173808ea48d","_type":"span","marks":["sup"],"text":"®"},{"marks":[],"text":", overseeing the publication's ","_key":"1c074ec7251f","_type":"span"},{"text":"Center on Health Equity \u0026 Access","_key":"e68159433236","_type":"span","marks":["324bbc17fbcd"]},{"_type":"span","marks":[],"text":". Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.","_key":"c2e2da920bfb"}],"_type":"block","style":"normal","_key":"7644d0957596"},{"children":[{"marks":[],"text":"Before Giuliana joined ","_key":"cd7292039254","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"ad727be45f99"},{"_type":"span","marks":[],"text":", she delved into rare disease coverage at HCPLive","_key":"c140cf0f19d0"},{"_type":"span","marks":["sup"],"text":"®","_key":"39ac8edb75a8"},{"_key":"6a1265a483a0","_type":"span","marks":[],"text":", a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in "},{"marks":["em"],"text":"Population Health, Equity \u0026 Outcomes","_key":"cf2d12c38dca","_type":"span"},{"text":"®","_key":"aa763d202117","_type":"span","marks":["sup"]},{"_type":"span","marks":[],"text":" (formerly ","_key":"61f88e04956e"},{"_type":"span","marks":["em"],"text":"The American Journal of Accountable Care","_key":"17e5c52377f8"},{"_type":"span","marks":["sup"],"text":"®","_key":"5504bfff7017"},{"_type":"span","marks":[],"text":"), ","_key":"19512dc0b299"},{"text":"Evidence-Based Oncology","_key":"3cb7d49a81f9","_type":"span","marks":["em"]},{"_type":"span","marks":["sup"],"text":"®","_key":"22ab5aeaa59a"},{"text":",","_key":"b1d13339e368","_type":"span","marks":[]},{"_type":"span","marks":["sup"],"text":" ","_key":"fcd8255a68b5"},{"_type":"span","marks":[],"text":"NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.","_key":"e4e8d0128520"}],"_type":"block","style":"normal","_key":"cf123c823686","markDefs":[]},{"_type":"block","style":"normal","_key":"59a199fedfec","markDefs":[],"children":[{"text":"She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.","_key":"5f3ea2ee587e","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"marks":[],"text":"\n","_key":"e7fe8691814f","_type":"span"}],"_type":"block","style":"normal","_key":"cd682b512e51"}]}]},{"thumbnail":{"_type":"mainImage","alt":"Cleveland Ohio | Image Credit: © Ai - stock.adobe.com.jpeg","asset":{"metadata":{"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"ExposureBiasValue":0.33,"FocalPlaneXResolution":2083.4231274638632,"LensSpecification":[18,55,2.8,4],"ExposureTime":0.08333333333333333,"MaxApertureValue":2.9708536585365852,"DateTimeOriginal":"2016-07-24T18:28:07.000Z","LightSource":11,"SubjectDistanceRange":0,"MeteringMode":5,"Sharpness":0,"CustomRendered":0,"DateTimeDigitized":"2016-07-24T00:00:00.000Z","ColorSpace":1,"SensingMethod":2,"SensitivityType":1,"ShutterSpeedValue":3.584962502403692,"SceneCaptureType":0,"_type":"sanity.imageExifMetadata","ApertureValue":8.643856143856144,"WhiteBalance":1,"ExposureProgram":3,"LensModel":"XF18-55mmF2.8-4 R LM OIS","LensSerialNumber":"48A03748","Saturation":1,"FocalPlaneResolutionUnit":3,"ISO":500,"FocalLengthIn35mmFormat":27,"FNumber":20,"BrightnessValue":5.84,"LensMake":"FUJIFILM","FocalLength":18,"PixelYDimension":800,"ExposureMode":0,"FocalPlaneYResolution":2083.4231274638632,"PixelXDimension":1200},"isOpaque":true,"blurHash":"VwHx:8$xRit5WA_4$~jEaej[T1oMWEa}axENR-f6bIWC","_type":"sanity.imageMetadata","palette":{"lightMuted":{"title":"#fff","population":2.56,"background":"#8897be","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#0d90d3","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.13},"dominant":{"population":6.22,"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.79,"background":"#30384f"},"muted":{"title":"#fff","population":6.22,"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":2.52,"background":"#efc989","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"background":"#043484","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0}}},"mimeType":"image/jpeg","_createdAt":"2024-06-07T15:42:37Z","_type":"sanity.imageAsset","size":501001,"originalFilename":"Cleveland Ohio - Ai - stock.adobe.com.jpeg","_updatedAt":"2024-06-07T15:42:37Z","uploadId":"gcL2RcGUNOwVnVWGsh0ao9mQiEvDHrKK","sha1hash":"264df279db594adda69bc3737a08c6773f27a6ef","path":"images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","assetId":"264df279db594adda69bc3737a08c6773f27a6ef","_rev":"FTf7O3KU2GxuMy4tElpSB4","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","_id":"image-264df279db594adda69bc3737a08c6773f27a6ef-1200x800-jpg","extension":"jpg"}},"published":"2024-06-13T19:00:00.000Z","authorDetails":[{"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"_type":"slug","current":"laura-joszt"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_key":"4a950aea97b3","markDefs":[],"children":[{"marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"3e92e7080a4e"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"text":" (","_key":"4fcef11aec7b","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"083d2efe5747"},{"_key":"04c0192c7b85","_type":"span","marks":["sup"],"text":"®"},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_type":"span","marks":["sup"],"text":"®","_key":"5d07912e2fa4"},{"_type":"span","marks":[],"text":". She has been working on ","_key":"f8966f9273cf"},{"text":"AJMC","_key":"ad2148a7aae1","_type":"span","marks":["em"]},{"text":" since 2014 and has been with ","_key":"60560b0a7800","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3193684b48c2"},{"_type":"span","marks":[],"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50"},{"marks":["sup"],"text":"®","_key":"f08f3edc84e9","_type":"span"},{"marks":[],"text":", since 2011.","_key":"641e0208eef5","_type":"span"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"text":".","_key":"67a67d3764f04","_type":"span","marks":[]}]}],"showSocialShare":true}],"issueGroup":{"_type":"reference","_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0"},"title":"Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity ","summary":"The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.","url":"experts-highlight-how-glp-1s-have-revolutionized-management-of-t2d-and-obesity","factCheckBy":[{"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_type":"reference","_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg"}},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Laura is the vice president of content for ","_key":"67a67d3764f00"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"3e92e7080a4e"},{"_type":"span","marks":["sup"],"text":"®","_key":"8db7645e2c87"},{"_type":"span","marks":[],"text":" (","_key":"4fcef11aec7b"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"083d2efe5747"},{"text":"®","_key":"04c0192c7b85","_type":"span","marks":["sup"]},{"_type":"span","marks":[],"text":") and all its brands, including Population Health, Equity \u0026 Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars","_key":"56aab0fa0b1d"},{"_type":"span","marks":["sup"],"text":"®","_key":"5d07912e2fa4"},{"_type":"span","marks":[],"text":". She has been working on ","_key":"f8966f9273cf"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"ad2148a7aae1"},{"_type":"span","marks":[],"text":" since 2014 and has been with ","_key":"60560b0a7800"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3193684b48c2"},{"_type":"span","marks":[],"text":"’s parent company, MJH Life Sciences","_key":"ceecbf068d50"},{"_key":"f08f3edc84e9","_type":"span","marks":["sup"],"text":"®"},{"marks":[],"text":", since 2011.","_key":"641e0208eef5","_type":"span"}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on ","_key":"48d199d8ecd5"},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"text":" or ","_key":"67a67d3764f02","_type":"span","marks":[]},{"text":"Twitter","_key":"67a67d3764f03","_type":"span","marks":["c419f18a7ffe"]},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"}}],"_id":"4d553701-915f-4873-8b9f-4f53893d6561"},{"_id":"e881417a-9e64-48ca-9b72-7daafa2dd9c4","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"summary":"The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.","authorDetails":[{"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans","url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Warren Fisher, DO","firstName":"Warren"},{"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null}],"title":"Reducing Delays in Breast Cancer Care Using an Innovative Digital Health Platform","thumbnail":{"alt":"Medical technology and digital health network concept | Image Credit: © ipopba - stock.adobe.com","asset":{"sha1hash":"1e602bba35858bd62230432132517d1d42061e3d","_id":"image-1e602bba35858bd62230432132517d1d42061e3d-1280x800-jpg","originalFilename":"Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept - ipopba - stock.adobe.com.jpeg","_rev":"pEhoUqandJkxjPidorVwRV","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","size":323017,"assetId":"1e602bba35858bd62230432132517d1d42061e3d","_createdAt":"2023-09-25T20:33:46Z","uploadId":"hTRTLrPbL2uAPSQkjvmAG41W4tGru8UX","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","extension":"jpg","metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.6,"height":800},"isOpaque":true,"blurHash":"VKJ01o~pIBTJo#K6MxxuRjs:R6xuNGxuRORi-;IUSexb","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"background":"#655176","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.14},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.54,"background":"#629eb9"},"lightVibrant":{"population":3.38,"background":"#badff5","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47,"background":"#205a7b"},"lightMuted":{"background":"#a4c2d3","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":4.58},"vibrant":{"population":1.22,"background":"#2bc4d6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47,"background":"#205a7b"}},"hasAlpha":false},"mimeType":"image/jpeg","_updatedAt":"2023-09-25T20:33:46Z"},"_type":"mainImage"},"url":"reducing-delays-in-breast-cancer-care-using-an-innovative-digital-health-platform","published":"2024-06-13T13:00:00.000Z","factCheckBy":[{"showSocialShare":null,"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null},{"lastName":"Evans","url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven"},{"displayName":"Warren Fisher, DO","firstName":"Warren","lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"_type":"slug","current":"darren-wheeler-md"},"profileImage":null,"biography":null},{"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]}],"isLiveSite":true,"host":"www.ajmc.com","settings":{"title":"AJMC","networkID":"4688","adUnit":"ajmc.com","liveDomain":"www.ajmc.com","publicationName":"AJMC","logo":"/ajmc_logo_inverted.png","white_logo":"/ajmc_logo_inverted.png","logoHeight":"50px","enableEdgeCache":true,"sMaxAge":300,"staleWhileRevalidate":359,"clinicalTopicTopLatestNews":true,"megaMenuTaxName":"topic","megaMenuChildren":true,"sharingImageUrl":"https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png","twitterHandle":"@AJMC_Journal","publicationMapping":"publications","useNewSubNavMegaMenu":true,"redesignDetail":true,"redesignSAP":true,"useNewFooter":true,"newFooterLogos":[{"img":"/CHA_Logo.png","alt":"CH Logo","mobileWidth":"158px","mobileHeight":"42px","link":"/topic/center-on-health-equity-and-access","target":"_self"},{"img":"/CB.png","alt":"Center for Biosimilars Logo","mobileWidth":"170px","mobileHeight":"42px","link":"https://www.centerforbiosimilars.com/","target":"_blank"}],"useV3Components":true,"useAuthorRedesign":true,"navigationOptions":{"version":"2","variant":"4","customSpecialtyText":"Speciality Area"},"gateEnabled":"modal"},"homepage_creative_layout":{"creativeLayout":null}},"targeting":{"content_placement":["compendium/multiple-myeloma"],"document_url":["compendium/multiple-myeloma"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"statusCode":200,"data":{"page":{"url":{"current":"/compendium","_type":"slug"},"externalLinks":null,"excludeFromSitemap":false,"disableEpisode":null,"parent":null,"creativeLayoutDetail":null,"docGroup":null,"articleDetailConfig":{"downloadCitation":true,"shareOptions":{"hideFacebook":false,"SocialIconSize":32,"twitterSiteName":"@AJMC_Journal","hidePinterest":false,"shareSubject":"Check out this article!","twitterHandle":"AJMC","siteName":"ajmc"},"brightcovePlayerID":"pbDmfQhRw","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/publications","enableSegmentRecommend":true,"brightcoveAccountID":"10203567001","disqusShortName":"www-ajmc-com"},"styling":{"titleOptions":{"_type":"titleOptions","titleSize":"1rem"},"useDefaultLayout":true,"border":{"borderType":"lines","borderRadius":{"topRight":"0rem","bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem"},"_type":"border","borderSize":0},"contentControl":{"showSummary":true,"_type":"contentControl","showPublished":true,"readMore":true,"showAuthor":true},"imageControl":{"showImage":true,"thumbnailRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"},"_type":"imageControl"},"divider":{"_type":"divider","dividerSize":1}},"isDsoGated":null,"videoPlayerConfig":null,"creativeLayout":null,"filterRequired":false,"contentCategories":null,"theme":"default","featureContent":null,"pageSliders":null,"franchise":null,"cmeConfig":null,"searchConfig":{"baseUrl":"/view/"},"fixIdentifier":null,"relatedMegaMenu":null,"gateCode":null,"title":"Compendium","content":null,"label":null,"pages":null,"useV3":true,"identifier":null,"taxonomy":{"isMainTopic":true,"_updatedAt":"2024-04-09T09:14:18Z","_createdAt":"2020-03-30T18:16:46Z","_rev":"oruil6rlosjyltJbhrNMGF","_type":"taxonomy","identifier":"compendium","_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","pixelTrackingCode":null},"contentCategory":null,"linkedPage":null,"archived":false,"filters":null,"labelRequired":false,"pageType":"Clinical Topic","intro":null,"orderDesc":null,"hasSubCategory":false,"creativeLayoutLatestNews":null},"pageData":{"totalCount":295,"pageSize":30,"pageNumber":5,"data":[{"factCheckAuthors":null,"title":"Study Identifies Treatment Outcomes Impacting HRQOL in Multiple Myeloma","summary":"The review aimed to characterize the impacts of clinical response, delayed disease progression, and lines of therapy on health-related quality of life (HRQOL) for patients with multiple myeloma. ","published":"2023-04-15T14:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"_id":"e1718b0b-3e38-4382-a851-10e37d0e262b","url":"study-identifies-treatment-outcomes-impacting-hrqol-in-multiple-myeloma","thumbnail":{"asset":{"_ref":"image-5cb1b1799fda7be235244ab4533721830a9dea20-1280x853-jpg","_type":"reference"},"_type":"mainImage","alt":"Patient in hospital"},"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"}},{"_id":"d7f030cf-feca-476e-93bc-1872c9d8fc10","title":"Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma","thumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-85c5cc435f9ad6f8516674d60db04a982ea9384d-1000x500-jpg"}},"summary":"A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"url":"ixazomib-shows-pfs-benefit-across-age-and-frailty-subgroups-in-multiple-myeloma","published":"2023-04-12T20:16:12.758Z","updatedOn":null,"factCheckAuthors":null},{"summary":"The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.","published":"2023-04-08T14:00:00.000Z","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"updatedOn":null,"authors":[{"displayName":"Jason Harris","url":"jason-harris"}],"factCheckAuthors":null,"_id":"75fe4c0b-e41b-432e-9415-9876cba3ac14","title":"FDA Fast Tracks BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma","url":"fda-fast-tracks-bcma-targeted-car-t-cell-therapy-for-r-r-multiple-myeloma","thumbnail":{"asset":{"_ref":"image-5e7e53531c567cf65c0116940955c2b7e0e99daa-268x188-jpg","_type":"reference"},"_type":"mainImage"}},{"summary":"Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}],"factCheckAuthors":null,"published":"2023-04-03T19:59:00.000Z","updatedOn":null,"_id":"9c1a16ff-7171-4496-95ef-48eef6778565","title":"Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma","url":"characteristics-of-relapse-affect-treatment-choices-in-multiple-myeloma","thumbnail":{"_type":"mainImage","caption":"NCCN logo","asset":{"_ref":"image-6ded36225173042d811302852e27644955729b26-240x245-jpg","_type":"reference"}}},{"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"_id":"c4928c76-a53b-46e9-ac10-26bf2373390f","title":"Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma","published":"2023-03-30T19:27:00.000Z","factCheckAuthors":null,"url":"ide-cel-shows-benefit-vs-standard-regimens-in-heavily-pretreated-r-r-multiple-myeloma","thumbnail":{"asset":{"_ref":"image-92b8d6a11dd16453fd5493233ba4e5549a4ae097-1200x800-jpg","_type":"reference"},"_type":"mainImage","alt":"CAR T cell"},"summary":"Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.","updatedOn":null},{"title":"Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma","url":"study-characterizes-infections-in-patients-treated-with-bispecific-antibodies-for-multiple-myeloma","summary":"A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits. ","_id":"ebebedb8-9786-4a62-b651-ff635fe7cf87","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-d616fdfdf8859d3a7c9f83f7d32c8f7f5d6c532e-2699x1518-jpg","_type":"reference"}},"published":"2023-03-23T21:13:32.957Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null},{"_id":"9d02fdb6-223c-4dc9-8cd1-8827515d9b33","title":"The Information Patients Receive During Multiple Myeloma Treatment May Differ From What They Want to Know","thumbnail":{"_type":"mainImage","alt":"Doctor speaking to patient","asset":{"_ref":"image-28668d9bbd3173fef97cb49c3785f65f9530e4df-5175x3386-jpg","_type":"reference"}},"published":"2023-03-15T15:55:36.066Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null,"url":"the-information-patients-receive-during-multiple-myeloma-treatment-may-differ-from-what-they-want-to-know","summary":"There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found. ","updatedOn":null},{"_id":"f78691c4-a048-4e27-987d-eb6d1bfb45e2","title":"Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}],"factCheckAuthors":null,"url":"dr-ajai-chari-patients-in-high-risk-subgroups-benefited-from-daratumumab-plus-triplet","thumbnail":{"asset":{"_ref":"image-67ca4b5ff59476fd318153a42915ca90d30d440e-130x170-jpg","_type":"reference"},"_type":"mainImage"},"summary":"Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial. ","published":"2023-03-09T15:15:00.000Z"},{"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"factCheckAuthors":null,"_id":"7d4b779d-1b51-4928-8fa5-fce31a82bdc8","title":"Screening Protocols During Early Phase of COVID-19 Improved Outcomes in MM","thumbnail":{"alt":"Image of clinician running a multiple myeloma test: angellodeco - stock.adobe.com","asset":{"_ref":"image-a4a846d81399f3b79dffead23818297dc2dc8d04-1200x600-jpg","_type":"reference"},"_type":"mainImage"},"authors":[{"displayName":"Jaime Rosenberg","url":"jaime-rosenberg"}],"url":"screening-protocols-during-early-phase-of-covid-19-improved-outcomes-in-mm","summary":"Researchers retrospectively analyzed data from patients who visited 2 myeloma centers between March and October 2020, before vaccines were widely available but during large-scale implementation of regular screening processes.\n","published":"2023-03-06T12:00:00.000Z","updatedOn":null},{"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"factCheckAuthors":null,"_id":"b1f110e6-7103-4490-9e7c-412086cec5d4","url":"diagnosis-of-second-primary-malignancies-associated-with-prolonged-survival-among-patients-with-mm","summary":"Incidences of certain second primary malignancies were associated with increased overall survival among patients with multiple myeloma in a retrospective analysis of real-world data. ","published":"2023-03-03T14:15:00.000Z","updatedOn":null,"authors":[{"displayName":"Matthew Gavidia","url":"matthew-gavidia"}],"title":"Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM","thumbnail":{"_type":"mainImage","alt":"Multiple myeloma ","asset":{"_ref":"image-661fb0cf373b8ba0be010d838bc722bf422821f2-5472x3648-jpg","_type":"reference"}}},{"title":"Ide-Cel Shows Superior Survival in Hard-to-Treat Patients With R/R MM","url":"ide-cel-shows-superior-survival-in-hard-to-treat-patients-with-r-r-mm","thumbnail":{"_type":"mainImage","alt":"Image of red blood cells","asset":{"_ref":"image-588a791508f7415f901139b3d5d3ea54c0b55704-1000x667-jpg","_type":"reference"}},"updatedOn":null,"authors":[{"displayName":"Jaime Rosenberg","url":"jaime-rosenberg"}],"factCheckAuthors":null,"summary":"Idecabtagene vicleucel (ide-cel) reduced the risk of disease progression or death by 51% in patients with triple-class–exposed relapsed or refractory multiple myeloma (R/R MM).\n","published":"2023-03-01T21:30:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"dfecee95-09aa-41b0-8ec5-7193fd111854"},{"published":"2023-02-23T21:36:24.469Z","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null,"url":"population-based-study-finds-increased-risk-of-stroke-heart-attack-in-patients-with-mm","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-5bdbbd61ca37e863c013eb9ac01a5a101b0b79ba-1200x600-jpg","_type":"reference"}},"summary":"Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.","updatedOn":null,"_id":"9ecb66eb-5311-493c-b436-c6c2300349bc","title":"Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM"},{"published":"2023-02-15T00:00:12.368Z","updatedOn":null,"authors":[{"displayName":"Jaime Rosenberg","url":"jaime-rosenberg"}],"title":"Cases of SCC-Related Hospitalizations Increasing Among Patients With Multiple Myeloma","thumbnail":{"alt":"Image of a hospital corridor","asset":{"_ref":"image-07e9f03995bb4832572c0e57331346bd60825bfd-1200x602-jpg","_type":"reference"},"_type":"mainImage"},"summary":"Throughout this study's 12-year period, the average annual percent change showed an uptrend for all groups in hospitalization for spinal cord compression (SCC), and this was higher for non-Hispanic Black patients vs Hispanic patients and non-Hispanic White patients.\n","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null,"_id":"cbe5bb49-1994-4932-97d2-8bf9c64b0db0","url":"cases-of-scc-related-hospitalizations-increasing-among-patients-with-multiple-myeloma"},{"authors":null,"factCheckAuthors":null,"title":"Preferred Treatment Sequencing for Patients with MM","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.","published":"2023-02-08T16:53:26.250Z","updatedOn":null,"_id":"ae248cf2-dd42-4eca-9398-dac7ba4a6f88","url":"preferred-treatment-sequencing-for-patients-with-mm","contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"}},{"title":"Partnering Academic and Community Settings to Optimize Care for Patients with MM","summary":"Dr Nadeem provides community and clinical strategies to treat patients with MM.","published":"2023-02-08T16:42:29.471Z","_id":"b7b5eb5f-4810-488e-a749-058a5428fca7","url":"partnering-academic-and-community-settings-to-optimize-care-for-patients-with-mm","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"authors":null,"factCheckAuthors":null},{"_id":"c2f1d7f5-3075-43a8-aaa7-84d5cf587902","summary":"The effects of physical activity and exercise have previously been reported, with data pointing to improvements in quality of life as well as such clinical markers as immune response in tumors","published":"2023-02-08T12:00:00.000Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"title":"Daily Physical Activity Has Positive Impact on Immune Stimulation in MM","url":"daily-physical-activity-has-positive-impact-on-immune-stimulation-in-mm","thumbnail":{"_type":"mainImage","alt":"Image of exercise equipment","asset":{"_type":"reference","_ref":"image-74ae2eb7b76346c7dca9c40e7252e18ef7258610-1000x667-jpg"}},"authors":[{"displayName":"Jaime Rosenberg","url":"jaime-rosenberg"}],"factCheckAuthors":null},{"url":"allogeneic-stem-cell-transplant-shows-minimal-os-pfs-benefits-in-mm","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-f644f044981a59647daa7d201b84487c66cfee12-1279x853-jpg","_type":"reference"}},"summary":"Although allogenic stem cell transplant is increasingly used to treat multiple myeloma (MM) and other hematological conditions, there have been mixed efficacy results in the context of MM.","published":"2023-02-05T16:10:00.000Z","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null,"_id":"b4424e42-5776-4327-85b7-2846e102a1c6","title":"Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in MM"},{"_id":"65275c66-9af3-4994-ad27-954f19bb7858","title":"Including MRD Status Reduces Uncertainty in Long-term Survival Models of NDMM","thumbnail":{"_type":"mainImage","alt":"Image of blood cells","asset":{"_ref":"image-3d9dcde1c8a02070f0dded76bb52e5b8fc0b79b7-1200x600-jpg","_type":"reference"}},"summary":"Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM).\n","published":"2023-02-03T21:00:00.000Z","updatedOn":null,"authors":[{"displayName":"Jaime Rosenberg","url":"jaime-rosenberg"}],"factCheckAuthors":null,"url":"including-mrd-status-reduces-uncertainty-in-long-term-survival-models-of-ndmm","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"}},{"authors":null,"_id":"c71997fc-add1-435e-91b8-9ea1462d05c6","title":"Differences in Care Between Academic and Community Settings in Multiple Myeloma","summary":"Dr Lipe shares disparities between academic and community practice settings for patients with MM.","published":"2023-02-01T18:58:03.527Z","updatedOn":null,"factCheckAuthors":null,"url":"differences-in-care-between-academic-and-community-settings-in-multiple-myeloma","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"}},{"title":"Updates in NCCN Guidelines of Frontline Treatment for MM ","url":"updates-in-nccn-guidelines-of-frontline-treatment-for-mm","updatedOn":null,"authors":null,"_id":"32af8a99-846d-4619-87d3-de31ed8b2d1f","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.","published":"2023-02-01T18:55:28.607Z","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"factCheckAuthors":null},{"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}],"factCheckAuthors":null,"title":"Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"1e12e76d-9086-4cb7-a408-e69c3fc7bbea","url":"griffin-daratumumab-plus-rvd-improved-responses-for-older-and-some-high-risk-patients-compared-with-triplet-alone-in-newly-diagnosed-mm","thumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-e12b86c6334b0e40b3e09e96b16174283026cafd-673x378-jpg"}},"summary":"The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.","published":"2023-01-29T15:00:00.000Z"},{"_id":"5d63fdef-7af4-48ec-bbc8-13c57a4f46b2","title":"In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups ","url":"in-community-based-study-switching-to-ixazomib-in-newly-diagnosed-mm-brought-improved-responses-across-age-groups","summary":"An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib. ","published":"2023-01-25T19:10:35.876Z","factCheckAuthors":null,"thumbnail":{"_type":"mainImage","alt":"Patient and Doctor","asset":{"_ref":"image-661fb0cf373b8ba0be010d838bc722bf422821f2-5472x3648-jpg","_type":"reference"}},"updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}]},{"url":"product-preference-with-nccn-category-1-status","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.","updatedOn":null,"_id":"c9be8394-9eda-4e7a-b0d8-a88836ef854c","title":"Product Preference with NCCN Category 1 Status","published":"2023-01-25T14:55:30.673Z","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"authors":null,"factCheckAuthors":null},{"title":"Providing Incentives for Provider Adherence to MM Pathway","url":"providing-incentives-for-provider-adherence-to-mm-pathway","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.","published":"2023-01-25T14:48:25.473Z","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"factCheckAuthors":null,"_id":"e3c2fdda-8df7-45ce-a688-c86f5a826d43","updatedOn":null,"authors":null},{"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-57ab17d634d1804c6b621d69ba7eeaefb7bfc5bf-300x200-jpg","_type":"reference"}},"published":"2023-01-20T21:46:11.506Z","updatedOn":null,"factCheckAuthors":null,"title":"Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits","summary":"A recent study found that ixazomib was associated with better progression-free survival versus a placebo in multiple myeloma regardless of cytogenetic risk status.","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"_id":"90a66c3f-fbba-43c4-aa19-1769f610c88f","url":"study-finds-ixazomib-beneficial-in-mm-patients-with-high-risk-cytogenic-traits"},{"url":"clinical-collaboration-driving-mm-treatment-pathways","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.","published":"2023-01-18T18:28:56.424Z","updatedOn":null,"contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"authors":null,"factCheckAuthors":null,"_id":"9f9fd111-20f0-44be-8b49-cdb237b15f1f","title":"Clinical Collaboration Driving MM Treatment Pathways"},{"contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"authors":null,"_id":"df65295b-8f72-427a-a436-338bdbf86a48","url":"clinical-pathways-guiding-treatment-selection-in-multiple-myeloma","thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"summary":"A panel of experts discuss the value of clinical pathways in MM disease management.","factCheckAuthors":null,"title":"Clinical Pathways Guiding Treatment Selection in Multiple Myeloma","published":"2023-01-18T18:24:31.437Z","updatedOn":null},{"title":"Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments","url":"disparities-in-multiple-myeloma-quality-improvement-initiative-reveals-gaps-between-oncology-providers-patients-in-views-of-costs-risk-of-treatments","published":"2023-01-12T16:00:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"_id":"350ff281-8831-483b-b895-a92a2dca31fb","thumbnail":{"_type":"mainImage","caption":"Joseph R. Mikhael, MD, MEd","asset":{"_ref":"image-ec0ad2dac13cc1703b788d3fcaefd1ae093fa212-500x624-png","_type":"reference"}},"summary":"An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona. ","authors":[{"displayName":"Interview by Mary Caffrey","url":"interview-by-mary-caffrey"}]},{"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png","_type":"reference"}},"published":"2023-01-11T17:51:49.520Z","updatedOn":null,"authors":null,"_id":"4ef4deb7-fbbd-4832-9926-4cb667c58cb2","title":"Utilizing Available Frontline Treatment in MM","url":"utilizing-available-frontline-treatment-in-mm","summary":"Daratumumab can be an effective frontline MM treatment option.","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"factCheckAuthors":null},{"contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"factCheckAuthors":null,"_id":"52a6d546-e9bc-4436-b856-6d9b5819bfc7","summary":"Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.","authors":null,"title":"Adequate Treatment Response in Transplant-Ineligible MM Patients","url":"adequate-treatment-response-in-transplant-ineligible-mm-patients","thumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-bb5ec09ce66de1dbc655d055d81beb0986861a5e-1188x672-png"}},"published":"2023-01-11T17:44:45.091Z","updatedOn":null}],"targeting":{"content_placement":["compendium/multiple-myeloma"],"document_url":["compendium/multiple-myeloma"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"currentTopic":{"summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"b477264366c1"},{"text":"AJMC","_key":"3a355a7e133a","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"cmeType":"per","perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"ptceKeywordMapping":null,"parent":{"_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","url":"compendium","parent":null},"pixelTrackingCode":null,"_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","name":"Multiple Myeloma","thumbnail":null,"url":"multiple-myeloma"},"filterData":[],"relatedTopics":null,"podcastsData":[],"videoSeriesData":[],"videoNonSeriesData":[{"is_visible":true,"body":[{"_type":"video","caption":"Don M. Benson, MD, PhD, James Cancer Hospital","videoID":"6366622220112","disableAutoPlayVideo":false,"source":"brightcove","_key":"3e77cf5923aa","videoObject":{"thumbnail":{"_type":"image","asset":{"_type":"reference","_ref":"image-6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080-jpg"}},"videoDuration":"PT3M1S","videoDescription":"Interview with Don M. Benson, MD, PhD, Ohio State","_type":"videoDetails","videoTitle":"Honoring Patient Wishes in Myeloma Treatment Journeys"}},{"children":[{"_type":"span","marks":[],"text":"","_key":"21c3e29923d2"}],"_type":"block","style":"normal","_key":"d6a9dba973a2","markDefs":[]},{"_key":"e7630af590eb","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"11b6b6fe5bf3"}],"children":[{"_key":"2485660f21260","_type":"span","marks":[],"text":"Continuing our discussion with The Ohio State University Comprehensive Cancer Center’s Don M. Benson, MD, PhD, hematologist-oncologist, he explains how he navigates the intricacies of conversations with patients when quality-of-life preferences may conflict with treatment goals, always keeping patient preferences top of mind. One of Benson’s top priorities it to always deliver personalized patient care by taking into account their specific "},{"_type":"span","marks":["11b6b6fe5bf3"],"text":"type of cancer","_key":"6f098ab85d16"},{"marks":[],"text":" and their desires and goals for treatment.","_key":"abb26f5377e4","_type":"span"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"e8717a0c3960","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b30eb7aa53fb0"}]},{"_key":"12a876c1f931","markDefs":[],"children":[{"text":"For parts 1 through 3 of our conversation with Benson, please click on the links below:","_key":"6bcec8e3888e0","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"9b61a7c9e3d9","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/elevating-myeloma-care-amidst-complex-treatment-choices","_key":"95142be1edc6"}],"children":[{"_type":"span","marks":[],"text":"Part 1: ","_key":"91b41534893a0"},{"_type":"span","marks":["95142be1edc6"],"text":"Elevating Myeloma Care Amidst Complex Treatment Choices","_key":"91b41534893a1"}]},{"style":"normal","_key":"27c84112f3f5","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/balancing-life-and-myeloma-a-patient-centered-approach","_key":"3c5fd72b9000"}],"children":[{"_type":"span","marks":[],"text":"Part 2: ","_key":"408fdf8057900"},{"marks":["3c5fd72b9000"],"text":"Balancing Life and Myeloma: A Patient-Centered Approach","_key":"408fdf8057901","_type":"span"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/unlocking-myeloma-outcomes-the-role-of-immunity","_key":"845051b4c8b8"}],"children":[{"_key":"8a53e28ce63e0","_type":"span","marks":[],"text":"Part 3: "},{"text":"Unlocking Myeloma Outcomes: The Role of Immunity","_key":"8a53e28ce63e1","_type":"span","marks":["845051b4c8b8"]}],"_type":"block","style":"normal","_key":"e8964863146f"},{"markDefs":[],"children":[{"_key":"735d9d26701d0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"70b9bc91cd44"},{"_key":"d1b5e9132595","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"f763bb048e5a0"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7be931c97b870"}],"_type":"block","style":"normal","_key":"ac92bca3e896"},{"_key":"148061619d69","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"8a814089a43c0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"132ba7aedee8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"72576216ef380"}]},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"When patients choose quality of life over continuing treatment, how do you navigate those conversations?","_key":"75b3a3d25d000"}],"_type":"block","style":"normal","_key":"524fda236bd4"},{"_type":"block","style":"normal","_key":"14018079716f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a1d035c38bc60"}]},{"markDefs":[],"children":[{"_key":"01fa067ca3940","_type":"span","marks":[],"text":"There was a wonderful study published a few years ago where they looked at patient expectations as a function of where they were in the journey of their myeloma disease. It's striking, because at diagnosis, their number 1 goal—in this paper anyway—was overall survival. Nothing else mattered. And in the relapse/refractory setting, the number 1 goal, by far and away, was survival. The reason it's such an interesting paper is that that middle, that in-between, when the disease is in remission, it's all about quality of life. It's energy, fatigue, pain, cognitive function, independence, freedom. Those metrics take on substantially more meaning and importance for patients overall and beyond survival."}],"_type":"block","style":"normal","_key":"543a1fa11842"},{"style":"normal","_key":"b3547bc19325","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"2c11316f10510"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Myeloma is not a sprint, it's a marathon. And I think as physicians, as specialists, we need to be sensitive to where patients are in the journey. When somebody is newly diagnosed, their risk tolerance is very different than when their disease is in remission and you're trying to cajole them into taking a maintenance pill that might cause diarrhea or it might cause a rash. This is what I mean by taking into account patients' desires and goals.","_key":"9c2dc2e2f59f0"}],"_type":"block","style":"normal","_key":"2c54f82fe451"},{"style":"normal","_key":"0519421b2b46","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"9c6eae269a0d0"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"I'll give you another example. We had a patient last year who was diagnosed in the early part of the year, got induction treatment, got into remission, we collected his stem cells, and then his daughter got engaged. And she wanted to get married while dad was well. The wedding was in October, and he came in and said, “I want to walk my daughter down the aisle with a full head of hair and I want to dance at her reception with a full head of hair.” And so we delayed his transplant.","_key":"ba83c7a6b4cb0"}],"_type":"block","style":"normal","_key":"4cab7ee5b2bf"},{"children":[{"_type":"span","marks":[],"text":"","_key":"67ca22e152540"}],"_type":"block","style":"normal","_key":"437d3974a0b5","markDefs":[]},{"_type":"block","style":"normal","_key":"5ecbc0dc03fc","markDefs":[],"children":[{"_type":"span","marks":[],"text":"That's sort of what I mean by tailoring treatment to individuals. And he's doing great, by the way; he got a transplant, he's killing it, he's doing awesome.","_key":"7a55dcf4d9110"}]},{"children":[{"marks":[],"text":"","_key":"0bab6b7347800","_type":"span"}],"_type":"block","style":"normal","_key":"00a2d1dfc181","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"I can tell you with great confidence that I've taken so much more from my patients than I could ever give them. When you're confronted with your mortality and being told you have an incurable cancer, I'm truly humbled to walk into… I hesitate to even call it ","_key":"daaf359a649e0"},{"marks":["em"],"text":"work","_key":"daaf359a649e1","_type":"span"},{"_key":"daaf359a649e2","_type":"span","marks":[],"text":". It's just a privilege to come in and be with these people. And in some way, if I can help them, that's great. But they've taught me so much more about how to live and how to love and how to sacrifice and what life really means."}],"_type":"block","style":"normal","_key":"11e763c7488d"}],"_rev":"bAl93RvH29PY4NpeQioWdS","_updatedAt":"2025-01-02T17:41:18Z","taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews"},{"_createdAt":"2020-04-23T19:36:16Z","_rev":"UoosHf5LKj69ImzsXs4QZt","_type":"taxonomy","name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm"},{"_id":"abac4670-ca81-4c11-91d1-509e07110acc","_updatedAt":"2022-02-22T17:30:46Z","identifier":"ivbm-events","_createdAt":"2022-02-22T17:30:46Z","_rev":"2Cg3jaFTpU6hQKfUrgINsp","_type":"taxonomy","name":"IVBM Events"},{"cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836","markDefs":[]}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z"},{"identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2020-04-14T15:02:13Z","_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","name":"Hematology","_id":"compendium_hematology","_type":"taxonomy","_updatedAt":"2020-07-30T14:48:10Z"}],"updatedOn":null,"factCheckAuthorMapping":null,"summary":"In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.","_type":"article","contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"ExcludeFromPubMedXML":false,"url":{"current":"honoring-patient-wishes-in-myeloma-treatment-journeys","_type":"slug"},"_id":"5a339dfc-a748-45b2-b3bf-7a60f16c83b5","thumbnail":{"asset":{"extension":"jpg","metadata":{"palette":{"dominant":{"background":"#48463c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.05},"_type":"sanity.imagePalette","darkMuted":{"background":"#48463c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.05},"muted":{"title":"#fff","population":2.73,"background":"#97825f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"title":"#fff","population":6.31,"background":"#eabf81","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.35,"background":"#342c19","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#cbc9b0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.84},"vibrant":{"population":0.59,"background":"#56c1ab","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080},"isOpaque":true,"blurHash":"MeO:%[D$?wIUM{?a%MkXoyj=ShM{IANGbb","_type":"sanity.imageMetadata"},"sha1hash":"6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf","_updatedAt":"2024-11-15T20:07:56Z","_rev":"1U42a9jxrELBwJpoIYPEMt","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg","path":"images/0vv8moc6/ajmc/6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg","_createdAt":"2024-11-15T20:07:56Z","originalFilename":"Don Benson TN.jpg","uploadId":"oJqJClpxHvoUf6wQ8XcE8UuxW71TFiif","mimeType":"image/jpeg","assetId":"6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf","_id":"image-6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080-jpg","size":224236}},"articleType":"Commentary","authorMapping":[{"biography":[{"children":[{"_key":"abc0e18a29ce0","_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor."}],"_type":"block","style":"normal","_key":"643be033259e","markDefs":[]},{"_type":"block","style":"normal","_key":"f4070c315fab","markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}]}],"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"_updatedAt":"2024-08-07T15:47:36Z","displayName":"Maggie L. Shaw","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","url":{"current":"maggie-l-shaw","_type":"slug"},"_createdAt":"2020-05-05T10:50:09Z","_rev":"4vyIlJfwMwqB8NbLEufdwW","_type":"author"}],"seoTag":["multiple myeloma","personalized patient care","risk tolerance"],"source":null,"published":"2025-01-02T17:35:00.000Z","title":"Honoring Patient Wishes in Myeloma Treatment Journeys","_createdAt":"2025-01-02T16:39:03Z","link":"/view/honoring-patient-wishes-in-myeloma-treatment-journeys"},{"url":{"current":"using-mrd-patient-preference-to-optimize-multiple-myeloma-care","_type":"slug"},"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews","name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy"},{"summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma"}],"title":"Using MRD, Patient Preference to Optimize Multiple Myeloma Care","_createdAt":"2024-12-09T21:02:52Z","_updatedAt":"2024-12-10T16:30:50Z","body":[{"videoObject":{"videoTitle":"Using MRD, Patient Preference to Optimize Multiple Myeloma Care","thumbnail":{"_type":"image","asset":{"_ref":"image-106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616-png","_type":"reference"}},"videoDuration":"PT2M26S","videoDescription":"Using MRD, Patient Preference to Optimize Multiple Myeloma Care","_type":"videoDetails"},"_type":"video","videoID":"6365775830112","disableAutoPlayVideo":false,"source":"brightcove","_key":"0e9d20b9329f"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"dfabb509bd95"}],"children":[{"_type":"span","marks":[],"text":"Minimal residual disease (MRD) testing is becoming a pivotal tool in personalizing ","_key":"241da874f6360"},{"_type":"span","marks":["dfabb509bd95"],"text":"multiple myeloma","_key":"241da874f6361"},{"_type":"span","marks":[],"text":" treatment, explains Hans Lee, MD, director of multiple myeloma clinical research, associate professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center.","_key":"241da874f6362"}],"_type":"block","style":"normal","_key":"51cd7aee96db"},{"style":"normal","_key":"a9cfc449b3a2","markDefs":[],"children":[{"marks":[],"text":"","_key":"120c766e6c2e0","_type":"span"}],"_type":"block"},{"_key":"090d78e69a1f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"During this conversation, Lee delves into the growing role of MRD testing and how results guide transplant timing and maintenance therapy deintensification. He also highlights the balance between patient preferences and long-term outcomes with advanced therapies like CAR T-cell and bispecific antibodies.","_key":"b47447158e4c0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"038adba04fa0","markDefs":[],"children":[{"text":"","_key":"65537e4769700","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_key":"fa3a1bd88ed10","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}],"_type":"block","style":"normal","_key":"e2f5e5b8617b"},{"children":[{"text":"","_key":"ed920c4aa7230","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"54004ac97e2a","markDefs":[]},{"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"78bb39a8a7160"}],"_type":"block","style":"normal","_key":"903521709c9b","markDefs":[]},{"style":"normal","_key":"f46ec350cebc","markDefs":[],"children":[{"marks":[],"text":"","_key":"8a4031c8f2cf0","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What role do biomarkers like MRD play in refining treatment decisions for transplant-eligible vs ineligible patients?","_key":"2095d848c7320"}],"_type":"block","style":"normal","_key":"1034ca7bd32d"},{"children":[{"_key":"dd2fcd8a789f0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"c79da17df608","markDefs":[]},{"_key":"0032007dc552","markDefs":[],"children":[{"_type":"span","marks":[],"text":"We have been using MRD testing more and more in the recent years to help guide therapy as more and more data comes out regarding this. For newly diagnosed patients, I may use MRD testing to decide whether or not to pursue upfront transplant or a delayed transplant approach in standard-risk multiple myeloma patients. So, if a patient has standard risk multiple myeloma [and] has attained MRD negativity to frontline induction therapy, I may consider deferring transplant after a conversation about the risks and benefits with the patient.","_key":"d4446f7bfe000"}],"_type":"block","style":"normal"},{"style":"normal","_key":"d1b6f79c406d","markDefs":[],"children":[{"marks":[],"text":"","_key":"54e82bb05eda0","_type":"span"}],"_type":"block"},{"_key":"98ed3d66e8a9","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think on the back end, where MRD can also be very helpful is knowing when to deintensify therapy. I think we're getting more and more data about perhaps there are some patients who have been on long-term lenalidomide maintenance therapy after transplant who have sustained MRD negativity where we could potentially stop therapy. And there's now data coming out of a couple of groups, such as the University of Chicago and Memorial Sloan Kettering, that have shown that this approach is feasible, even after stopping lenalidomide maintenance in patients with sustained embryonic negativity, that these patients can remain in remission for a very long time. So, that's something else that I've also started to incorporate in my practice as well. And there are more and more prospective studies that are looking at this sort of deintensification of maintenance therapy based on MRD testing that will be reported in the future.","_key":"3fd1096fd92d0"}],"_type":"block","style":"normal"},{"_key":"06a001f80440","markDefs":[],"children":[{"marks":[],"text":"","_key":"8270d04002160","_type":"span"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"cc116d7556740","_type":"span","marks":["strong"],"text":"How do you balance patient treatment selection with the need to optimize long-term outcomes and cost-effectiveness?"}],"_type":"block","style":"normal","_key":"c6b3def6ae8a"},{"children":[{"_type":"span","marks":[],"text":"","_key":"261db23806ad0"}],"_type":"block","style":"normal","_key":"f24eb04bce5a","markDefs":[]},{"markDefs":[],"children":[{"_key":"ea66ee16a1870","_type":"span","marks":[],"text":"It's really great that we have both options, CAR T therapies and bispecific antibodies, available for our patients in 2024. Both are highly efficacious; they both have pros and cons. I think that it's nice that we can tailor the therapies according to patient preference and what they could potentially receive depending on other circumstances—social circumstance, if they have a caregiver or not, whether they have a more active lifestyle where perhaps a more one-and-done approach might be more appealing to them with CAR T therapy. So [it's] really a great thing that we have lots of options for our patients to consider in this context."}],"_type":"block","style":"normal","_key":"b85680e41780"}],"_rev":"hiH1TfK5TgzpyVqIUNBTrC","seoTag":["mrd testing multiple myeloma","patient preference car t therapy","md anderson"],"articleType":"Commentary","is_visible":true,"summary":"Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.","link":"/view/using-mrd-patient-preference-to-optimize-multiple-myeloma-care","updatedOn":null,"source":null,"factCheckAuthorMapping":null,"published":"2024-12-19T14:09:00.000Z","_id":"016f7497-db88-44d0-a3c5-37fc6b4b64c1","ExcludeFromPubMedXML":false,"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"authorMapping":[{"_id":"d4608bc5-b145-4495-9c67-41163578c9f2","_updatedAt":"2025-01-09T21:09:27Z","url":{"current":"hayden-e-klein","_type":"slug"},"firstName":"Hayden","_rev":"A9UM2QVfJg2GpKiBNN7TLb","_type":"author","biography":[{"_type":"block","style":"normal","_key":"038a30bd95f3","markDefs":[],"children":[{"_key":"607fdc2dfcbb0","_type":"span","marks":[],"text":"Hayden is an associate editor for "},{"text":"The American Journal of Managed Care","_key":"e52dc3c8644d","_type":"span","marks":["em"]},{"marks":[],"text":"® (","_key":"594c03a8d658","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a496fbfb2459"},{"_type":"span","marks":[],"text":"®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.","_key":"421f44e793ed"}]},{"markDefs":[{"_key":"b0bea7fd1873","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies from Rutgers University. You can connect with Hayden on ","_key":"3c55bddd8456"},{"_type":"span","marks":["b0bea7fd1873"],"text":"LinkedIn","_key":"607fdc2dfcbb1"},{"_type":"span","marks":[],"text":".","_key":"607fdc2dfcbb2"}],"_type":"block","style":"normal","_key":"0c154c4abedd"}],"profileImage":{"_type":"mainImage","alt":"Hayden E. Klein","asset":{"_ref":"image-9a2a017c03e16e188b88d86afed2b268b4b00214-430x430-png","_type":"reference"}},"lastName":"Klein","authorType":"author","displayName":"Hayden E. Klein","_createdAt":"2021-07-07T19:05:23Z"}],"thumbnail":{"asset":{"extension":"png","size":5870533,"_id":"image-106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616-png","uploadId":"0Fil4EzfLS6kHsptl0y93KHvHtQcUASb","sha1hash":"106dfac46d902fb8f2bcbd5dcae8a70cb599f74a","assetId":"106dfac46d902fb8f2bcbd5dcae8a70cb599f74a","_updatedAt":"2024-12-09T19:55:22Z","_rev":"hiH1TfK5TgzpyVqIUM3ykb","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616.png","path":"images/0vv8moc6/ajmc/106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616.png","_createdAt":"2024-12-09T19:55:22Z","metadata":{"_type":"sanity.imageMetadata","palette":{"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.51,"background":"#1e506f","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.6,"background":"#c4b9b0","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#4494bc","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"background":"#a78165","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.63},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.19,"background":"#563d2f"},"muted":{"background":"#a78165","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.63},"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0,"background":"#74b4d4"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"height":1616,"_type":"sanity.imageDimensions","width":2879,"aspectRatio":1.7815594059405941},"isOpaque":true,"blurHash":"MIH.4x4T9ZyDIo~poe9G%MRjS%SiROemNG"},"mimeType":"image/png","originalFilename":"Hans Lee, MD.png"}},"_type":"article"},{"thumbnail":{"asset":{"extension":"jpg","metadata":{"isOpaque":true,"blurHash":"MeO:%[D$?wIUM{?a%MkXoyj=ShM{IANGbb","_type":"sanity.imageMetadata","palette":{"muted":{"population":2.73,"background":"#97825f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#fff","population":6.31,"background":"#eabf81","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.35,"background":"#342c19","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"background":"#cbc9b0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.84},"vibrant":{"background":"#56c1ab","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.59},"dominant":{"population":7.05,"background":"#48463c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"background":"#48463c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.05}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1920,"aspectRatio":1.7777777777777777,"height":1080}},"sha1hash":"6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf","_updatedAt":"2024-11-15T20:07:56Z","_rev":"1U42a9jxrELBwJpoIYPEMt","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg","path":"images/0vv8moc6/ajmc/6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080.jpg","_createdAt":"2024-11-15T20:07:56Z","originalFilename":"Don Benson TN.jpg","uploadId":"oJqJClpxHvoUf6wQ8XcE8UuxW71TFiif","mimeType":"image/jpeg","assetId":"6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf","_id":"image-6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080-jpg","size":224236}},"title":"Unlocking Myeloma Outcomes: The Role of Immunity","_type":"article","factCheckAuthorMapping":null,"published":"2024-12-17T16:39:57.790Z","articleType":"Commentary","_rev":"bAl93RvH29PY4NpeOn6NTS","summary":"In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature. ","updatedOn":null,"is_visible":true,"body":[{"_key":"7579ad0b2b09","videoObject":{"videoDescription":"Interview with Don M. Benson, MD, PhD, Ohio State","_type":"videoDetails","videoTitle":"Unlocking Myeloma Outcomes: The Role of Immunity","thumbnail":{"_type":"image","asset":{"_ref":"image-6c4eacfe9c992d1f7ea48bbb7606ade7b9a0b9cf-1920x1080-jpg","_type":"reference"}},"videoDuration":"PT2M36S"},"_type":"video","caption":"Don M. Benson, MD, PhD, James Cancer Hospital","videoID":"6366109255112","disableAutoPlayVideo":false,"source":"brightcove"},{"_key":"78349da3e99d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"f889f300c1a9"}],"_type":"block","style":"normal"},{"markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"236c024fed1f"}],"children":[{"text":"In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of ","_key":"26fdb80864330","_type":"span","marks":[]},{"_type":"span","marks":["236c024fed1f"],"text":"multiple myeloma","_key":"4b058bc20a9d"},{"text":" (MM) outcomes and their multifactorial nature. He also addresses the role of the immune system in this hematologic disease, the potential of curative therapies, and long-term survivors.","_key":"453d8b1aaaab","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"30e462e8b6c4"},{"style":"normal","_key":"7ff6bf525271","markDefs":[],"children":[{"_key":"99fcaa0793a30","_type":"span","marks":[],"text":""}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"“I think about it like a regression model,” Benson says. “There's multiple variables that go into determining this outcome. It might be patient age, it might be their fitness, it might be the cytogenetics, the kind of myeloma they have.”","_key":"e3fc5e8a26ef0"}],"_type":"block","style":"normal","_key":"04c04cf4052a","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"1e023d13caf30"}],"_type":"block","style":"normal","_key":"76e1ebffd56e"},{"_type":"block","style":"normal","_key":"c8001884187e","markDefs":[],"children":[{"marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"98ea44b4e0000","_type":"span"}]},{"_type":"block","style":"normal","_key":"803fc2afe27f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"6c49190d356f0"}]},{"children":[{"_key":"f938ba68c49c0","_type":"span","marks":["strong","underline"],"text":"Transcript"}],"_type":"block","style":"normal","_key":"671a1365ad69","markDefs":[]},{"style":"normal","_key":"111758ac1160","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a6282b0d10eb0"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"b63dae261fca0","_type":"span","marks":["strong"],"text":"What factors contribute to the significant variation in survival outcomes seen in MM?"}],"_type":"block","style":"normal","_key":"bf695a6ea412"},{"children":[{"_type":"span","marks":[],"text":"","_key":"dd0b7089e3ab0"}],"_type":"block","style":"normal","_key":"be1304703e81","markDefs":[]},{"children":[{"marks":[],"text":"I wish I could tell you. I think that it's a multifactorial outcome. So I think sometimes we, as physicians, feel like we have control of things because we have so many good treatments, we have combinations of treatments, we have radiation, we have all kinds of things at our disposal and things should work the way we want them to. And sometimes they don't. I've had patients with high-risk cytogenetics who, if they read the book, would have lived 2 years and are still alive 10 years later. And I've seen young patients with “standard risk” cytogenetics who die 3 or 4 years into their disease.","_key":"c54ba13314780","_type":"span"}],"_type":"block","style":"normal","_key":"2f68b6638915","markDefs":[]},{"_type":"block","style":"normal","_key":"9834839c2b79","markDefs":[],"children":[{"_type":"span","marks":[],"text":"So I think about it like a regression model. There's multiple variables that go into determining this outcome. It might be patient age, it might be their fitness, it might be the cytogenetics, the kind of myeloma they have. I had several patients who died of COVID-19 in the pandemic—in complete remission, and out of the blue, this global pandemic comes.","_key":"f14ca3a6a3200"}]},{"_type":"block","style":"normal","_key":"a1e49745593a","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think colloquially we call that variable ","_key":"9ed9dabe3bca0"},{"_type":"span","marks":["em"],"text":"luck","_key":"9ed9dabe3bca1"},{"_key":"9ed9dabe3bca2","_type":"span","marks":[],"text":", but a lot of the research we do in our laboratory is looking at how the immune system interacts with the tumor. It’s not the molecular subtype of the myeloma that's driving outcome; it's the way the patient's immune system is trying to recognize and respond to the disease that's driving outcome. It's very clear in a basic science laboratory, but how do we make that actionable? How do we bring that to a bedside and exploit it for the patient's benefit?"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think we're scratching the surface, frankly, with things like BiTEs [bispecific T-cell engagers] and bispecifics. I hesitate to say it since it's being recorded, but I think that's where curative therapies are going to come from.","_key":"046beae5073b0"}],"_type":"block","style":"normal","_key":"13f8fedaf4bc"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We all have those patients that we've taken care of them for over 10 years, over 15 years; they're still in remission, they've never relapsed, they're off treatment. And I get that question, “Do I need to come back?” And the answer is always, “You need to come back for me. You don't need to come back for you anymore. I need you to come.”","_key":"4056d00972350"}],"_type":"block","style":"normal","_key":"424a28f187e7"}],"link":"/view/unlocking-myeloma-outcomes-the-role-of-immunity","source":null,"contentCategory":{"_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76"},"url":{"current":"unlocking-myeloma-outcomes-the-role-of-immunity","_type":"slug"},"_updatedAt":"2024-12-17T16:36:41Z","seoTag":["multiple myeloma","mukltifactorial nature","curative therapies","bispecifics"],"_id":"f6d61648-a9ca-4f33-9a23-92f5da0bda05","authorMapping":[{"displayName":"Maggie L. Shaw","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","url":{"current":"maggie-l-shaw","_type":"slug"},"_createdAt":"2020-05-05T10:50:09Z","_rev":"4vyIlJfwMwqB8NbLEufdwW","_type":"author","biography":[{"markDefs":[],"children":[{"_key":"abc0e18a29ce0","_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor."}],"_type":"block","style":"normal","_key":"643be033259e"},{"_type":"block","style":"normal","_key":"f4070c315fab","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}]}],"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"_updatedAt":"2024-08-07T15:47:36Z"}],"ExcludeFromPubMedXML":false,"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews","name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z"},{"_rev":"UoosHf5LKj69ImzsXs4QZt","_type":"taxonomy","name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm","_createdAt":"2020-04-23T19:36:16Z"},{"_type":"taxonomy","name":"IVBM Events","_id":"abac4670-ca81-4c11-91d1-509e07110acc","_updatedAt":"2022-02-22T17:30:46Z","identifier":"ivbm-events","_createdAt":"2022-02-22T17:30:46Z","_rev":"2Cg3jaFTpU6hQKfUrgINsp"},{"_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z"}],"_createdAt":"2024-12-17T13:45:55Z"},{"_type":"article","title":"How Anti–CD-38 Antibodies Are Changing the Standard of Myeloma Care","_createdAt":"2024-12-09T19:17:45Z","_id":"e4cb71b7-fa1e-45a1-ba7c-c191f59042b0","ExcludeFromPubMedXML":false,"is_visible":true,"seoTag":["multiple myeloma","car t cell therapy","anti cd38","monoclonal antibodies multiple myeloma","bispecific antibodies multiple myeloma"],"authorMapping":[{"biography":[{"_key":"038a30bd95f3","markDefs":[],"children":[{"_key":"607fdc2dfcbb0","_type":"span","marks":[],"text":"Hayden is an associate editor for "},{"text":"The American Journal of Managed Care","_key":"e52dc3c8644d","_type":"span","marks":["em"]},{"marks":[],"text":"® (","_key":"594c03a8d658","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a496fbfb2459"},{"_type":"span","marks":[],"text":"®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.","_key":"421f44e793ed"}],"_type":"block","style":"normal"},{"markDefs":[{"_key":"b0bea7fd1873","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies from Rutgers University. You can connect with Hayden on ","_key":"3c55bddd8456"},{"_type":"span","marks":["b0bea7fd1873"],"text":"LinkedIn","_key":"607fdc2dfcbb1"},{"_type":"span","marks":[],"text":".","_key":"607fdc2dfcbb2"}],"_type":"block","style":"normal","_key":"0c154c4abedd"}],"profileImage":{"_type":"mainImage","alt":"Hayden E. Klein","asset":{"_ref":"image-9a2a017c03e16e188b88d86afed2b268b4b00214-430x430-png","_type":"reference"}},"lastName":"Klein","authorType":"author","displayName":"Hayden E. Klein","_createdAt":"2021-07-07T19:05:23Z","_id":"d4608bc5-b145-4495-9c67-41163578c9f2","_updatedAt":"2025-01-09T21:09:27Z","url":{"current":"hayden-e-klein","_type":"slug"},"firstName":"Hayden","_rev":"A9UM2QVfJg2GpKiBNN7TLb","_type":"author"}],"source":null,"contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"_type":"taxonomy","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews","name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD"},{"cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z"}],"body":[{"_key":"68cc1f0a0ea3","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616-png","_type":"reference"}},"videoDuration":"PT1M57S","videoDescription":"How Anti–CD-38 Antibodies Are Changing the Standard of Myeloma Care","_type":"videoDetails","videoTitle":"How Anti–CD-38 Antibodies Are Changing the Standard of Myeloma Care"},"_type":"video","videoID":"6365772053112","disableAutoPlayVideo":false,"source":"brightcove"},{"_key":"a01c38dccacb","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"44cca15ea464"}],"children":[{"_type":"span","marks":[],"text":"At a recent Institute for Value-Based Medicine","_key":"7c6fbead35850"},{"marks":["sup"],"text":"®","_key":"7c6fbead35851","_type":"span"},{"_type":"span","marks":[],"text":" event in Houston, Hans Lee, MD, director of multiple myeloma clinical research, associate professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center, shared his insights on the evolving treatment pathways for multiple myeloma. Here, he highlights the transformative impact of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies on relapsed/refractory (R/R) ","_key":"7c6fbead35852"},{"_type":"span","marks":["44cca15ea464"],"text":"multiple myeloma","_key":"7c6fbead35853"},{"_type":"span","marks":[],"text":" and discusses the incorporation of anti–CD-38 monoclonal antibodies into frontline therapy.","_key":"7c6fbead35854"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"","_key":"22d42371530b0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"fac09999331e"},{"style":"normal","_key":"45069e05dc90","markDefs":[],"children":[{"_key":"f66f90853b1d0","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}],"_type":"block"},{"style":"normal","_key":"3ae850d64365","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"76918c44cf920"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"0ff2bc8ee9b90","_type":"span","marks":["strong","underline"],"text":"Transcript"}],"_type":"block","style":"normal","_key":"d599dbc20e1f"},{"children":[{"_type":"span","marks":[],"text":"","_key":"2e027d9499ec0"}],"_type":"block","style":"normal","_key":"fc5d45dda00a","markDefs":[]},{"_type":"block","style":"normal","_key":"053de7b5df1c","markDefs":[],"children":[{"_key":"105ea2b9526d0","_type":"span","marks":["strong"],"text":"How has integrating bispecific antibodies and CAR T-cell therapies altered treatment sequencing for R/R multiple myeloma?"}]},{"children":[{"_key":"3f85535a5d390","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"35b1d09f25b6","markDefs":[]},{"style":"normal","_key":"62f2c6107b36","markDefs":[],"children":[{"_key":"35259bc671090","_type":"span","marks":[],"text":"Bispecific T-cell antibodies and CAR T therapies have really transformed the treatment landscape for relapsed/refractory multiple myeloma over the last 2 to 3 years or so. Before their regulatory pools, we had very limited options for treatment of what we call triple class refractory multiple myeloma—these are patients who are refractory to IMiDs [immunomodulatory drugs], proteasome inhibitors, anti–CD-38 monoclonal antibodies. And the advent of bispecific antibodies and CAR T therapies have really provided a very efficacious therapy with not only high overall response rates, but durable responses for this challenging patient population to treat."}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e8f5b16920380"}],"_type":"block","style":"normal","_key":"f3a737c48663"},{"_type":"block","style":"normal","_key":"1414ad39d343","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How do you see anti–CD-38 monoclonal antibodies changing the standard of care in multiple myeloma?","_key":"eaa6a68663540"}]},{"style":"normal","_key":"1512c5089a63","markDefs":[],"children":[{"marks":[],"text":"","_key":"39c1e7980b390","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"marks":[],"text":"Anti–CD-38 monoclonal antibodies like daratumumab and isatuximab have really transformed the landscape for the treatment of multiple myeloma, both in the relapsed setting [and] the newly diagnosed setting. And I think one of the most exciting things recently in the last couple years has been the incorporation of anti–CD-38 monoclonal antibodies in frontline therapy. Now, we have multiple studies showing the addition of anti–CD-38 monoclonal antibodies with the backbone of bortezomib/lenalidomide/dexamethasone, or even carfilzomib/dexamethasone really adds benefit in terms of not only MRD-negative rates, but also in some studies, progression-free survival as well.","_key":"8e35b01d26a80","_type":"span"}],"_type":"block","style":"normal","_key":"50a86098159b"},{"_key":"fcd75efd10e5","markDefs":[],"children":[{"_key":"8868838ac6600","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"_key":"ca52ad217044","markDefs":[],"children":[{"_type":"span","marks":[],"text":"I think most of us would consider that the standard of care for newly diagnosed multiple myeloma should incorporate an anti–CD-38 monoclonal antibody plus a protease inhibitor [and] IMiD backbone as standard of care for both transplant-eligible and even transplant-ineligible patients who are fit to receive a quadruple-based therapy.","_key":"c0e4a800675e0"}],"_type":"block","style":"normal"}],"_updatedAt":"2024-12-09T21:38:31Z","published":"2024-12-10T19:17:00.000Z","url":{"current":"how-anti-cd-38-antibodies-are-changing-the-standard-of-myeloma-care","_type":"slug"},"summary":"Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways. ","thumbnail":{"asset":{"assetId":"106dfac46d902fb8f2bcbd5dcae8a70cb599f74a","_updatedAt":"2024-12-09T19:55:22Z","_rev":"hiH1TfK5TgzpyVqIUM3ykb","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616.png","path":"images/0vv8moc6/ajmc/106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616.png","_createdAt":"2024-12-09T19:55:22Z","metadata":{"_type":"sanity.imageMetadata","palette":{"muted":{"background":"#a78165","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.63},"lightVibrant":{"background":"#74b4d4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.51,"background":"#1e506f"},"lightMuted":{"population":1.6,"background":"#c4b9b0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#4494bc","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"background":"#a78165","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.63},"_type":"sanity.imagePalette","darkMuted":{"background":"#563d2f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.19}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"height":1616,"_type":"sanity.imageDimensions","width":2879,"aspectRatio":1.7815594059405941},"isOpaque":true,"blurHash":"MIH.4x4T9ZyDIo~poe9G%MRjS%SiROemNG"},"mimeType":"image/png","originalFilename":"Hans Lee, MD.png","extension":"png","size":5870533,"_id":"image-106dfac46d902fb8f2bcbd5dcae8a70cb599f74a-2879x1616-png","uploadId":"0Fil4EzfLS6kHsptl0y93KHvHtQcUASb","sha1hash":"106dfac46d902fb8f2bcbd5dcae8a70cb599f74a"}},"articleType":"Commentary","link":"/view/how-anti-cd-38-antibodies-are-changing-the-standard-of-myeloma-care","updatedOn":null,"factCheckAuthorMapping":null,"_rev":"Wk5bXdTaWvRA2U0620pKFt"},{"seoTag":["bispecifics","multiple myeloma","car t"],"summary":"Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.","thumbnail":{"asset":{"_rev":"1U42a9jxrELBwJpoIvM3P0","sha1hash":"30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d","extension":"png","uploadId":"9d8zQwaTQkOFBznTL3PRtNzypnHnjN2z","_updatedAt":"2024-11-18T21:32:01Z","originalFilename":"Matias Sanchez IVBM image.png","metadata":{"_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"population":17.67,"background":"#353546","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"population":4.16,"background":"#977d70","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"background":"#ec8c9c","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.69,"background":"#28638a"},"lightMuted":{"population":0.12,"background":"#cec6ac","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#3685b6","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.03},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":17.67,"background":"#353546"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":1920,"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"MNKnk[.7_M9Fe.~pE2IVt6WBIWWVV@ozt7"},"mimeType":"image/png","size":3679772,"assetId":"30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d","_createdAt":"2024-11-18T21:32:01Z","_id":"image-30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080-png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080.png","path":"images/0vv8moc6/ajmc/30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080.png"}},"published":"2024-12-02T14:20:00.000Z","factCheckAuthorMapping":null,"_rev":"nNCuPaSBidMsBQeqyVEEth","url":{"current":"balancing-cutting-edge-therapies-with-cost-in-multiple-myeloma-treatment","_type":"slug"},"_id":"61d4380f-c614-43a5-bdb9-a0ee875af223","_type":"article","_updatedAt":"2024-11-20T17:25:44Z","articleType":"Commentary","contentCategory":{"_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z"},"link":"/view/balancing-cutting-edge-therapies-with-cost-in-multiple-myeloma-treatment","taxonomyMapping":[{"_type":"taxonomy","name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso"},{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews","name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z"},{"_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu"},{"_rev":"UoosHf5LKj69ImzsXs4QZt","_type":"taxonomy","name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm","_createdAt":"2020-04-23T19:36:16Z"},{"identifier":"ivbm-events","_createdAt":"2022-02-22T17:30:46Z","_rev":"2Cg3jaFTpU6hQKfUrgINsp","_type":"taxonomy","name":"IVBM Events","_id":"abac4670-ca81-4c11-91d1-509e07110acc","_updatedAt":"2022-02-22T17:30:46Z"},{"_type":"taxonomy","_updatedAt":"2020-07-30T14:48:10Z","identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2020-04-14T15:02:13Z","_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","name":"Hematology","_id":"compendium_hematology"},{"identifier":"healthcare-cost","_type":"taxonomy","_id":"topic_healthcare-cost","_updatedAt":"2022-11-29T18:34:38Z","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_rev":"52vAUxG62nnEnK65ZDnwlC","name":"Health Care Cost"}],"body":[{"videoID":"6364957824112","disableAutoPlayVideo":false,"source":"brightcove","_key":"1c411d37f63e","videoObject":{"thumbnail":{"_type":"image","asset":{"_ref":"image-30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080-png","_type":"reference"}},"videoDuration":"PT2M13S","videoDescription":"Matias Sanchez, MD talking MM 1","_type":"videoDetails","videoTitle":"Matias Sanchez, MD talking MM 1"},"_type":"video"},{"_type":"block","style":"normal","_key":"0e468b6c749c","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"fc8efaa06ce1"}],"children":[{"_key":"3bbd1ae076b50","_type":"span","marks":[],"text":"In a recent interview, Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed notable advancements in the treatment of multiple myeloma. He also expressed excitement about the potential of cell therapies and bispecific antibodies in "},{"_type":"span","marks":["fc8efaa06ce1"],"text":"myeloma","_key":"e3956bf44a07"},{"marks":[],"text":" treatment. Systems need to balance the cost-effectiveness with the clinical effectiveness of newer treatments like chimeric antigen receptor T-cell therapies (CAR T) and bispecific monoclonal antibodies, he explained.","_key":"e3830b99cffb","_type":"span"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"9029875d9f34"}],"_type":"block","style":"normal","_key":"aeb764836d2c"},{"style":"normal","_key":"dc380efa847e","markDefs":[],"children":[{"text":"Sanchez participated in a panel discussion on best practices in multiple myeloma care at a recent Institute for Value-Based Medicine","_key":"6df76e649f4f","_type":"span","marks":[]},{"_type":"span","marks":["superscript"],"text":"®","_key":"18f9f111d84a"},{"_type":"span","marks":[],"text":" event in Chicago.","_key":"28270978d2ac"}],"_type":"block"},{"children":[{"text":"","_key":"f78659e583b3","_type":"span","marks":["em"]}],"_type":"block","style":"normal","_key":"398fd8110714","markDefs":[]},{"style":"normal","_key":"7915019e56e0","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"dd34b87b605e"}],"_type":"block"},{"children":[{"_type":"span","marks":["strong","underline"],"text":"","_key":"cdb81f287a21"}],"_type":"block","style":"normal","_key":"1f8c276e87c4","markDefs":[]},{"style":"normal","_key":"d9bed6a84632","markDefs":[],"children":[{"text":"Transcript","_key":"7389bc8ad90b","_type":"span","marks":["strong","underline"]}],"_type":"block"},{"_type":"block","style":"normal","_key":"58144b501006","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"","_key":"c7f6c0a660e3"}]},{"children":[{"_type":"span","marks":["strong"],"text":"What are some of the most notable advancements you’ve seen in the treatment of multiple myeloma in recent years, and how have they impacted patient outcomes?","_key":"feb1221a7d480"}],"_type":"block","style":"normal","_key":"e021c39f3590","markDefs":[]},{"_type":"block","style":"normal","_key":"1b81852ae5ad","markDefs":[],"children":[{"_key":"089e81a84ce2","_type":"span","marks":[],"text":""}]},{"style":"normal","_key":"0c4723cc0a2c","markDefs":[],"children":[{"text":"We've seen great achievements. I think one of the most important ones has been the addition of the anti–CD-38 monoclonal antibodies, and adding them to the backbone of RBD [lenalidomide (Revlimid), bortezomib, and dexamethasone] or KRD [carfilzomib (Kyprolis), lenalidomide, and dexamethason] previous treatments. With those [as] induction chemotherapy, we've had the greatest responses that we've ever seen in multiple myeloma. So I think that has certainly affected the outcome in terms of response rates, progression-free survival, and hopefully overall survival in the future. We're excited to see that. Additionally, cell therapies and bispecifics are very interesting therapies. So we're excited to see myeloma [treatments] moving there as well.","_key":"280466ff607e0","_type":"span","marks":[]}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"","_key":"34db0c36d057"}],"_type":"block","style":"normal","_key":"a1eaeb9b1b92"},{"_type":"block","style":"normal","_key":"61201454f0bf","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How do you approach the challenge of balancing cost-effectiveness with clinical effectiveness when incorporating novel therapies like CAR T and bispecific antibodies into multiple myeloma care?","_key":"e145ab661d3b0"}]},{"markDefs":[],"children":[{"text":"","_key":"fa6d961b679e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"e941fa925dcf"},{"_key":"42f8940512f7","markDefs":[],"children":[{"marks":[],"text":"That's a great question. [With] all of our therapies, the better they get, the more expensive they get. So that's a challenge, and it's a challenge for our system. For the most part, so far, I think we always put efficacy first. In that way, I think using CAR Ts are the most efficacious treatments, and then bipecifics. But again, I think that's the challenge we all have. I work where we see a patient population who is insured by Medicare or Medicaid, so we are more limited than other institutions in the state, so we have to be cognizant of that or of what treatments we're going to give. But I think efficacy goes first from our standpoint.","_key":"cecba4879a770","_type":"span"}],"_type":"block","style":"normal"}],"authorMapping":[{"_rev":"4vyIlJfwMwqB8NbLEufc9y","_type":"author","displayName":"Skylar Jeremias","_createdAt":"2020-05-05T10:50:10Z","_id":"author_23eb58ee573d6006f4342daadc88b50b","biography":[{"_type":"block","style":"normal","_key":"f73a10e9267d","markDefs":[],"children":[{"marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span"}]},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"marks":[],"text":".","_key":"6fba991875ae2","_type":"span"}],"_type":"block","style":"normal","_key":"95aad26356ef","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/","_key":"510f2efa56c7","nofollow":true,"blank":true}]}],"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"_updatedAt":"2024-08-07T15:46:57Z","url":{"current":"skylar-jeremias","_type":"slug"},"profileThumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-1c1b3fe8f75d7099cec82cef128b20d15b4a4497-849x755-jpg"}}}],"is_visible":true,"ExcludeFromPubMedXML":false,"updatedOn":null,"source":null,"title":"Balancing Cutting-Edge Therapies With Cost in Multiple Myeloma Treatment","_createdAt":"2024-11-18T20:45:16Z"},{"title":"Transforming Multiple Myeloma Care With Education and Advanced Therapies","ExcludeFromPubMedXML":false,"articleType":"Commentary","_updatedAt":"2024-11-29T14:21:02Z","authorMapping":[{"displayName":"Skylar Jeremias","_createdAt":"2020-05-05T10:50:10Z","_id":"author_23eb58ee573d6006f4342daadc88b50b","biography":[{"markDefs":[],"children":[{"marks":[],"text":"Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.","_key":"6fba991875ae0","_type":"span"}],"_type":"block","style":"normal","_key":"f73a10e9267d"},{"markDefs":[{"_key":"510f2efa56c7","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/skylar-jeremias-0b8879116/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on ","_key":"8bc8c321c24e"},{"_type":"span","marks":["510f2efa56c7"],"text":"LinkedIn","_key":"6fba991875ae1"},{"marks":[],"text":".","_key":"6fba991875ae2","_type":"span"}],"_type":"block","style":"normal","_key":"95aad26356ef"}],"profileImage":{"_type":"mainImage","asset":{"_ref":"image-eca9090f66344b90a493123dfc0035ae7b6b1976-800x800-jpg","_type":"reference"}},"_updatedAt":"2024-08-07T15:46:57Z","url":{"current":"skylar-jeremias","_type":"slug"},"profileThumbnail":{"_type":"mainImage","asset":{"_type":"reference","_ref":"image-1c1b3fe8f75d7099cec82cef128b20d15b4a4497-849x755-jpg"}},"_rev":"4vyIlJfwMwqB8NbLEufc9y","_type":"author"}],"body":[{"_type":"block","style":"normal","_key":"5e6586224405","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"","_key":"5ea7f0666417"}]},{"source":"brightcove","_key":"380e83e50b35","videoObject":{"thumbnail":{"asset":{"_type":"reference","_ref":"image-30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080-png"},"_type":"image"},"videoDuration":"PT2M31S","videoDescription":"Matias Sanchez, MD talks about MM 2","_type":"videoDetails","videoTitle":"Matias Sanchez, MD talks about MM 2"},"_type":"video","videoID":"6364871448112","disableAutoPlayVideo":false},{"style":"normal","_key":"b9815fe9077d","markDefs":[],"children":[{"text":"","_key":"d1037141246d","_type":"span","marks":[]}],"_type":"block"},{"markDefs":[{"href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"abdb1fdbc9e0","nofollow":false,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago (UIC), emphasizes the importance of patient education and caregiver support in navigating complex therapies like transplants, while advising oncologists to embrace innovative treatments such as bispecific antibodies and chimeric antigen receptor T-cell (CAR T) therapy for ","_key":"1902900baf440"},{"marks":["abdb1fdbc9e0"],"text":"multiple myeloma","_key":"6421af3e0c04","_type":"span"},{"text":", tailoring them to patients' frailty levels.","_key":"b6a68e85a56c","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f747f8e6fdd9"},{"style":"normal","_key":"05f59bb9a784","markDefs":[],"children":[{"marks":[],"text":"","_key":"9d126d654bbc","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"text":"Sanchez participated in a panel discussion on best practices in multiple myeloma care at a recent Institute for Value-Based Medicine","_key":"55b80f01a76d","_type":"span","marks":[]},{"_key":"2aab7ea2699c","_type":"span","marks":["superscript"],"text":"®"},{"marks":[],"text":" event in Chicago.","_key":"4d252f52135d","_type":"span"}],"_type":"block","style":"normal","_key":"a513aa60e198"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d01c9f5ff85a"}],"_type":"block","style":"normal","_key":"8726a90f9cfa"},{"markDefs":[],"children":[{"_key":"89dee18d3f31","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}],"_type":"block","style":"normal","_key":"cd5353fbd065"},{"_type":"block","style":"normal","_key":"ddfb9c23fa8d","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"","_key":"b6ae712ff75c"}]},{"markDefs":[],"children":[{"text":"Transcript","_key":"95b401fddc05","_type":"span","marks":["underline","strong"]}],"_type":"block","style":"normal","_key":"cc7f86a962e8"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"\nWhat role does patient education play in managing expectations and outcomes, especially with the increased use of innovative but complex therapies?","_key":"8c500e2ff26b0"}],"_type":"block","style":"normal","_key":"a7cbd86c3c45"},{"style":"normal","_key":"0c309c01d5ac","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"","_key":"0c5d1f5dd791"}],"_type":"block"},{"style":"normal","_key":"bb5cef088d35","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Education is crucial in terms of supportive care. I'm from the transplant world, so that's where we really need to make sure the patient has a caregiver or has someone who can help them navigate the system and help them with the chores. Usually with our patient population that we take care at UIC, we try to always make sure the patient has someone who can help navigate everything, the whole transplant or chemotherapy process, everything. I think it's the most important thing. And it's a team, so our nurses do a great job there, too.","_key":"5ae18d7fd6f60"}],"_type":"block"},{"_key":"40cfee73e7c7","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"aae1b40ec78e"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What advice would you give to other oncologists who are looking to adopt more value-based approaches to managing multiple myeloma?","_key":"2ad7234542580"}],"_type":"block","style":"normal","_key":"fe3ab3738fcd"},{"children":[{"_type":"span","marks":["strong"],"text":"","_key":"5d2c058d87ea"}],"_type":"block","style":"normal","_key":"2268d18ece05","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"My advice would be to, first, use the most effective therapies for myeloma that you have up front, and don't be afraid to use the new therapies that are available, especially the bispecifics and CAR T. We can select the patients who are the best patients to whom we can give those treatments. Make sure patients are not very frail or ultra frail; we can adapt those treatments according to their frailty status. But don't be afraid either to use them. Because these are all new treatments that make us anxious and make us go, \"What are we going to do if the patient gets a fever?\"—all those things, yeah— but don't be afraid to try to use targeted therapies in the right patient.","_key":"f29cd95236790","_type":"span"}],"_type":"block","style":"normal","_key":"5c501a207014"}],"url":{"_type":"slug","current":"transforming-oncology-care-with-education-and-advanced-therapies"},"updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"summary":"Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.","is_visible":true,"_id":"6d707e29-0c97-4b7d-b39f-1639a9fc354c","published":"2024-11-29T14:21:00.000Z","taxonomyMapping":[{"name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy"},{"identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z"},{"parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"_createdAt":"2020-04-23T19:37:55Z","_rev":"NuKmNEJEtqI7CGtQXk1JuD","_type":"taxonomy","_id":"385b1a25-0f07-45fd-906a-410c8acbd92e","identifier":"interviews","name":"Interviews","_updatedAt":"2023-12-19T21:06:11Z"},{"summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma"},{"_type":"taxonomy","name":"IVBM","_id":"d39ec421-0b9c-48cf-874a-1003391b925f","_updatedAt":"2022-02-18T12:08:18Z","identifier":"ivbm","_createdAt":"2020-04-23T19:36:16Z","_rev":"UoosHf5LKj69ImzsXs4QZt"},{"_updatedAt":"2022-02-22T17:30:46Z","identifier":"ivbm-events","_createdAt":"2022-02-22T17:30:46Z","_rev":"2Cg3jaFTpU6hQKfUrgINsp","_type":"taxonomy","name":"IVBM Events","_id":"abac4670-ca81-4c11-91d1-509e07110acc"},{"_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","name":"Hematology","_id":"compendium_hematology","_type":"taxonomy","_updatedAt":"2020-07-30T14:48:10Z","identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2020-04-14T15:02:13Z"},{"identifier":"value-based-care","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_createdAt":"2020-05-04T23:46:13Z","_type":"taxonomy","name":"Value-Based Care","_id":"topic_value-based-care","_rev":"N3gjDAQ7Gje4d3HLJ0sWGv","_updatedAt":"2022-11-29T18:34:06Z"},{"identifier":"news","_createdAt":"2020-04-23T19:37:01Z","_rev":"HexDiduX8d6Nqnq1EColxB","parent":{"_ref":"d39ec421-0b9c-48cf-874a-1003391b925f","_type":"reference"},"pixelTrackingCode":{"_ref":"c42e5374-778f-4c0d-9f48-73dc34bb9008","_type":"reference"},"_type":"taxonomy","name":"Value-Based Medicine News","_id":"5897667f-446d-406b-af6e-a66f5ef21e43","_updatedAt":"2022-02-18T11:56:28Z"}],"_rev":"h252A9RcdzVgZdAVXYPH3d","_type":"article","_createdAt":"2024-11-18T20:45:04Z","seoTag":["multiple myeloma","bispecifics","car t"],"link":"/view/transforming-oncology-care-with-education-and-advanced-therapies","thumbnail":{"asset":{"metadata":{"palette":{"dominant":{"title":"#fff","population":17.67,"background":"#353546","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"population":17.67,"background":"#353546","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.16,"background":"#977d70"},"lightVibrant":{"background":"#ec8c9c","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.69,"background":"#28638a","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#fff","population":0.12,"background":"#cec6ac","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#3685b6","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.03}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"width":1920,"aspectRatio":1.7777777777777777,"height":1080,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"MNKnk[.7_M9Fe.~pE2IVt6WBIWWVV@ozt7","_type":"sanity.imageMetadata"},"mimeType":"image/png","size":3679772,"assetId":"30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d","_createdAt":"2024-11-18T21:32:01Z","_id":"image-30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080-png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080.png","path":"images/0vv8moc6/ajmc/30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d-1920x1080.png","_rev":"1U42a9jxrELBwJpoIvM3P0","sha1hash":"30b8cfa357f6d845f910ccf9ad8ae82a42bb5a8d","extension":"png","uploadId":"9d8zQwaTQkOFBznTL3PRtNzypnHnjN2z","_updatedAt":"2024-11-18T21:32:01Z","originalFilename":"Matias Sanchez IVBM image.png"}},"source":null,"factCheckAuthorMapping":null},{"seoTag":["multiple myeloma","isatuximab","surrogate end point"],"summary":"In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease (MRD) status.","is_visible":true,"link":"/view/mrd-a-game-changer-in-multiple-myeloma","updatedOn":null,"source":null,"factCheckAuthorMapping":null,"taxonomyMapping":[{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu"},{"identifier":"clinical","parent":{"_type":"reference","_ref":"15012229-f713-4f0a-8f82-7667530bb382"},"name":"Clinical","summary":[{"children":[{"_key":"e80c79954e08","_type":"span","marks":[],"text":"The "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"text":"®","_key":"f7d4dddf7edd","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_type":"span","marks":["superscript"],"text":"®","_key":"2babb3e59bb3"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17"},{"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.","_key":"b59bef533cdf","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[]}],"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z"},{"identifier":"hematology","parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"_createdAt":"2020-04-14T15:02:13Z","_rev":"GeM6ny2T6Y1Qp0cm9jBxeg","name":"Hematology","_id":"compendium_hematology","_type":"taxonomy","_updatedAt":"2020-07-30T14:48:10Z"}],"body":[{"videoObject":{"videoDescription":"Interview with Surbhi Sidana, MD, MBBS","_type":"videoDetails","videoTitle":"MRD: A Game Changer in multiple myeloma","thumbnail":{"_type":"image","asset":{"_ref":"image-d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675-jpg","_type":"reference"}},"videoDuration":"PT2M17S"},"_type":"video","caption":"Surbhi Sidana, MD, MBBS","videoID":"6363688938112","disableAutoPlayVideo":false,"source":"brightcove","_key":"f4b14cd49936"},{"_type":"block","style":"normal","_key":"001a5aba3648","markDefs":[],"children":[{"_key":"bd8a0bbc0d55","_type":"span","marks":[],"text":""}]},{"markDefs":[],"children":[{"_key":"2999cc26c4f60","_type":"span","marks":[],"text":"In part 2 of our interview with Surbhi Sidana, MD, MBBS, vice chair of the American Society of Hematology’s Committee on Communications and associate professor of medicine and director of the Myeloma Disease Focused Group at Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: minimal residual disease status."}],"_type":"block","style":"normal","_key":"27b9cd91ebb2"},{"children":[{"text":"","_key":"57a82be0d7bd0","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"d5dfea1bc93f","markDefs":[]},{"_key":"bc4a0fe69eed","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Here she explains just what are these remnants of cancer that remain after completion of treatment and their significance to future treatment decisions and outcomes.","_key":"065a56b787ac0"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"d6240b2a7d170"}],"_type":"block","style":"normal","_key":"53e48d35b7f6","markDefs":[]},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/isatuximab-approval-highlights-role-of-anti-cd38-antibody-in-myeloma-care","_key":"33ff064e5a57"},{"_key":"45288976db66","blank":true,"_type":"link","href":"https://www.ajmc.com/view/fda-approves-isatuximab-with-vrd-as-first-line-option-for-transplant-ineligible-multiple-myeloma"},{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"b8fbc6cb991c"}],"children":[{"marks":[],"text":"Also make sure to check our ","_key":"233a7b9cfdfd0","_type":"span"},{"text":"part 1","_key":"233a7b9cfdfd1","_type":"span","marks":["33ff064e5a57"]},{"_type":"span","marks":[],"text":" of our exclusive interview with her regarding the recent ","_key":"233a7b9cfdfd2"},{"_type":"span","marks":["45288976db66"],"text":"FDA approval of isatuximab","_key":"233a7b9cfdfd3"},{"_key":"233a7b9cfdfd4","_type":"span","marks":[],"text":" (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide (Revlimid; Celgene), and dexamethasone (VRd) in the first line for patients with "},{"marks":["b8fbc6cb991c"],"text":"multiple myeloma","_key":"759af42b30ba","_type":"span"},{"text":" (MM) ineligible for transplant.","_key":"88a1e14a5bbb","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"42505e0bddbf"},{"_type":"block","style":"normal","_key":"83e09869ba92","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ad2f18b425d00"}]},{"markDefs":[],"children":[{"text":"This transcript has been lightly edited","_key":"0a5abaffc4620","_type":"span","marks":["em"]},{"text":".","_key":"0a5abaffc4621","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"6edfca3655e4"},{"style":"normal","_key":"ec9e40d38cc3","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"acfe1769097a0"}],"_type":"block"},{"_key":"3fe4ac0dbacd","markDefs":[],"children":[{"text":"Transcript","_key":"25b494b65bd70","_type":"span","marks":["strong","underline"]}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"e817b690afd20"}],"_type":"block","style":"normal","_key":"91547337254a","markDefs":[]},{"_key":"033033bf6c86","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"What is the role of MRD status in multiple myeloma and how does it direct treatment decisions and outcomes?","_key":"779ec60978e30"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"6e442d7034d40","_type":"span"}],"_type":"block","style":"normal","_key":"5938bc942673"},{"_key":"aad2e34a659e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Minimal residual disease is a sensitive way to measure disease that our current criteria cannot measure through blood-based testing or bone marrow–based testing.","_key":"00d2568842c00"}],"_type":"block","style":"normal"},{"style":"normal","_key":"8c0d279326bc","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"17912850dabd0"}],"_type":"block"},{"children":[{"marks":[],"text":"Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg: you can detect something on the surface, then you do a bone marrow [test and] you can detect something under the surface. But we know that even with those techniques, a lot of disease was left behind that they were just not sensitive enough to detect. So, MRD, or minimal residual disease, testing is just a more sensitive technique to detect disease that cannot be detected by conventional technologies.","_key":"4b3feb5ff4ea0","_type":"span"}],"_type":"block","style":"normal","_key":"42663d1d89af","markDefs":[]},{"children":[{"_key":"963bac9bb6f30","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"d5c4a53f535f","markDefs":[]},{"markDefs":[],"children":[{"_key":"8f9de165a7cc0","_type":"span","marks":[],"text":"There's a couple of ways to do it by our current methodologies. Both of them right now rely on bone marrow testing: next-generation flow cytometry, which is an advanced flow cytometry to [provide a] more sensitive way of detection, or next-generation sequencing that detects the clone in myeloma at the time of diagnosis or relapse and tracks that clone through sequencing of the VDJ region in the plasma cell and just tracks that one clone to detect it at a very low level."}],"_type":"block","style":"normal","_key":"9cd8bd26c74c"},{"style":"normal","_key":"10f739c2a94b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bcb4ac9e5d860"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"It's just a sensitive way to detect disease that we couldn't previously detect. And what this tells us is that if you have low-level disease that we cannot detect by MRD—it doesn't mean there's no disease, just that these techniques cannot detect—those patients do better. We've seen that historically.","_key":"38d06ac96fe20"}],"_type":"block","style":"normal","_key":"005a8ef2b630"},{"_key":"cf90ac37678c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e40841cfd7a60"}],"_type":"block","style":"normal"},{"children":[{"_key":"54b2dae43cf80","_type":"span","marks":[],"text":"Now, the FDA ODAC [Oncologic Drugs Advisory Committee] came out "},{"_type":"span","marks":["17839c83ace1"],"text":"with a decision","_key":"54b2dae43cf81"},{"_type":"span","marks":[],"text":" that MRD will be used as a surrogate end point. They're open to that as a surrogate end point for drug approval. So, I think the field is moving in that direction. So, yes, MRD negativity rates were actually higher in this clinical trial [IMROZ, NCT03319667] with a quadruplet induction.","_key":"54b2dae43cf82"}],"_type":"block","style":"normal","_key":"1759ec02d35c","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/after-odac-what-s-next-for-mrd-testing-in-multiple-myeloma-","_key":"17839c83ace1"}]},{"_type":"block","style":"normal","_key":"042a745eb7bc","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d5e4a676c1f00"}]},{"style":"normal","_key":"d888804a3c5d","markDefs":[{"blank":true,"_type":"link","href":"https://www.ajmc.com/view/cepheus-sub-q-daratumumab-with-vrd-improves-mrd-negativity-pfs-in-myeloma-if-transplant-deferred","_key":"379fada9485e"}],"children":[{"_key":"b4c7a478db150","_type":"span","marks":[],"text":"We just had the IMS 2024 meeting in Brazil, and there they presented another clinical trial, which was very similar, just used a different anti-CD38, "},{"text":"the CEPHEUS trial","_key":"b4c7a478db151","_type":"span","marks":["379fada9485e"]},{"text":", where the primary end point was actually MRD negativity. So, in the IMROZ trial, the primary end point was PFS [progression-free survival], but there the primary end point was MRD negativity. So, our field is changing rapidly.","_key":"b4c7a478db152","_type":"span","marks":[]}],"_type":"block"}],"_id":"51b5be8a-83c6-4679-83e9-28c65886cfc3","authorMapping":[{"_createdAt":"2020-05-05T10:50:09Z","_rev":"4vyIlJfwMwqB8NbLEufdwW","_type":"author","biography":[{"children":[{"_key":"abc0e18a29ce0","_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor."}],"_type":"block","style":"normal","_key":"643be033259e","markDefs":[]},{"_type":"block","style":"normal","_key":"f4070c315fab","markDefs":[{"_key":"159c764717fb","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_type":"span","marks":[],"text":".","_key":"abc0e18a29ce2"}]}],"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"}},"_updatedAt":"2024-08-07T15:47:36Z","displayName":"Maggie L. Shaw","_id":"author_51b2956e2bd42e0d6e35a66971fd60bc","url":{"current":"maggie-l-shaw","_type":"slug"}}],"thumbnail":{"asset":{"path":"images/0vv8moc6/ajmc/d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg","uploadId":"KmeVYjwEdoE53rfAVfEednO41NJQUR2N","_rev":"2oSzY2xHyUGh6118HqAcjB","mimeType":"image/jpeg","_createdAt":"2024-10-02T16:08:51Z","_type":"sanity.imageAsset","size":134400,"assetId":"d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac","_updatedAt":"2024-10-02T16:08:51Z","originalFilename":"Sidana Thumbnail.jpg","metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7777777777777777,"height":675},"isOpaque":true,"blurHash":"MeLqa}lA_MWDV@_2ozM{xuV[M{n%Rjofxu","_type":"sanity.imageMetadata","palette":{"vibrant":{"population":0,"background":"#4073be","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"title":"#fff","population":4.38,"background":"#cebdad","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":1.74,"background":"#343f59","_type":"sanity.imagePaletteSwatch"},"muted":{"background":"#647a9c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"lightVibrant":{"foreground":"#000","title":"#000","population":1.53,"background":"#e5d4bc","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.69,"background":"#1c3252","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"foreground":"#000","title":"#fff","population":4.38,"background":"#cebdad","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false},"sha1hash":"d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac","_id":"image-d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675-jpg","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/d2d71ee7e41fc353ec8dc2a9dfdc27cc40cb40ac-1200x675.jpg"}},"_type":"article","contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"_createdAt":"2024-10-24T16:14:55Z","_updatedAt":"2024-10-24T17:16:26Z","articleType":"Commentary","_rev":"Nphhc06GU7PslEeOdbRtob","title":"MRD: A Game Changer in Multiple Myeloma","ExcludeFromPubMedXML":false,"published":"2024-10-24T16:59:06.697Z","url":{"current":"mrd-a-game-changer-in-multiple-myeloma","_type":"slug"}},{"source":null,"ExcludeFromPubMedXML":false,"articleType":"Commentary","_id":"58b86721-21c2-4ef0-a879-e426c525a59a","summary":"Speakers at the 2024 International Myeloma Society (IMS) conference share the updates from the myeloma space that they were most excited about this year.","link":"/view/ims-2024-speakers-look-back-on-exciting-myeloma-updates","title":"IMS 2024 Speakers Look Back on Exciting Myeloma Updates","published":"2024-10-01T18:23:24.621Z","authorMapping":[{"firstName":"Cameron","lastName":"Santoro","_createdAt":"2023-11-22T18:35:06Z","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"markDefs":[],"children":[{"_key":"93662c5c4cfd","_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for "},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"text":"®","_key":"7c809e803edb","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"text":"®","_key":"8ddca200bc46","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal","_key":"3da8fced8696"}],"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"_updatedAt":"2024-05-20T19:28:22Z","displayName":"Cameron Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","_type":"author","url":{"current":"cameron-santoro","_type":"slug"}},{"lastName":"Gallagher","displayName":"Ashley Gallagher","_createdAt":"2022-11-23T19:49:06Z","_type":"author","_updatedAt":"2022-11-23T19:49:06Z","url":{"current":"ashley-gallagher","_type":"slug"},"firstName":"Ashley","_rev":"52vAUxG62nnEnK65YmG5ja","_id":"930acce9-21e2-4ba4-bd26-97bdfa82bdd7"},{"firstName":"Aislinn","lastName":"Antrim","displayName":"Aislinn Antrim","_createdAt":"2023-03-16T17:42:50Z","_type":"author","_id":"401d7aa2-c737-425a-8a3e-6a8587b363ef","_updatedAt":"2023-03-16T17:42:50Z","url":{"current":"aislinn-antrim","_type":"slug"},"_rev":"cejbFjqp0SNu6k7v9JvYJx"}],"url":{"current":"ims-2024-speakers-look-back-on-exciting-myeloma-updates","_type":"slug"},"is_visible":true,"documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"body":[{"_type":"video","caption":"IMS Recap","videoID":"6362724980112","disableAutoPlayVideo":false,"source":"brightcove","_key":"2f25a6efa2c8","videoObject":{"videoDuration":"PT3M35S","videoDescription":"IMS Recap","_type":"videoDetails","videoTitle":"IMS Recap","thumbnail":{"_type":"image","asset":{"_ref":"image-2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250-png","_type":"reference"}}}},{"style":"normal","_key":"1df999cbcef5","markDefs":[{"_key":"49ff5da8a62e","blank":true,"_type":"link","href":"https://www.ajmc.com/conference/ims"}],"children":[{"_type":"span","marks":[],"text":"We spoke with the following global experts who attended the ","_key":"a74b3d3afe900"},{"_type":"span","marks":["49ff5da8a62e"],"text":"2024 International Myeloma Society ","_key":"a74b3d3afe901"},{"_type":"span","marks":[],"text":"meeting regarding what they believe was the most interesting update in the myeloma space this year:","_key":"a74b3d3afe902"}],"_type":"block"},{"_type":"block","style":"normal","_key":"bba4eee10a79","listItem":"bullet","markDefs":[],"children":[{"_key":"973599256d640","_type":"span","marks":[],"text":"Pieter Sonneveld, MD, PhD, professor of hematology at the Erasmus University Medical Center, chairman of the Multiple Myeloma Working Group and European Myeloma Network"}],"level":1},{"_key":"7822449cbc1c","listItem":"bullet","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Saad Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center","_key":"2142d338fb010"}],"level":1,"_type":"block","style":"normal"},{"level":1,"_type":"block","style":"normal","_key":"b27f651e080a","listItem":"bullet","markDefs":[],"children":[{"_key":"c6d5a73b502d0","_type":"span","marks":[],"text":"Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin"}]},{"style":"normal","_key":"90a6708ef6de","markDefs":[],"children":[{"marks":[],"text":"","_key":"c4cab8f17bde","_type":"span"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"1cc15d0f07b80","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}],"_type":"block","style":"normal","_key":"ba76b9cbc224"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e2abfa9ade9e"}],"_type":"block","style":"normal","_key":"ea9e45f011e7"},{"style":"normal","_key":"72824939b46f","markDefs":[],"children":[{"_key":"f23aae87ea070","_type":"span","marks":["strong","underline"],"text":"Transcript"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"","_key":"b0599dd59c96"}],"_type":"block","style":"normal","_key":"a06af72e3eda","markDefs":[]},{"_type":"block","style":"normal","_key":"d916fb3f46b0","markDefs":[],"children":[{"_key":"91c40933d98e0","_type":"span","marks":["strong"],"text":"What update in the myeloma space this year has been the most interesting to you?"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"ea23e1476f7b"}],"_type":"block","style":"normal","_key":"c214d90ea3c2","markDefs":[]},{"children":[{"marks":["strong"],"text":"Sonneveld:","_key":"40aa8e33d1930","_type":"span"},{"_key":"a5df4fb4ab66","_type":"span","marks":[],"text":" The most interesting update to me is the "},{"marks":["90babe82269a"],"text":"PERSEUS study","_key":"4d89f3738a50","_type":"span"},{"_type":"span","marks":[],"text":", a study using traditional drugs like VRd [bortezomib, lenalidomide, and dexamethasone] and adding the monoclonal antibody daratumumab. This results in a great effect in the frontline setting of treatment for multiple myeloma.","_key":"702b7894016e"}],"_type":"block","style":"normal","_key":"6337904d02fc","markDefs":[{"_type":"link","href":"https://www.ajmc.com/view/daratumumab-quadruplets-show-durable-outcomes-in-transplant-eligible-multiple-myeloma","_key":"90babe82269a","nofollow":true,"blank":true}]},{"_key":"00472c80195a","markDefs":[],"children":[{"_key":"45e024e269ba0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"At the same time, we are also aware of new developments like CAR [chimeric antigen receptor] T-cell treatments and treatments with bispecific antibodies.","_key":"542a2e47377b0"}],"_type":"block","style":"normal","_key":"4f659b993f62"},{"_type":"block","style":"normal","_key":"6659f5c3e0a4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"f456171e3d8c0"}]},{"_key":"b53aaf0fb805","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The organization for which I'm working, The European Myeloma Network [EMN], also coordinates 2 important trials in the frontline setting. One trial is comparing CAR T-cell treatment with standard autologous stem cell transplantation. This trial is ongoing in many countries around the world, coordinated by EMN.","_key":"6c8862d0afd30"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"ce37f7ff812d0","_type":"span"}],"_type":"block","style":"normal","_key":"306dac0fb23e"},{"_key":"25f3bbc12420","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The other trial is about the use of bispecifics in the maintenance setting—in this case, teclistamab, also for a frontline treatment for patients with multiple myeloma. Trials have been done in the relapse setting and we know they are very effective, have very high response rates, and lasting responses of good quality.","_key":"4703da37a2820"}],"_type":"block","style":"normal"},{"style":"normal","_key":"d58d43cba6ea","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"3da478fac5c10"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"We expect that when moving these novel agents from the relapse setting to the frontline setting, the impact on the treatment in terms of response rate, but especially duration of response, will be huge.","_key":"feccf4e2f14d0"}],"_type":"block","style":"normal","_key":"48e5ff43a8c4","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"","_key":"5ac4d28ffae00"}],"_type":"block","style":"normal","_key":"6ba987eb24c5","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We expect that this will be the next step in myeloma treatment that will set the new standard of care and we expect a lot from that. Over the next 5 to 10 years, we will see the developments with these new agents. I think the whole world of myeloma treatment will change with the results of these new trials.","_key":"2fb0ffc23d630"}],"_type":"block","style":"normal","_key":"623e2a2f8348"},{"style":"normal","_key":"0dfb971ca3eb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"918bea17fc430"}],"_type":"block"},{"_key":"3b93783ed2a3","markDefs":[],"children":[{"marks":["strong"],"text":"Usmani:","_key":"22b115cf62df0","_type":"span"},{"text":" The movement from 3-drug combinations to anti-CD38–based quadruplet induction approaches for patients has been a very important step forward for patients. The next important avenue that we have to figure out is what kind of maintenance strategies would suffice for standard-risk patients, what do we need for high-risk patients? We need to look at the duration of therapy. These will be important things to consider for the future research directions.","_key":"2eee7ce32be0","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"93613732e47f0"}],"_type":"block","style":"normal","_key":"dced72f92372","markDefs":[]},{"_key":"e5dce6eeacc5","markDefs":[],"children":[{"text":"Dhakal:","_key":"6a3a154730bb0","_type":"span","marks":["strong"]},{"_type":"span","marks":[],"text":" There are a lot of new CAR T [therapies] being developed, both against BCMA [B-cell maturation antigen] and non-BCMA, like GPRC5D. Under this, it has been pretty encouraging and shows some very good results. In addition, there are small molecules that are being developed, particularly for the protein integrators, BCL-2 inhibitors, and a lot of developments in the bispecific antibodies, but not only for BCMA, but also GPRC5D/FcRH5. More importantly, things are moving earlier in the early-line setting and are showing very impressive efficacy and safety, and this really kind of sets this platform for us to have a very deep, durable response in majority of the patients in the future.","_key":"85f0c1b89c03"}],"_type":"block","style":"normal"}],"_updatedAt":"2024-10-01T17:30:07Z","seoTag":["PERSEUS","daratumumab","CAR T-cell treatment","BCMA","GPRC5D"],"taxonomyMapping":[{"_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z","identifier":"conference","_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference"},{"identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z"},{"name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"_type":"block","style":"normal","_key":"f1088709f836","markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}]}],"identifier":"multiple-myeloma"}],"factCheckAuthorMapping":null,"thumbnail":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png","size":4039572,"assetId":"2fa4d6766aabad75eb6f160b7ecb099788f2be9d","_createdAt":"2024-10-01T17:08:45Z","_type":"sanity.imageAsset","path":"images/0vv8moc6/ajmc/2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250.png","_id":"image-2fa4d6766aabad75eb6f160b7ecb099788f2be9d-3750x2250-png","extension":"png","_rev":"YVH2fYgeJpexFIow4LOQC6","uploadId":"WiWdoMEnQ8H8mhrjsn3sbaaLHWnGfMjO","mimeType":"image/png","_updatedAt":"2024-10-01T17:08:45Z","originalFilename":"IMS - 2024 Recap.png","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":3750,"aspectRatio":1.6666666666666667,"height":2250},"isOpaque":true,"blurHash":"MCEy[U_4rvVDr_-@R6n4$%s?H=IVnixZM}","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#304a5b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.24},"muted":{"title":"#fff","population":7.95,"background":"#667ba1","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#e8a39d","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":3.7},"darkVibrant":{"background":"#26535e","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"population":4.73,"background":"#a3b4c7","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"title":"#fff","population":0.02,"background":"#6cb2c3","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"dominant":{"background":"#667ba1","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.95},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"sha1hash":"2fa4d6766aabad75eb6f160b7ecb099788f2be9d"}},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"_createdAt":"2024-10-01T16:38:43Z","_type":"article","_rev":"LKAfGsMVtGrsTVLa3APUAH","documentGroupMapping":[{"_type":"reference","_key":"fe376d98d56e","_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48"}],"updatedOn":null},{"authorMapping":[{"_type":"author","url":{"current":"cameron-santoro","_type":"slug"},"firstName":"Cameron","lastName":"Santoro","_createdAt":"2023-11-22T18:35:06Z","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"_type":"block","style":"normal","_key":"3da8fced8696","markDefs":[],"children":[{"_key":"93662c5c4cfd","_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for "},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"text":"®","_key":"7c809e803edb","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"text":"®","_key":"8ddca200bc46","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}]}],"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"_updatedAt":"2024-05-20T19:28:22Z","displayName":"Cameron Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm"},{"_rev":"cejbFjqp0SNu6k7v9JvYJx","firstName":"Aislinn","lastName":"Antrim","displayName":"Aislinn Antrim","_createdAt":"2023-03-16T17:42:50Z","_type":"author","_id":"401d7aa2-c737-425a-8a3e-6a8587b363ef","_updatedAt":"2023-03-16T17:42:50Z","url":{"current":"aislinn-antrim","_type":"slug"}}],"articleType":"Commentary","_type":"article","_updatedAt":"2024-09-26T21:06:26Z","updatedOn":null,"ExcludeFromPubMedXML":false,"published":"2024-09-26T21:06:15.917Z","body":[{"_key":"b3d640f01a05","videoObject":{"videoTitle":"Rahul Banerjee, MD, FACP.","thumbnail":{"asset":{"_ref":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png","_type":"reference"},"_type":"image"},"videoDuration":"PT4M57S","videoDescription":"Rahul Banerjee, MD, FACP","_type":"videoDetails"},"_type":"video","caption":"Rahul Banerjee, MD, FACP","videoID":"6362509035112","disableAutoPlayVideo":false,"source":"brightcove"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"There are limited randomized data on studies that focus on T-cell–directed therapies in the first-line setting for multiple myeloma. However, the ongoing CARTITUDE-5 and CARTITUDE-6 studies are comparing chimeric antigen receptor (CAR) T-cell therapies with traditional treatments, said Rahul Banerjee, MD, FACP, assistant professor for the Division of Hematology and Oncology at the University of Washington.","_key":"edfcbaf8cf060"}],"_type":"block","style":"normal","_key":"23b179bc4e8c"},{"_type":"block","style":"normal","_key":"2358f285af15","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a28672cf3d900"}]},{"_key":"504e33b94215","markDefs":[{"href":"https://www.ajmc.com/conference/ims","_key":"6e454f708090","blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Banerjee attended the annual ","_key":"eab5f55bf6680"},{"_type":"span","marks":["6e454f708090"],"text":"International Myeloma Society","_key":"eab5f55bf6681"},{"_type":"span","marks":[],"text":" conference to discuss how to determine the type of T-cell–directed therapies to use for patient populations. Although newer CAR T-cell therapies are expected to be more effective based on less T-cell exhaustion, he expressed concerns regarding infectious complications and the unmet need for specialized centers that are equipped to treat CAR T-cell therapies.","_key":"eab5f55bf6682"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"02e2f039893e"}],"_type":"block","style":"normal","_key":"e88b91739c27"},{"_key":"cac7b08d0157","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://clinicaltrials.gov/study/NCT04923893","_key":"51836a73e689"}],"children":[{"marks":[],"text":"The ","_key":"83574bfa980b0","_type":"span"},{"_type":"span","marks":["51836a73e689"],"text":"CARTITUDE-5 study","_key":"83574bfa980b1"},{"_type":"span","marks":[],"text":" is comparing the efficacy of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) vs VRd induction followed by lenalidomide and dexamethasone maintenance in newly diagnosed patients with multiple myeloma.","_key":"83574bfa980b2"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c9918a1be4e80"}],"_type":"block","style":"normal","_key":"dddaf339b189"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://clinicaltrials.gov/study/NCT05257083","_key":"6a267c6d9669"}],"children":[{"_type":"span","marks":[],"text":"Banerjee also addressed the ","_key":"774674be57ef0"},{"_type":"span","marks":["6a267c6d9669"],"text":"CARTITUDE-6 study","_key":"774674be57ef1"},{"_key":"774674be57ef2","_type":"span","marks":[],"text":" that is comparing the efficacy of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) followed by cilta-cel vs DVRd followed by autologous stem cell transplant in newly diagnosed patients with multiple myeloma."}],"_type":"block","style":"normal","_key":"3c533929ed22"},{"style":"normal","_key":"3f74f5cb7312","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7404ddff69d20"}],"_type":"block"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://clinicaltrials.gov/study/NCT05552222","_key":"5f0064ee00eb"}],"children":[{"marks":[],"text":"\"Bispecifics are also being explored in the front-line setting. There are several studies that have been looking at this; ","_key":"87a59d2302ff0","_type":"span"},{"marks":["5f0064ee00eb"],"text":"MajesTEC-7","_key":"87a59d2302ff1","_type":"span"},{"marks":[],"text":" comes to mind.\"","_key":"87a59d2302ff2","_type":"span"}],"_type":"block","style":"normal","_key":"b2e64e806882"},{"children":[{"_key":"39a33d70bbec0","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"0864143ad372","markDefs":[]},{"style":"normal","_key":"8124e4de41e8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Banerjee explains the purpose of MajesTEC-7 was to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide and talquetamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone.","_key":"059640affc600"}],"_type":"block"},{"_key":"e49c915ff5ca","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d9eacc94e100"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"Additionally, he mentions the ","_key":"b0d684a351620"},{"marks":["4c843eeb0f89"],"text":"MAIA study","_key":"b0d684a351621","_type":"span"},{"_type":"span","marks":[],"text":" as an example where bispecifics were explored in a front-line setting. Banerjee states that although the study results thus far have shown some success, the risk of infections was found to be greater than he would like them to be, and he suggests the safety profiles of the drugs should be examined further.","_key":"b0d684a351622"}],"_type":"block","style":"normal","_key":"976b06638dbc","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00466-6/abstract","_key":"4c843eeb0f89"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"cbce38a7848f0"}],"_type":"block","style":"normal","_key":"82a01628945e"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"\"Even if tomorrow, teclistamab were to be approved for front-line therapy in any subset of patients, I would hazard a guess that 90% of Americans do not live within 30 minutes of a bispecific-capable center.\"","_key":"13fd846fa6880"}],"_type":"block","style":"normal","_key":"014401dcbb2a"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"7e2abfa289500","_type":"span"}],"_type":"block","style":"normal","_key":"583adbff2871"},{"_type":"block","style":"normal","_key":"a9648d4137ad","markDefs":[],"children":[{"marks":[],"text":"Banerjee concludes the interview by recognizing the specific outpatient dosing they have access to but how this falls short on a global scale.","_key":"bc8775a279c60","_type":"span"}]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"d52f591db5c90","_type":"span"}],"_type":"block","style":"normal","_key":"0a6f95fabcbf"},{"markDefs":[],"children":[{"marks":[],"text":"\"I do want to put a very clear note of caution there that we need to look before we leap into this world of BCMA [B-cell maturation antigen] as front-line therapy.\"","_key":"eb63f0ae57bb0","_type":"span"}],"_type":"block","style":"normal","_key":"ffc86c96d22c"}],"title":"Evaluating T-Cell Therapies in First-Line Multiple Myeloma Treatment","documentGroupMapping":[{"_key":"31bdf80a59e5","_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"}],"seoTag":["T-cell therapy","multiple myeloma","IMS"],"is_visible":true,"taxonomyMapping":[{"identifier":"conference","_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z"},{"_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma"}],"documentGroup":{"_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48","_type":"reference"},"thumbnail":{"asset":{"metadata":{"isOpaque":true,"blurHash":"MtH2ZjNGoIRjMx~qM|ayWBRjofWBafoLkC","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"foreground":"#000","title":"#000","population":0.09,"background":"#dce3f4","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.26,"background":"#040514"},"lightMuted":{"title":"#fff","population":5.27,"background":"#b8c5ce","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.05,"background":"#3b6a84"},"dominant":{"foreground":"#fff","title":"#fff","population":7.29,"background":"#553e2f","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"background":"#553e2f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.29},"muted":{"population":4.74,"background":"#91817b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.7527539779681762,"height":1634,"_type":"sanity.imageDimensions","width":2864}},"uploadId":"Sx7CAsCvpN5rOfk8tPbySDnAMfCtZAXP","_type":"sanity.imageAsset","extension":"png","mimeType":"image/png","path":"images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","size":4623212,"_createdAt":"2024-09-25T15:37:16Z","_id":"image-790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634-png","originalFilename":"Screenshot 2024-09-23 at 2.24.02 PM.png","_rev":"dB2TH3ETy51FRPfE8a93kc","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/790660959e556ef9c9d3b479bb627446ee9ecc80-2864x1634.png","assetId":"790660959e556ef9c9d3b479bb627446ee9ecc80","sha1hash":"790660959e556ef9c9d3b479bb627446ee9ecc80","_updatedAt":"2024-09-25T15:37:16Z"}},"_createdAt":"2024-09-26T15:03:54Z","_id":"85749e24-afc5-4611-b062-69f03d911ded","_rev":"hNQIYgKOTVo7tcUOb3Te2y","url":{"current":"evaluating-t-cell-therapies-in-first-line-multiple-myeloma-treatment","_type":"slug"},"contentCategory":{"_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z"},"link":"/view/evaluating-t-cell-therapies-in-first-line-multiple-myeloma-treatment","summary":"Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers. ","source":null,"factCheckAuthorMapping":null},{"taxonomyMapping":[{"identifier":"conference","_createdAt":"2020-03-30T19:06:53Z","_rev":"Zzg2CQjl4x3UedGJkY3tyu","_type":"taxonomy","name":"Conference","_id":"1862ee25-8e65-4dbe-8fd3-d4c11642b211","_updatedAt":"2022-07-31T01:47:04Z"},{"_createdAt":"2020-03-30T19:16:54Z","_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","sortOrder":3,"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320"},{"parent":{"_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","_type":"reference"},"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_rev":"J9E0v654gKdSlGLhTDCsAu","_id":"26bcac93-deb1-4f11-9290-5efec6d9e357","_updatedAt":"2023-11-03T18:19:22Z","cmeType":"per","_createdAt":"2021-11-30T14:08:52Z","_type":"taxonomy","name":"Multiple Myeloma","summary":[{"markDefs":[],"children":[{"text":"The ","_key":"b477264366c1","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3a355a7e133a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"a63fce3889ac"},{"_type":"span","marks":[],"text":" Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.","_key":"4063e54b1813"}],"_type":"block","style":"normal","_key":"f1088709f836"}],"identifier":"multiple-myeloma"}],"updatedOn":null,"source":null,"factCheckAuthorMapping":null,"_createdAt":"2024-09-25T16:18:16Z","authorMapping":[{"firstName":"Cameron","lastName":"Santoro","_createdAt":"2023-11-22T18:35:06Z","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"markDefs":[],"children":[{"_key":"93662c5c4cfd","_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for "},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"text":"®","_key":"7c809e803edb","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"text":"®","_key":"8ddca200bc46","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal","_key":"3da8fced8696"}],"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"_updatedAt":"2024-05-20T19:28:22Z","displayName":"Cameron Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","_type":"author","url":{"current":"cameron-santoro","_type":"slug"}}],"title":"Creating Equitable AI Models for Multiple Myeloma","ExcludeFromPubMedXML":false,"_type":"article","documentGroup":{"_type":"reference","_ref":"fe8a172f-0a1e-4659-a196-c58cee727b48"},"body":[{"videoObject":{"videoTitle":"Anant Madabhushi, PhD","thumbnail":{"_type":"image","asset":{"_ref":"image-f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611-png","_type":"reference"}},"videoDuration":"PT2M54S","videoDescription":"Anant Madabhushi, PhD","_type":"videoDetails"},"_type":"video","caption":"Anant Madabhushi, PhD.","videoID":"6362446486112","disableAutoPlayVideo":false,"source":"brightcove","_key":"f47590081a4e"},{"_type":"block","style":"normal","_key":"186a6e2b3487","markDefs":[{"_type":"link","href":"https://www.ajmc.com/conference/ims","_key":"59e7bd1c11bc","nofollow":false,"blank":true}],"children":[{"marks":[],"text":"The ","_key":"a98f93c5e1a40","_type":"span"},{"_type":"span","marks":["59e7bd1c11bc"],"text":"International Myeloma Society","_key":"a98f93c5e1a41"},{"_type":"span","marks":[],"text":"'s 21st annual conference is set to take place in Rio de Janeiro, Brazil, from September 25 to 27. This gathering will bring together leading experts in the field to discuss the latest advancements in myeloma research, covering fundamental, preclinical, and clinical aspects of the disease.\n","_key":"a98f93c5e1a42"}]},{"children":[{"_type":"span","marks":[],"text":"Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes using AI to address disparities in ","_key":"1108eff9e41c0"},{"_type":"span","marks":["15fb77974f47"],"text":"multiple myeloma","_key":"f088e1ce541c"},{"_type":"span","marks":[],"text":" care. He argues that systemic racism contributes significantly to these disparities, but there may also be subtle phenotypic differences between populations that can be identified to develop more tailored treatment approaches.","_key":"864dbe5dac2c"}],"_type":"block","style":"normal","_key":"53c17d5757f7","markDefs":[{"href":"https://www.ajmc.com/compendium/multiple-myeloma","_key":"15fb77974f47","nofollow":false,"blank":true,"_type":"link"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"ce9cc94aed4b"}],"_type":"block","style":"normal","_key":"b1a9ae95941e"},{"_type":"block","style":"normal","_key":"2335b8176cbd","markDefs":[],"children":[{"_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity.","_key":"769a338eb5770"}]},{"children":[{"text":"","_key":"d0e7e9787911","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"3f173340cb04","markDefs":[]},{"_key":"6b46ee6339b3","markDefs":[],"children":[{"text":"Transcript","_key":"54bbe7c7b5ac0","_type":"span","marks":["strong","underline"]}],"_type":"block","style":"normal"},{"_key":"27e27c896cae","markDefs":[],"children":[{"_key":"c6e67eaa3420","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"85210111e6fa0","_type":"span","marks":["strong"],"text":"How can AI help address disparities in multiple myeloma care and outcomes?"}],"_type":"block","style":"normal","_key":"2f92b3120dc4"},{"style":"normal","_key":"04f32e0dfea7","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"548faa8a9993"}],"_type":"block"},{"_type":"block","style":"normal","_key":"c28ee0147ae6","markDefs":[],"children":[{"text":"I will react by saying that the issue of disparities in cancer care is well established. We know that there are several different reasons for the disparities that we observe across different populations in the context of cancer care. Let's call out the 800-pound gorilla in the room. A lot of it has been the issue of systemic racism that has caused significant disparities in access and subsequently outcomes for different populations, particularly populations of color. As we look to better understand the disease, and we're seeing this in other cancers and other diseases, that beyond the social determinants of health and beyond the socioeconomic factors and access, we also are starting to acknowledge that there are subtle differences in the phenotype of the disease across different populations. And our work in prostate cancer and endometrial cancer has shown that using technologies like AI, we can start to tease out very subtle differences in the appearance of the disease across different populations. For instance, in prostate cancer and endometrial cancer, our work has revealed that there are cellular-level differences in the pathology images of, say, Black patients and White patients in the context of endometrial cancer and prostate cancer.","_key":"70260210740c0","_type":"span","marks":[]}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"0a521e9fdba00"}],"_type":"block","style":"normal","_key":"0b4194fdb87c"},{"children":[{"_type":"span","marks":[],"text":"Again, I will repeat what I initially said. I know very little about multiple myeloma and I'm looking to learn at this particular meeting but I think that there's an opportunity to really use powerful technologies like AI to start to dive into understanding phenotypic differences between populations. I'm not suggesting that there are necessarily differences, but if there are differences, then we need to be cognizant of those differences and try to start accounting for that, potentially in starting to create more tailored AI models.","_key":"98c04f43b1950"}],"_type":"block","style":"normal","_key":"3bfeca32011f","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"2bd9a88cbc0d0","_type":"span"}],"_type":"block","style":"normal","_key":"04db5b94f6da"},{"_key":"c5a25d8ecef2","markDefs":[],"children":[{"_type":"span","marks":[],"text":"One of the things that AI has been accused of, quite rightly, is the fact that it is very prone to bias. It is very prone to exacerbating inequity and the only way to really address that is to be intentional about the way we develop the AI. To do that, we have to look at these approaches to try to understand, first and foremost, are there differences in the appearance of the disease across different populations? If there are, let's celebrate those differences and account for those differences in creating a more unbiased, more equitable AI model, or if need be, create a more population specific AI model that is more geared and catered to specific populations.","_key":"b1b28e0174360"}],"_type":"block","style":"normal"}],"seoTag":["artificial intelligence","IMS","multiple myeloma","systemic racism"],"link":"/view/creating-equitable-ai-models-for-multiple-myeloma","thumbnail":{"asset":{"extension":"png","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png","_updatedAt":"2024-09-25T16:23:19Z","_rev":"NEmhylHz7zejTih5tt0QTP","path":"images/0vv8moc6/ajmc/f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611.png","size":2194636,"_createdAt":"2024-09-25T16:23:19Z","originalFilename":"Screenshot 2024-09-19 at 11.19.40 AM.png","metadata":{"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAALCAYAAAB/Ca1DAAAACXBIWXMAABYlAAAWJQFJUiTwAAADCElEQVQokS2M3U+bdQCF3z/BG+/0wguNmdONDBdHmFZXhpJusQ0QxwZuFtoSnbCRCiY6/GDTaIcCUQYzLdDSOCdIMhI1MQQHS0Cw20qgDXSMUrq2KS20pR+0b3+Poe4kJyfPSc6RskKQEwL5cWaEIClyxOUUkVSEUHyD8E6AeDZBVsgIIUCIQuYLzv/fPZa0KwR7pzKCHII9zog8STlDeCeMx7/MwuoinkdetpM75PP5wnDvRM7L5ORcodtjIfJIsd0dEtk0ydwuKTlLOp8lLbJspWPML93DcsPKtz3f02sZYOLODMHNCDlZJpfPkcwkiacSJDMp0rtp0pkUkndznY1ogGA8zGYyylZmm3gujjfswz76C81N59GfOUWzTkfHlW/4c3KaSCxGJpshEosSjIaJxreIJWIFS671JZb9KzwMreGLbhBMBIlkIixveBiwWmgzNNBSrablnUqa9Aa6+80sejxsbkfxBvw88K3jCwbwh0L4Q0GkhQdOXF43K/5VHobW8UUfEUiEcfk82OxWWvU6DCdVaFUV1NfU0PH1V0xMT+J0LzB738HU3BxT/8wyNTPL7ZkZpLtuJ84VN4urHpbWVlnyreEO+LjrcWG3DWLUvkdd+XE0itepOXmCT9ouMmTrY3T8JvaxX+m32/jBYqZ/cADzsA3pjsPB9LyD23MOJuf/ZfKegymXk7/vzzE8cJ1Pte9yruwYb5ccofINBfWnNTRfqKet3Yjxy0voPjJS98H7NBpbaP28Henm+Dg3xm4xPPIbQyOjDN0a4+e/fmdk4g/6rvXQdPoUFYdfpnT/fpRHiqkoK6WsvBSlSklZlRqFRo1CrUZVe4ZqfQOS2Wqm96d+OkwmPr58mfbOq5iu99FrHaKzu4uG2lqOHizi0L59vKVUUFWl4tjxV3mh+CWeKTrA8yUlvKbRUGnQo9HVI1kGr3G1y0TjxQucO/8hbV90cKWzC1P3j5i+66FRZ+DooWJeOXgAbV0Nn11qRdtQx4uHi3ji6ad48tnnKC5/kxNnz6KsruI/5/CeMz1dyU0AAAAASUVORK5CYII=","dimensions":{"width":2846,"aspectRatio":1.766604593420236,"height":1611,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"M=MQ|txu%MoLMx~qRjofofWBs;WBRQj[tQ","_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#51a8ad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.53,"background":"#ebfcf0"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01,"background":"#56362c"},"muted":{"title":"#fff","population":0.02,"background":"#9c6459","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#ebfcf0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.53},"darkVibrant":{"background":"#102122","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.14},"lightMuted":{"background":"#b2c0cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.01}},"hasAlpha":true},"sha1hash":"f1df35f419ab459055c6d9a978f09de3f2488375","uploadId":"Vj9sRqfPxNBexgSmi604SFjrwNjJAWdR","mimeType":"image/png","assetId":"f1df35f419ab459055c6d9a978f09de3f2488375","_id":"image-f1df35f419ab459055c6d9a978f09de3f2488375-2846x1611-png"}},"_id":"4289c42c-d19c-4624-b1f7-9c80d4dc226b","_rev":"dB2TH3ETy51FRPfE8alLpO","url":{"current":"creating-equitable-ai-models-for-multiple-myeloma","_type":"slug"},"articleType":"Commentary","_updatedAt":"2024-09-25T18:49:58Z","summary":"Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, proposes AI-based solutions to address health care disparities, emphasizing systemic racism and phenotypic variations.","is_visible":true,"published":"2024-09-26T16:18:00.000Z","contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"}}],"topArticlesData":[{"_id":"1ec0ae59-08f0-4818-9f4e-a44779df7514","url":"rapid-iv-isatuximab-could-shift-care-practices-in-mm","thumbnail":{"caption":"Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com","asset":{"_ref":"image-11ee9be36fc4be88ca66a17e7b37ebc45bb91d87-6048x4024-jpg","_type":"reference"},"_type":"mainImage","alt":"Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com"},"authors":[{"displayName":"Kyle Munz","url":"kyle-munz"}],"factCheckAuthors":null,"title":"Rapid IV Isatuximab Could Shift Care Practices in MM","summary":"Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike. ","published":"2025-02-13T14:47:00.000Z","updatedOn":null,"source":null},{"summary":"The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics. ","authors":[{"displayName":"Kyle Munz","url":"kyle-munz"}],"factCheckAuthors":null,"published":"2025-02-07T15:39:00.000Z","updatedOn":null,"source":null,"_id":"066524a3-35d6-4450-9e7a-5b489790532b","title":"Prolonged Survival in MM: Insights From the Largest Ongoing US Registry","url":"prolonged-survival-in-mm-insights-from-the-largest-ongoing-us-registry","thumbnail":{"_type":"mainImage","alt":"cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com","caption":"cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com","asset":{"_ref":"image-712ebcfc9e4a74f95125a3aa12de4fbfe735b3d7-10000x6600-jpg","_type":"reference"}}},{"title":"An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna","url":"dr-kirollos-hanna-an-argument-for-outpatient-bispecific-antibody-delivery","thumbnail":{"_type":"mainImage","alt":"Kirollos Hanna, PharmD","asset":{"_ref":"image-f698018f94ae99ba6f548f81a15462f47765951b-1280x720-png","_type":"reference"}},"summary":"Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings. ","updatedOn":null,"factCheckAuthors":null,"_id":"95323b9f-9e54-4b5c-8646-89145ff99e3a","published":"2025-01-25T15:12:00.000Z","source":null,"authors":[{"displayName":"Kyle Munz","url":"kyle-munz"},{"displayName":"Kirollos Hanna, PharmD","url":"kirollow-hanna-pharmd"}]},{"url":"study-of-prophylactic-tocilizumab-may-soon-add-talquetamab-arm","updatedOn":null,"source":null,"authors":[{"displayName":"Luke Halpern","url":"luke-halpern"},{"displayName":"Laura Joszt, MA","url":"laura-joszt"}],"factCheckAuthors":null,"_id":"aecadc3d-7263-4f78-9dd0-fa1c3dc48c8a","title":"Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm","thumbnail":{"asset":{"_ref":"image-fc139fac19e253d5099151f537e4fe6cddfd07a0-1600x1600-webp","_type":"reference"},"_type":"mainImage","alt":"Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers"},"summary":null,"published":"2025-01-22T18:05:00.000Z"},{"_id":"ff7394fe-4a94-47e3-9b3f-40df8aed73a5","title":"High Infection Risk in MM: Insights From the Preimmunotherapy Era","url":"high-infection-risk-in-mm-insights-from-the-pre-immunotherapy-era","thumbnail":{"_type":"mainImage","alt":"Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com","caption":"Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com","asset":{"_ref":"image-7286b9eed868f8255bff55121b38c06742c21073-4032x2688-jpg","_type":"reference"}},"summary":"Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies. ","updatedOn":null,"source":null,"factCheckAuthors":null,"published":"2025-01-21T15:19:00.000Z","authors":[{"displayName":"Kyle Munz","url":"kyle-munz"}]}],"features":[],"cmeData":{"msg":"","data":[{"id":"a5cbd8bf-fdcc-4c2d-ba39-a4a9116a0449","brandName":"Ajmc","dataType":"ptce","title":"Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png","description":"1.5 Credits / Hematology, Hematologic Cancer, Oncology","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2025-02-10T12:05:53.379316+00:00","TI_id":"3f5fc85c-88a5-4d21-9e76-047d384b88f2","slug":"addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Hematology\",\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":"","eventData":null,"imageUrl":null},{"id":"12fd7f9e-81d9-4057-8766-586fbb17f357","brandName":"Ajmc","dataType":"ptce","title":"Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/hvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png","description":"1.5 Credits / Oncology, Hematology, Hematologic Cancer","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2025-02-10T12:05:53.690757+00:00","TI_id":"e2a1de76-f5f4-4393-85a1-e17a243a9853","slug":"keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":"","eventData":null,"imageUrl":null},{"id":"e7461055-aba3-4aea-bc45-bc12fdb0fd6e","brandName":"Ajmc","dataType":"ptce","title":"Closing Gaps in CLL Care: Managed Care Insights and Strategies","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/1erko2mgi7qi-PTCE_CLL_Virtual-Symposium_111324v3_800x385.png","description":"1.5 Credit / Hematologic Cancer, Oncology","releaseDate":"2024-11-25T14:15:41.881Z","expirationDate":"2025-11-26","creditType":"On-Demand","creditAmount":"1.5","created_at":"2025-02-10T12:05:52.596303+00:00","TI_id":"bf82e6cf-f564-4ba6-8fa0-0d281a97bbba","slug":"closing-gaps-in-cll-care-managed-care-insights-and-strategies-sy5b","delReference":true,"contentTypeLabel":"Virtual Symposium","activity-type":null,"specialty":"[\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2025-11-26T04:59:59.999+00:00","cventUrl":"","eventData":null,"imageUrl":null},{"id":"4b06c045-2383-4cde-be29-758255ff6e1c","brandName":"Ajmc","dataType":"ptce","title":"ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/jr9xakbtsqhw-PTCE_ASH-CML_Webinar_110624v2_800x385.png","description":"1.0 Credit / Oncology, Hematology, Hematologic Cancer","releaseDate":"2024-12-19T05:00:00.000Z","expirationDate":"2025-12-20","creditType":"On-Demand","creditAmount":"1","created_at":"2025-02-10T12:05:52.348962+00:00","TI_id":"d8ff14fa-b00b-4c1e-9799-6e93987c1381","slug":"ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care-4c5t","delReference":true,"contentTypeLabel":"On-Demand Webinar","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2025-12-20T04:59:59.999+00:00","cventUrl":"","eventData":null,"imageUrl":null}],"fail":false},"videoData":{}},"queryString":{"page":"5","slug":["compendium","multiple-myeloma"]}},"host":"www.ajmc.com"},"__N_SSP":true},"page":"/[...slug]","query":{"page":"5","slug":["compendium","multiple-myeloma"]},"buildId":"T5sqxRTLols3JYvQxG45F","isFallback":false,"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>